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ABSTRACT:
CD23 (FceRII), the low affinity receptor for IgE, is a single chain 45kDa Type II 
membrane glycoprotein member of the C- type lectin family. The CD23 molecule is 
a multifunctional receptor/ligand and cytokine, playing a role in antigen 
presentation, macrophage activation and cell adhesion. There are two distinct 
isoforms of human CD23, termed CD23a and CD23b, with the only difference being 
noted in a 6 or 7 amino acid region in the N-terminal cytoplasmic domain of the 
protein. These isoforms are generated from distinct transcription start sites and 
differential RNA splicing of the single CD23 gene, located on chromosome 19. 
CD23a is constitutively and cell type-specifically expressed on B cells, whereas 
CD23b can be expressed on B cells, monocytes and other cells of haematopoietic 
lineage when activated by stimuli including IL-4 and IL-13.
A large body of evidence suggests that CD23 plays a regulatory role in IgE 
production, and cross-linking of CD23 at the cell surface with IgE delivers a 
negative feed-back signal for IgE production and inhibits the release of soluble 
CD23 (sCD23), Cleaved sCD23 fragments larger than 25kDa are known to promote 
IgE production. Allergic disease is thought to be due to the dysregulation of 
CD23/IgE feed-back mechanisms, probably through increased cleavage of CD23 
from the cell surface, leading to increased IgE production and release of 
inflammatory mediators. Soluble CD23 is considerably elevated in atopic and 
neoplastic individuals, and this sCD23 can originate from either the a or b isoform 
on B ceUs or just from the b isoform on other cells of haematopoietic origin.
The patterns of CD23 gene expression and functional diversity has led to the 
assumption that CD23a and b are involved in B cell function and IgE-mediated 
immunity, respectively, with divergenj^ ih'&e signalling pathways attributed to the 
N-terminal amino acid differences. It was of importance and interest, therefore, to
study and elucidate those events which lead to the expression of each CD23 isoform 
and to pin-point these to differences in promoter activation and regulation. In this 
research, the activation of the promoter region of each CD23 isoform was studied in 
great detail, and reporter vector construct studies have shown that each isoform 
promoter is differentially activated by distinct stimuli. The CD23a promoter contains 
two IL-4 response elements (IL-4RE), an NFkB site, a glucocorticoid response 
element (GRE), a B-cell-specific activator protein (BSAP) or Pax-5 binding site, and 
is activated by IL-4 only. The CD23b promoter, on the other hand, contains two IL- 
4RE's separated by an NFkB site, two AP-1 binding sites and is stimulated by IL-4, 
anti-CD40, anti-|Li and PMA. Reporter vector constructs containing truncated 
promoters revealed that IL-4 stimulation of the CD23a promoter requires the 
presence of the first IL-4RE/STAT-6 site, while successful IL-4 stimulation of the 
CD23b promoter is dependent on the second IL-4RE/STAT-6 site. The discovery of 
these differentially regulated isoform promoter regions confirms the theory that 
CD23a and CD23b are involved in functionally different roles, and it is hypothesised 
that these include the prevention of plasma cell formation in B cells and IgE 
negative regulation, respectively.
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CHAPTER 1
INTRODUCTION
CHAPTER 1: INTRODUCTION
1.1: The Immune System
The immune system is the host's mechanism of protecting itself against disease- 
causing attacks from environmental infectious agents such as viruses, bacteria, 
protozoa and parasites (Janeway & Travers, 1997). The immune system involves a 
variety of specific and non-specific cells, known collectively as leukocytes (Roitt, et 
al., 1993), including B cells, T cells, monocytes, macrophages and granulocytes 
(Zucker-Franklin, et al,  1980). The immune response depends on two things; the 
ability of a host to recognise antigens as foreign material and then, secondly, the 
means to mount a response to the invader and eliminate it.
There are two primary categories of immune response, innate (non-adaptive) and 
adaptive. Innate immunity is non-specific and is present prior to the presentation of 
infectious agents (Ulevitch, 2000). Phagocytic cells such as monocytes and 
macrophages, granulocytes and the complement serum proteins (Yefenof, 2000) are 
the main mediators of innate immunity - with the opsonisation of micro-organisms 
with complement proteins aiding their internalisation and elimination. Granulocytes 
are so called because of the densely staining granules in their cytoplasm, and include 
neutrophils, eosinophils and basophils (Janeway & Travers, 1997). Neutrophils 
constitute over 90% of polymorphonuclear granulocytes and migrate in response to 
chemotactic agents such as complement, fibrinolytic and bacterial products. 
Eosinophils are thought to be important chiefly in the defence against parasitic 
infections, and are attracted by the products released by T cells, mast cells and 
basophils. Degranulation of eosinophils can be triggered by the appropriate stimuli 
and, although not their primary function, they appear to be capable of phagocytosing 
and killing ingested micro-organisms. Basophils are found in very small numbers in 
the circulatory system, and make up less than 0.2% of leukocytes. The function of
basophils is probably similar to that of mast cells, which are believed to play a part 
in protecting the mucosal surfaces of the body and degranulate to release substances 
which affect vascular permeability.
The adaptive immune response is, in comparison, highly specific for individual 
pathogens, and is only induced by exposure to them (Male, et ai,  1993). This type 
of immune response improves with each successive encounter with the same 
antigens and, in effect, induces immunological memory (Zinkernagel, et al,  1996). 
Lymphocytes make up about 20% of all blood leukocytes and are central to adaptive 
immune responses and the specific recognition of antigens. There are two basic 
categories of lymphocytes: B cells and T cells. B lymphocytes represent about 5- 
15% of the circulating lymphoid pool, and are defined by the presence of surface 
immunoglobulins that act as specific antigen receptors (Mellman, et al,  1988). The 
majority of human B cells in peripheral blood express IgM and IgD on their cell 
surface. A few express IgG, IgA or IgE, although large numbers of B cells 
expressing these immunoglobulins can be found in specific locations, such as IgA 
bearing cells in the intestinal mucosa. B cells also express MHC Class II molecules, 
which are important for co-operative interactions with T cells, complement receptors 
and various receptors for a variety of signalling molecules. These receptors include 
those for the Fc regions of antibodies and for B cell growth and differentiation 
factors.
Activated B cells proliferate and mature under the auspices of T cell help and 
influence and, ultimately, differentiate into memory B cells (or plasma cells - the 
latter of which are almost exclusively devoted to the production of secreted 
antibodies, the mediators of humoral immunity) which bind to particular target 
antigens. These target antigens can either be a molecule on the surface of a pathogen 
particle, or a toxin that it produces. Antibodies are the soluble form of the B cell 
antigen receptor and all have the same basic structure, with diversity being in the
antigen binding region. While one part of an antibody binds antigen, other parts 
interact with several innate immune system elements; such as phagocytes or 
complement. This allows for widespread recognition of specific pathogens. The 
effects of antibodies include; the neutralisation of soluble antigens, the activation of 
the complement system, the opsonisation of pathogen particles to enhance 
phagocytosis and antibody dependent cell-mediated cytotoxicity (ADCC).
T lymphocytes develop and differentiate in the thymus prior to seeding in the 
secondary, peripheral lymphoid tissues (Jenkinson, et ai,  1989). They recognise 
antigen and MHC molecules via a receptor molecule distinct from, but related to, 
immunoglobulin. This receptor consists of an antigen binding portion formed by 
two different polymorphic chains associated with CD3, the universal T cell 
differentiation marker (Strominger, 1989). There are two main subpopulations of T 
cells, distinguished by their expression of either CD4 or CD8, which act as receptors 
for class II and class I MHC molecules, respectively, and contribute towards T cell 
immune recognition and cellular activation. CD4“*“ T cells act primarily as helper T 
cells (TH), whereas CD8+ T cells are associated with the cytotoxic destruction of 
virally-infected cells. There are also sub-populations of both CD4+ and CD8+ T 
cells, with CD29+CD4+ cells being classed as activated or memory T cells and 
CD45R+ CD4"  ^ cells being generally naive or virgin T cells. Functionally, these 
subsets act as efficient helpers and inducers of suppression respectively.
Blood cells, therefore, all differ in function, morphology, number and life span. To 
maintain homeostasis of each of these populations, each ceil type is generated at an 
appropriate rate from a self-renewing population of pluripotent stem cells, found in 
the bone marrow (BM) of adult mammals. A stem cell has the capacity for 
unlimited self-renewal, and can divide asymmetrically to generate progenitor cells 
that are irreversibly committed to one or other of the haematopoietic lineages. These 
lineage restricted clones mature into specialised cells, such as B or T lymphocytes.
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1.2: B cell lymphopoiesis
B cell lymphopoiesis occurs throughout life in the intermeduilary cavity of the BM 
in adult mammals, and the stages of development are defined by the expression 
pattern of several B cell-restricted markers, cell size, growth properties and the re­
arrangement status of immunoglobulin (Ig) genes (Melchers & Rolink, 1998). An 
overview of B cell lymphopoiesis is shown on Figure 1.1, along with cell surface 
markers and gene expression patterns for transcriptional regulatory elements. B 
lymphocytes are generated from a lymphoid progenitor cell expressing CD34, B220 
(CD45) and CD 10, that is capable of producing B cells, T cells, natural killer and 
dendritic cells, but not erythroid or myeloid lineages (Galy, et al,  1995). The first 
identifiable stage of B cell development is the pro-B cell, which has un-re arranged Ig 
heavy and light chains, expresses B220 (CD45) (as do all cells committed to B 
lymphopoiesis) and CD43 (Hardy, et al,  1991; Li, et al, 1996; Melchers, et al,
1995). As progenitors progress through the pro-B cell stage, they express terminal 
deoxynucleotidyltransferase (TdT), RAG-1, RAG-2, the surrogate light chains A,5 
and VpreB, CD 19, Iga (mb-1) and Ig|3 (B29). The cells also rearrange their Ig 
heavy chain {Igh ) genes.
The subsequent pre-B cell stage is marked by a decrease in CD43 expression, lack of 
TdT expression, successful rearrangement of the IgH locus and the appearance of the 
pre-B cell receptor complex (pBCR) components (Karasuyama, et al,  1994). Early 
stage cycling of the pre-B cells is also marked by a decrease of RAG-1 and RAG-2 
expression (Grawunder, et al,  1995). As differentiation continues, Ig light chain 
gene rearrangement begins and completion of antigen independent B cell 
development is marked by successful light chain gene rearrangement and the 
expression of surface IgM. The cells then exit the BM and migrate to the periphery.
Functionally, B220 (CD45) is a phosphotyrosine phosphatase (PTPase) which 
appears to regulate B cell receptor signalling by dephosphorylating src family 
tyrosine kinases, such as lyn, and also Iga and Igp (Satterthwaite & Witte, 1996). 
CD45 is also assumed to integrate signals during development, although it is not 
absolutely required for B lymphopoiesis (Li, et ai,  1996). CD 19 is thought to be 
important for B cell signalling and interacts with a number of tyrosine kinases, 
although the actual role of this protein is unclear as mice lacking CD 19 still generate 
B cells. Appropriate expression of the surrogate light chain proteins, p, Iga and Ig(3 
is essential for B cell differentiation, and it is these molecules that form the pBCR 
that appears on the surface of the cell during the latter pro-B cell stage of 
development (Melchers, et aL, 1994; Rajewsky, 1996). The pBCR associates with 
non-receptor tyrosine kinases and provides critical signals for progressing to the pre- 
B cell stage and establishing IgH allelic exclusion (Loffert, et ai,  1996). Gene 
targeting experiments have confirmed that individual components of the pBCR are 
required for normal B cell differentiation, with IgP lacking mice being unable to 
progress past the pro-B cell stage (Gong & Nussenzweig, 1996). In addition, A.5 and 
p negative mice are blocked at the early pre-B stage of differentiation (Kitamura, et 
ai ,  1992) and mice with non-functional Iga have significant reductions in their 
numbers of peripheral B cells (Torres, et al,  1996). The role of pBCR signalling in 
lymphopoiesis may reflect cell fate decisions at the pro/pre-B cell transition stage. 
Consistent with this hypothesis is the finding that bcl-2 and bcl-x, which are 
involved in protecting cells against apoptosis, are differentially expressed during B 
cell development (Grillot, et ai,  1996).
Additional molecules involved in signalling that have a role in B cell development 
include; JAK 3, in which knockout mice lack B220**"/CD45+ progenitors; flk 2, a 
receptor tyrosine kinase that influences progenitor B cell development 
(Mackarehtschian, et al., 1995); syk, a tyrosine kinase necessary for generating pre- 
B cells (Turner, et al., 1995); the src-related kinase lyn, which may affect the
maturation of immature B cells (Hibbs, et ai,  1995) and BTK (Bruton’s tyrosine 
kinase), mutations of which are linked to X-linked immunodeficiency in mice and 
human X-linked agammaglobulinaemia (XLA). Other proteins that display B cell 
restricted functions include; TdT, which randomly adds nucleotides at the coding 
joins during IgH recombination; the IL-7 receptor (IL-7R), which is required for 
pro/pre-B cell generation, and integrin proteins that are necessary for mediating cell­
cell and cell-extracellular matrix interactions (Candeias, et al,  1997; Li, et al.,
1993).
1.2.1; Expression and rearrangement of immunoglobulin genes
Proper expression of Ig heavy and light chain genes is critical for B cell 
lymphopoiesis. In general, Ig genes are regulated by a number of tissue specific cis- 
acting promoters and enhancers (Calame & Ghosh, 1995), and are also partly 
governed by their assembly during B cell differentiation. V(D)J recombination 
occurs at specific times and begins during the pro-B cell stage of differentiation with 
D Jh recombination (Reth & Alt, 1984). Successful rearrangement of the Vh 
segment to the previously joined DJh chains results in the expression of cytoplasmic 
p chain, which is a characteristic of pre-B cells, In the final stages of primary B cell 
development, the pre-B cell must also successfully rearrange the V and J elements at 
one of its light chain loci.
V(D)J recombination is regulated by at least two mechanisms that both depend on 
transcription, namely the expression of RAG genes and the accessibility of the Ig 
genes to recombinase activity. The V(D)J recombination machinery components 
RAG-1 and 2, along with the DNA-dependent protein kinase complex, recognise 
recombination signal sequences and mediate cleavage (Ramsden, et a l ,  1997). 
Defects in any of these components leads to deficiencies in recombination 
(Mombaerts, et ai,  1992). RAG-1 and RAG-2 mRNA, which can first be detected
in pro-B cells, are down-regulated upon IgH rearrangement completion and then 
transcribed again in small pre-B cells to allow light chain re-arrangement 
(Grawunder, et ciL, 1995). The precise mechanism by which Ig genes are targeted 
for recombination is not completely understood, though is thought to involve 
multiple mechanisms, including changes in chromatin structure and variations in 
méthylation patterns (Sleckman, et al,  1996).
1.2.2: Transcriptional regulation of B cell differentiation: The roles of 
transcription proteins
As stated, after commitment to the B cell lineage, a cell transits through multiple 
stages of differentiation defined by many phenotypic and functional changes such as 
sequential immunoglobulin heavy and light chain re-arrangement and the expression 
of various cell surface molecules. External signals regulate lineage- and stage- 
specific expression of genes, including extracellular growth factors and cell to cell 
contact. Intracellularly, these signals are integrated by transcription factors which 
execute a programme of differentiation by directly regulating gene expression. 
Some of these transcription factors have been identified through studies of cis-acting 
regulatory elements of genes specifically expressed in individual haematopoietic 
lineages, and some have also been discovered by examining genes that are 
translocated or abberantly activated in leukaemias. Transcription factors are known 
to perform specific functions in cellular differentiation, suggested by the fact that 
they are expressed in a cell type specific manner. In vitro studies have shed further 
light on the biochemical and functional properties of these transcription factors, and 
definitive evidence for their role in vivo has come from the analysis of mice carrying 
targeted mutations.
A subset of transcription factors expressed in haematopoietic stem cells, as well as in 
B cell precursors, have been implicated in B cell lineage commitment and these are 
discussed below.
PU.l
PU.l (spi 1) is an Ets family transcription factor member that is expressed at high 
levels in immature and mature B cells and in myeloid cells. The importance of PU.l 
in B cell generation has been demonstrated by the analysis of mice carrying a 
targeted PU.l gene mutation, which display a profound loss of all lymphoid and 
myeloid cells. Stem cells were also reduced in number, and found to be unable to 
generate B lymphoid and myeloid cells.
PU.l is postulated to regulate various B cell specific genes; including mb-1 (Iga), 
immunoglobulin J chain and immunoglobulin p, K and X chains. In the context of 
the regulation of light chain genes, PU.l has been shown to act by co-operating with 
other transcription factors such as PIP (LSIRF, IRF-4), c-jun and c-fos (Pongubala & 
Atchison, 1997). PIP has been shown to be recruited to transcriptional control 
regions, such as the IgX chain enhancer, by PU.l and together these proteins are 
thought to be important in controlling the transcriptional activity and recombinatorial 
activity of immunoglobulin light chain genes. PIP also appears to repress 
transcription mediated by interferon a  or (3 in a PU.l-independent manner (Brass, et 
a i ,  1996; Yamagata, et al,  1996). A recent targeted mutation of the PIP gene 
revealed that it is not required for immunoglobulin K transcription and early B cell 
differentiation (Mittrucker, et al,  1997). PIP-deficient mice, however, lack germinal 
centres in peripheral lymphoid organs, are defective in B cell activation and display 
severe ly mp hade nop athy - which may be related to PIP's function as a repressor of 
interferon-induced transcription.
Ikaros
Committed lymphoid precursor generation is also regulated by Ikaros proteins, 
which belong to a family of zinc finger transcription factors that includes Aiolos and 
Helios (Georgopoulos, e ta l ,  1997; Hahm, et al, 1998). Ikaros is expressed in both 
stem cells and mature lymphocytes, and Ikaros-like proteins recognise binding sites 
in many B lymphocyte specific genes; including TdT, X5, VpreB and Ick 
(Georgopoulos, 1997), Alternative splicing of the Ikaros gene results in the 
generation of various isoforms (Ik 1-6) which differ in their DNA binding, 
dimerization and nuclear localisation potential (Sun, et al,  1996).
The DNA binding domains of Ikaros proteins are located at the amino terminus, 
consisting of four zinc fingers. Dimerization among Ikaros proteins and other family 
members is mediated by two individual zinc fingers at the carboxyl terminus (Hahm, 
et al ,  1998) and mice carrying a carboxyl terminal mutation have null mutant 
protein and no B cells in either foetus or adult. A different targeted mutation, 
removing the Ikaros gene DNA binding domain, enables the synthesis of a stable 
mutant protein (Georgopoulos, et al,  1994) and leads to a complete lack of B and T 
lymphocytes at all developmental stages.
Following B cell lineage commitment, cells differentiate into pro-B cells that 
undergo Ig D-Jh rearrangement and express the cell surface markers B220, CD43 
and heat stable antigen. The next stage of differentiation leads to the addition of 
expression of BP-1 and also Vh-DJh gene recombination and cells at both these 
stages express the immunoglobulin surrogate light chain genes, X5 and VpreB. 
Following rearrangement of the light chain gene, light chains are expressed on the 
cell surface together with mb-1 (Iga) and B29 (IgP) - which are involved in signal 
transduction.
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NFkB
NFkB is proposed to regulate several genes important in B cell differentiation, such 
as the Ig light chain, and this role of mediating growth factor generated signals has 
also led to the suggestion that it may be involved in the prevention of precursor cell 
apoptosis. NFkB is a heterodimer of p50 and p65 subunits, whose activity is 
regulated by interaction with IkB inhibitory proteins (Barnes & Karin, 1997). Both 
subunits of NFkB belong to the Rel family of transcription factors, which include 
p52, Rel-B and c-Rel. Targeted mutations in Rel family member genes, and 
subsequent analysis of these in mice, demonstrated that they are essential for 
multiple functions in the later stages of B cell differentiation (Baldwin, 1996). 
Analysis of mice carrying mutations in more than one NFkB subunit gene has shown 
that NFkB proteins also play a critical function in early B cell development. P65 
null mice die in utero (Doi, et al., 1997), so B cell development can only be 
monitored in adoptive transfer experiments, which reveal a reduction in cell number 
at each stage of B cell development. Mutant B cells were also found to be deficient 
in proliferative responses to mitogens and in the secretion of IgG and IgA (Horwitz, 
et al,  1997). In contrast, p50 null mice display normal B cell development, but 
show impaired mitogen-induced proliferation and antibody isotype production 
(Snapper, et a l ,  1996). Mice lacking both subunits have more severe defects than 
either of the single mutants, failing to generate any B cells whatsoever.
Interactions of a similar nature have been observed between p50 and other NFkB 
family members; Rel-B null mice have virtually normal B cell development, but 
show functional defects such as multi-organ failure, myeloid hyperplasia and 
splenomegaly (Weih, et al,  1995). In contrast, p50/Rel-B double knockout mice 
display a marked reduction of immature B cells in the bone marrow, as well as a 
reduction of mature IgM positive B cells in the bone marrow and spleen. Finally, 
while mutation of the p52 gene alone affects only peripheral B cell function,
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inactivation of both p50 and p52 subunits results in a block in the development of 
IgM+/IgD+ mature B cells .
E2A
Early B cell development is also regulated by E47 and E l2, members of the basic 
helix-loop-helix (bHLH) transcription factor family, which are generated by 
alternative splicing of RNA encoded by the E2A gene (Kadesch, 1992). These 
proteins recognise sequences in the transcriptional control regions of most lymphoid 
cell specific genes; either as homodimers or heterodimers with other proteins. While 
E12 and E47 are widely expressed, the homodimeric form of E47 is unique to B 
lymphocytes.
Products of E2A are thought to be involved in the transcriptional regulation of the \i, 
K and Ig heavy chain genes, and mice carrying mutations in E12 and E47 proteins 
have no mature B cells (Bain, et ai,  1994; Zhuang, et ai,  1994). These mice contain 
CD43+/B220+ (CD45) B cell precursors, arrested prior to D-Jh gene re­
arrangement. Mice lacking E12 alone have defects at later developmental stages, 
suggesting E12 and E47 are partially overlapping - but not identical in their 
influence on B cell development (Bain, et ai,  1997). There is also a noted gene dose 
effect with E47 proteins, with E47+/" heterozygotes showing exactly half the number 
of mature B cells relative to control mice (Zhuang, et al, 1994).
The E2A gene products may regulate targets in conjunction with other factors, such 
as p300, since the activation of the Ig heavy chain enhancer has been seen to be 
increased by the recruitment of p300 via interaction with the E47 DNA binding 
domain.
Besides its importance in regulating early B cell development, E2A may also play a 
role in later B cell differentiation. This is suggested by the fact that E2A is
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upregulated in lymphoid germinal centre cells and that class switching to some 
isotypes is inhibited in B cell lines that over express Id (inhibitor of development), 
which implies a role for bHLH family factors in terminal differentiation (Goldfarb, 
et al,  1996).
EBF
Early B cell factor (EBF) has been shown to regulate early events in B cell 
differentiation. It is expressed at all stages of differentiation, with the exception of 
plasma cells (Hagman, et al, 1991), and appears to be critical in the progression of 
B cell progenitors to the later stages of development. Both EBF and E2A deficient 
mice have defects at a similar B cell developmental stage and, therefore, these 
proteins may act co-operatively to regulate a common set of genes. Functional 
synergy between EBF and E47 is supported by the finding that ectopic expression of 
EBF, together with E47 dimers, induced the expression of VpreB and %5 B cell 
specific genes in in vitro studies (Sigvardsson, etal ,  1997).
BSAP/Pax-5
Differentiation stages that follow the early pro-B cell stage are regulated by BSAP 
(B cell specific activator protein), encoded by the pax-5 gene and expressed in all B 
cell types. Pax-5 is alternatively spliced into 4 different iso forms that are 
differentially expressed during B cell development (Zwollo, et al,  1997). Most 
isoforms are down-regulated during terminal differentiation, apart from pax-5b 
which remains expressed through this stage, suggesting different pax-5 isoforms 
may play distinct roles in B cell development. Mice carrying pax-5 gene targeted 
mutations are deficient in the progression of pro-B to pre-B cells in the BM 
(Urbanek, eta l ,  1994).
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Pax-5 is thought to function early in the development of foetal liver to allow cells to 
respond to stimuli specific to their micro-environment. Many genes are proposed to 
be potential pax-5 targets, but only CD 19 expression is extinguished in pax-5 
deficient B cells. Besides its role in early B cell development, pax-5 appears 
important in late B cell differentiation as well. This is indicated by the fact that anti­
sense oligos that reduce pax-5 expression levels block mature B cell proliferation in 
response to liposaccharide (Wakatsuki, eta l ,  1994). Also, cell lines overexpressing 
pax-5 display inefficient plasma cell formation, suggesting that down-regulation of 
pax-5 may be a prerequisite for terminal differentiation.
LEF-1
Lymphoid enhancer binding factor (LEF-1) is expressed in both pro- and pre-B cells, 
but not on immature or mature B lymphocytes (Reya, et ai,  2000). In the absence of 
LEF-1, B cell differentiation appears normal apart from a drop in the development of 
pro- and pre-B lymphocytes, which is thought to be a result of a decrease in the 
proliferation and survival of early B lineage progenitors. LEF-deficient pro-B 
lymphocytes have an increased level of Fas and c-myc RNA, both of which lead to 
an increase in apoptosis (Reya, et al., 2000). This paper also includes data which 
suggests that Wnt signalling is also important for the development of B lineage 
progenitors, with LEF-1 deficient pro-B cells showing a reduced response to Wnt-3. 
LEF-1 has been shown to be a target of Wnt signalling pathways (Behrens, et ai,
1996). In response to Wnt binding to its receptor (Frizzled) signal transduction leads 
to stabilisation of cytosolic p catenin, which then accumulates in the nucleus and 
functions as a co-activator for LEF-1 transcriptional responses.
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Regulation of late B cell differentiation
Following surface IgM expression mature B cells migrate to the periphery, express 
IgD and become fully capable of responding to antigen. Encounter of antigens 
induces other cascades of differentiation events which result in proliferation, plasma 
cell formation and immunoglobulin secretion. A number of transcription factors that 
are important for such events have been recently identified, including; oct-2, OCA- 
B, NFkB and Blimp-1 (Corcoran, et al,  1993; Schubert, et al,  1996; Turner, et al,
1994).
1.2.3: Antigen dependent B cell development
The very first encounter between naive B cells and antigen via the BCR activates 
proliferation leading to antigen uptake, processing, presentation and altered gene 
expression patterns. Molecules involved in T cell/B cell interactions are 
upregulated, including Class II MHC proteins, CD80 (B7-1), CD86 (B7-2) and 
CD40, which contacts CD40 ligand on T-cells (Clark & Lane, 1991; Glimcher & 
Kara, 1992).
Early B lineage cells face one type of choice during their maturation, to live or die. 
Their survival depends on the correct rearrangement of the antigen receptor gene 
segment at each stage of maturation (Rajewsky, 1996). Mature peripheral B cells 
face two types of choice during antigen-driven immune responses; firstly, to live or 
die and, secondly, to undergo terminal differentiation or to maintain their original 
identity. B cells have to make the choice between the plasma cell and the memory 
cell pathways upon activation. During early B cell activation, it is essential for some 
activated B cells to differentiate into plasma cells in order to produce the antibodies 
required for antigen fixation, uptake by macrophages and subsequent clearance. 
Mechanisms exist to prevent all cells from differentiating into plasma cells, in order
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for some to undergo affinity maturation to function as memory B cells. Similarly, 
after somatic mutation and selection in germinal centres (GC), high affinity GC B 
cells are required to differentiate into both plasma cells (to secrete high affinity 
antibody) and into memory B cells (which make a robust secondary response).
Germinal centre B cells will die unless they receive a positive signal, and this is 
clearly illustrated by the rapid onset of spontaneous apoptosis in isolated cultured 
cells (Liu, et al,  1989). This apoptosis-prone property correlates with a high 
expression of the apoptosis inducing genes; c-myc, p53, Bax and Fas and with the 
absence of the survival gene Bcl-2 (Martinez-Valdez, et al,  1996). Two surface 
signals have been identified as being able to rescue B cells from apoptosis; anti-Ig 
and anti-CD40. A model for positive selection would therefore be as such: after 
somatic hypermutation, mutants with low affinity antigen receptors apoptose due to 
their failure to bind antigens on follicular dendritic cells (FDC's). Those mutants 
with a high affinity antigen receptor will bind antigen on FDC's, pick it up, process 
and present it to GC T cells, thus activating them to deliver CD40 ligand (Kosco, et 
al, 1988; Liu, eta l ,  1992; MacLennan & Gray, 1986).
The danger of somatic hypermutation in GCs is the potential generation of high 
affinity autoreactive mutants, making a negative selection mechanism essential. The 
question is how the responding cells interpret an antigenic signal as positive or 
negative, and several factors have been found to influence this interpretation. The 
first is the length of antigen-receptor engagement or the concentration of antigen, 
and the second is dependent on T cell signals such as CD40 and Fas ligand. The 
survival effect of anti-Ig on GC B cells can be strongly enhanced and prolonged by 
anti-CD40 antibodies. In germinal centre B cells CD40 ligand represents the most 
powerful signal for maintenance of survival (Holder, et al,  1993), for promotion of 
proliferation (Banchereau & Rousset, 1991) and for inhibition of terminal 
differentiation of B cells (Callard, et al,  1995). Administration of anti-CD40 ligand
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antibodies or soluble CD40 to mice abolished their GCs and prevented memory B 
cell generation (Noelle, 1996). Germinal centre T cells not only express CD40 
ligand (Casamayor-Palleja, et al., 1995), but also Fas ligand. In vitro experiments 
demonstrated that anti-Fas antibodies could accelerate the rate of spontaneous 
apoptosis in GC B cells, and that CD40 ligand was not able to prevent this Fas- 
mediated apoptosis (Liu, et al., 1995). In fact, CD40 ligand can even prime resting 
B cells to be sensitive to Fas-mediated apoptosis, although anti-Ig can inhibit it 
(Rothstein, etai ,  1995).
Thus, germinal centre B cells will die if their antigen receptor is triggered for a 
prolonged period, if they do not interact with T cells within a short time scale or if 
they interact with CD40 ligand and Fas ligand-expressing T cells in the absence of B 
cell receptor triggering. The ability of Fas ligand to kill CD40 ligand-activated, but 
not antigen-activated, B cells provides a mechanism to prevent the survival of low- 
affinity or autoreactive GC B cells.
The third factor involved in GC B-cell response to antigen is the signal from 
follicular dendritic cells (FDCs). FDCs not only provide the optimal density of 
antigenic epitopes on their surface to stimulate high affinity GC B cells, but may 
also act as nurse cells (isolated GC B-cells survive well when they are in FDC 
clusters). The complement fragment, C3d, may signal GC B cells through CD21 and 
enhance the survival and proliferation effects of antigens (Dempsey, et al., 1996). 
CD23 might also be involved in this enhancing effect (Liu, etal., 1991).
1.2.4: Regulation of germinal centre B cell differentiation:
Germinal centre B cells can directly differentiate into both memory B cells and 
plasma cells (MacLennan, 1994; Zinkernagel, et al,  1996), the important question
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being whether a positive factor pushes the cells into a particular pathway or if 
negative signals prevent it from entering another.
Following successive rounds of somatic hypermutation (SHM), receptor editing, 
isotype switch recombination (ISR) and selection, germinal centre B cells are 
signalled to proliferate, exit the GC and differentiate into either memory or plasma 
cells. These cells lose their apoptotic phenotype by down-regulating Fas and 
increasing bcl-2, bcl-xL, cdk-4 and cdk-6 expression (Choe, et al,  1996; Ishida, et 
al,  1995). They switch from an autocrine to a paracrine dependence on IL-6, by 
down-regulating IL-6 expression and up-regulating IL-6R expression. In vitro 
experimental evidence (Arpin, et al,  1995) suggests that CD40 ligand directs the 
differentiation of GC B cells (CD20+/CD38+) towards the memory B cell pathway 
and, upon withdrawal of the CD40 ligand, their rapid differentiation into plasma 
cells. The inhibitory effect of CD40 ligand on B cell differentiation has been 
confirmed in other human B cell culture systems (Lane, et al,  1995). In vivo, CD40 
signalling induces a number of transcription factors, including; jun, NFkB and NF- 
AT (Choi, et al, 1994; Li, et al,  1996), and the timing and interplay of signals from 
the BCR, CD40, B7-1 and B7-2 and cytokines are also thought to determine cell fate 
(Urashima, etal ,  1996).
Cells exiting the germinal centre are still proliferating, but outside they rapidly 
become non-dividing plasma cells with a life-span of about one month. IL-6 
protects the plasma cells from apoptosis, induces Ig expression and leads to the 
activation of the cyclin-dependent kinase inhibitor p i8, blocking cell division 
(Morse, et al,  1997). Plasma cells have huge levels of Ig and J chain mRNA, with 
the expression of many genes being decreased, including; CD23, CD22, CD 19, 
Class-II MHC, c-myc, BSAP, EBF and CIITA.
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1.3: T cell lymphopoiesis
B lymphocytes are extremely important in the development of immune responses. 
As discussed, they express immunoglobulin and are activated when they bind to 
specific antigens. The story would not be complete, however, without mentioning a 
little about T-cell responses in this literature overview, as they play both a cytotoxic 
and helper role in the destruction of pathogen infected cells.
T lymphocytes are derived from bone marrow stem cells that differentiate as they 
pass through the thymus. The mature thymus is an epithelial lymphoid organ made 
up of three distinct regions, each containing cells in different maturational stages in 
the T cell pathway (Shortman & Wu, 1996; van Ewijk, 1991). Late in foetal 
development, BM derived T cell precursors arrive in the subcapsular region of the 
outer thymic cortex. Here, they are induced to undergo substantial proliferation into 
large lymphoblasts. These cells then progress to the deep cortex and pass through a 
network of dendritic epithelial cells, with the resulting small-medium lymphocytes 
passing into the medulla. The T-cells then mature further, under the influence of a 
loose network of epithelial and interdigitating dendritic cells. Following completion 
of maturation in the thymus, T cells leave the medulla by passing between the 
endothelial cells of small venules. Then, by acquiring specific surface molecules, 
they are able to bind selectively to the walls of post-capillary high endothelial 
venules. This enables T lymphocytes to cycle continuously from blood through the 
lymph nodes and spleen and to exit into the lymphatics, whence they return to the 
general circulation via the thoracic duct.
As in B cells, the process of maturation of T cells is accompanied by the acquisition 
of new properties and differentiation markers that include enzymes, glycoproteins 
and specific receptors (Petrie, et ai,  1990). The most important event in T cell 
maturation in the thymus is the acquisition of the specific antigen-recognising
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receptor. The T cell receptor (TCR) comprises an antigen recognising molecule (Ti) 
in tight association with a complex of invariant polypeptides (CD3). Two different 
types of Ti are found; the first is known as a(3 and the second as yô (Livak, et ai,
1995). An individual T cell can express either ap  or y6 as its receptor, but never 
both. The same fundamental principles of gene rearrangement, as were described in 
B cells, are applicable for the T cell receptor (Hardardottir, et a l ,  1995). 
Recombinase and joining sequences are used to link up a VJ or VDJ unit to generate 
the variable region specificity of particular polypeptide chains, T cell receptor genes 
also show allelic exclusion, ensuring that any one T cell makes a receptor with only 
a single antigenic specificity.
Other cell types involved in the immune response are the monocyte-macrophage 
series and the granulocytes. These cell types do not exhibit antigenic specificity, and 
among their many functions is the ability to process and present antigen to T cells.
1.4: Interleukin-4 (IL-4) 
1.4.1: Signalling and biological functions of IL-4
IL-4 is a pleiotropic type 1 cytokine produced by TH2 cells, basophils and mast cells 
in response to receptor-mediated activation events (Seder & Paul, 1994). Natural 
killer T cells (NK T cells), yô T cells and eosinophils have also been shown to 
produce IL-4 to a lesser extent (Dubucquoi, et al, 1994; Ferrick, et al,  1995), and 
mice lacking these cells fail to develop IL-4 dependent airway hypersensitivity upon 
immunisation with ovalbumin in alum (Zuany-Amorim, etal,  1998).
IL-4 plays a central role in regulating the differentiation of antigen-stimulated naive 
T cells, causing them to produce IL-4 and a series of other cytokines (including IL-5, 
IL-10 and IL-13). It also powerfully suppresses the appearance of interferon y (IFN-
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y) producing CD4+ T cells. Another function of major physiological importance is 
the role of IL-4 in the control of immunoglobulin class switching. IL-4 stimulation 
prompts human B cells to switch to the expression of IgE and IgG^ (Gascan, et al,
1991) and mouse B cells to IgE and IgGi (Vitetta, et al,  1985). In IL-4 and IL-4 
receptor knockout mice, as well as mice which lack STAT-6, IgE production is 
reduced by a factor of 100 or more (Akira & Kishimoto, 1997; Shimoda, et al,
1996) and IL-4 has a wide variety of other effects in haematopoietic tissues. IL-4 
increases the expression of class II MHC molecules in B cells (Noelle, et al,  1984), 
enhances CD23 expression (Defiance, etal ,  1987), upregulates expression of the IL- 
4 receptor (Ohara & Paul, 1988) and, in association with lipopolysaccharide, allows 
B cells to express Thy 1 (Snapper, et al,  1988). IL-4 also acts as a co-mitogen for B 
cell growth (Howard, et al,  1982). Although not a growth factor by itself for resting 
lymphocytes, IL-4 can prolong the lives of T and B cells in culture (Hu-Li, et al,  
1987) and can prevent apoptosis by factor-dependent myeloid lines that express IL-4 
receptors (Boise, e ta l ,  1995; Minshall, et al, 1997; Zamorano, e ta l ,  1996). IL-4 
has an important role in inflammation and adhesion, acting with tumour necrosis 
factor (TNF) to induce vascular cell adhesion molecule-1 (VCAM-1) expression on 
vascular endothelial cells (Thornhill, et al, 1991). This is thought to favour the 
recruitment of T cells and eosinophils, rather than granulocytes, into a site of 
inflammation.
1.4.2: The IL-4 receptor complex
IL-4 receptors are present in haematopoietic, endothelial, epithelial, muscle, 
fibroblast, hepatocyte and brain tissues, which is in keeping with the broad range of 
action of this cytokine (Lowenthal, et al,  1988). The receptor consists of a 140kDa 
IL-4Ra chain that binds IL-4 with high affinity, and heterodimerizes with a second 
chain to generate biochemical signals within the cell (Fujiwara, et al,  1997). This 
second chain is known as the gamma common (yc) chain, was first identified as a
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component of the ÏL-2 receptor (Leonard, et al,  1994; Letzelter, et al,  1998) and is 
thought to be the dominant chain involved in this heterodimerization.
The IL-4Ra chain also functions as a component of the IL-13 receptor (IL-13R) 
(Obiri, et al,  1997), which appears not to utilise the yc chains but employs IL-13Ra' 
chains in their place (Aman, et al,  1996). A number of cell lines lacking y: are still 
IL-4 responsive, raising the possibility that IL-13Ra' functions with IL-4Ra as a 
component of an IL-4R complex (Murata, et al,  1998). IL-4Ra is a member of the 
haematopoietin receptor superfamily, in which members share structural motifs in 
the extracellular region - consisting of type III fibronectin domains (Miyajima, et al,  
1992). These motifs include conserved paired Cys residues and a WSXWS motif, 
which is required for maintaining the receptor in a conformation favourable to 
cytokine binding (Livnah, et al,  1996). Structural alterations in the extracellular 
region of IL-4Ra results in altered receptor signalling capabilities. In fact, a variant 
of the human IL-4Ra chain containing an He 50 Val (150V) substitution has been 
isolated from atopic individuals, and has been shown to enhance signal transduction 
and increase production of IgE (Mitsuyasu, et al,  1998).
1.4.3; Activation of signal transduction by the IL-4R
The presence of IL-4 causes heterodimerization of the IL-4Ra chain with the yc 
chain, leading to the activation of IL-4R signalling pathways (Kammer, eta l ,  1996). 
This ligand-induced dimerization results in the activation of tyrosine kinases that 
phosphorylate cellular substrates and initiate signalling cascades (Miyajima, et al,  
1992). Since neither the IL-4Ra nor the yc chain has endogenous kinase activity, the 
IL-4R requires receptor-associated kinases for the initiation of signal transduction - a 
role which is filled by the Janus-family (JAK) tyrosine kinases (Ihle, 1995; 
Taniguchi, 1995).
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JAK 1, 2 and 3 have been demonstrated to be activated in response to IL-4R 
engagement and to associate with components of the IL-4R complex (Murata, et ai,  
1996; Witthuhn, et al,  1994). JAK 1 and JAK-2 have been proposed to associate 
with the IL-4Ra chain, while JAK-3 associates with the yc chain (Miyazaki, et al,  
1994; Russell, et a l ,  1994). IL-4 engagement of the IL-4Ra chain results in the 
tyrosine phosphorylation of JAK-1 and JAK-3, and studies have shown that it is the 
membrane proximal region containing the box 1 motif and the acidic region that are 
important for IL-4-mediated responses (Deutch, et al,  1995). The importance of this 
region may reflect the fact that it is a potential site for the interaction of JAK 1. In 
addition to the JAK family kinases, the Src family kinase Fes has also been reported 
to associate with the IL-4Ra and be activated in response to IL-4 stimulation 
(Izuhara, et al,  1994). Activation of the IL-4R-associated kinases leads to the 
tyrosine phosphorylation of the IL-4Ra chain itself, presumably on the 5 conserved 
Tyr residues in the cytoplasmic region. The identification of tyrosine residues 
critical for activation of signalling pathways and the analysis of molecules that 
interact with these residues has led to the biochemical characterisation of pathways 
activated by IL-4R engagement. Truncation and deletion mutants of the human IL- 
4 R a  chain were studied, with mutant receptors unable to transmit signals that 
normally result in phosphorylation (Keegan, et al,  1994; Koettnitz & Kalthoff, 
1993; Seldin & Leder, 1994).
Although the IL-4Ra C-terminal region does not appear to be essential for IL-4- 
stimulated proliferative responses, further analysis of deletion mutants have 
indicated that this region is important for the induction of IL-4 responsive genes 
(Ryan, et al,  1996). Thus, the IL-4Ra chain cytoplasmic region appears to have 3 
functionally distinct domains - one that acts as an interaction site for the Janus 
kinases, one required for activation of proliferative pathways and a third involved in 
pathways leading to the induction of gene expression. An overview of IL-4 induced 
signalling pathways is given in Figure 1.2, and these are described below.
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1.4.4: The insulin receptor substrate (1RS) signalling pathway
IL-4R activation was found to lead to the specific phosphorylation of a 170kDa 
phosphoprotein, initially termed the IL-4 phosphorylation substrate (4PS). This 4PS 
was subsequently shown to be related to insulin receptor substrate-1 (IRS-1), and 
was renamed IRS-2. The importance of IRS-1 and IRS-2 in response to IL-4 has 
been demonstrated using the factor-dependent myeloid progenitor cell line 32D, 
which does not express detectable levels of IRS-1 and IRS-2 (Wang, et al., 1993). 
These cells do not proliferate in response to IL-4 stimulation, but once stably 
transfected with IRS-1 and IRS-2 they phosphorylate the 1RS substrate they express 
when stimulated with IL-4 and show IL-4-dependent cell growth. These 
observations led to the conclusion that 1RS-1/2 molecules link the IL-4R to 
signalling pathways involved in cellular proliferation. IRS-1 and IRS-2 associate 
with IL-4Ra chain following activation and y: chain recruitment, and the tyrosine 
phosphorylation of IRS-1 and 2 is thought to involve the JAK kinases (Yin, et al,
1995). In proof, JAKs 1, 2 and 3 have been shown to directly phosphorylate IRS-1 
and experiments on JAK-deficient human fibrocarcinoma cells show that JAK-1 is 
essential for IL-4-driven IRS-1 stimulation (Yin, et al, 1995). The fact that the yc 
chain is required, suggests that other cytokines sharing this subunit may also use 1RS 
activation to promote cellular proliferation (Johnston, et al,  1995). The primary 
pathway linked to IRS-1 and IRS-2 phosphorylation is the PI-3 kinase pathway.
1.4.5: The phosphoinositide-3-kinase (PI-3-K) pathway
The principal form of PI-3-K activated by IL-4 is a complex of two subunits, an 
85kDa regulatory (p85) and a llOkDa catalytic (pi 10) subunit. The p85 subunit 
contains tandem SH2 domains in the C-terminus and an N-terminal SH3 domain 
(Kapeller & Cantley, 1994; Kapeller, et al, 1994). These SH2 domains flank a 104
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amino acid sequence that mediates the interaction with the pi 10 catalytic subunit 
(Dhand, et al,  1994); thus the p85 subunit acts as an adapter molecule linking the 
pi 10 subunit to tyrosine-phosphorylated molecules. IL-4 stimulation leads to the 
binding of the p85 subunit of the PI-3-K to phosphorylated 1RS-1/2 molecules, with 
IRS-1 and 2 having 4 and 10 potential sites of p85 subunit binding, respectively 
(Sun, et al,  1993). Interaction of the p85 subunit with phosphorylated 1RS-1/2 
results in a conformational change in the PI-3-K complex, leading to the activation 
of the pi 10 subunit (Dhand, et al,  1994). Once activated, the pi 10 subunit is 
capable of phosphorylating membrane lipids as well as Ser/Thr residues of proteins, 
and the lipid kinase activity mediates the transfer of phosphate from ATP to the D3 
position of inositol in the cellular membrane (Stephens, et al, 1993; Toker & Cantly,
1997). The most biologically important forms of phosphorylated 
phosphatidylinositol appear to be phosphatidylinositol-(3,4,5)-trisphosphate and 
phosphatidylinositol-(3,4)-bisphosphate, which are produced within seconds of 
stimulation (Stephens, et al,  1993) and are thought to act as second messenger 
molecules for IL-4 function. Phosphoinositides have also been implicated in the 
activation of a number of downstream kinases, including protein kinase C (PKC) and 
protein kinase B (PKB), that play a key role in cell survival (Franke, et al,  1997). It 
can be hypothesised that the activation of the PI-3-K pathway by IL-4 enhances cell 
survival through the production of phosphoinositides and the subsequent activation 
of kinases critical for cell survival, with inhibitors of PI-3-K (e.g. Wortmannin) 
blocking the ability of IL-4 to prevent apoptosis (Zamorano, et al ,  1996). It is 
thought that activation of the PI-3-K Ser/Thr kinase activity may result in a negative 
feedback loop that contributes to the regulation of the 1RS-1/2 signalling pathway.
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1.4.6: The Ras/MAPK pathway
Activation of the 1RS-1/2 pathway is associated with the activation of the 
Ras/MAPK pathway in response to a number of cytokines. Phosphorylated 1RS-1/2 
has been proposed to interact with the SH2 domain of the adapter Grb2, which is 
constitutively complexed to the guanine nucleotide exchange protein Sos (Chardin, 
et al,  1993). The primary function of Sos is to catalyse the exchange of GDP in 
inactive Ras for GTP, producing the active form of Ras (Downward, 1996).
The MAPK pathway is initiated by the Ser/Thr kinase Raf following its activation 
with Ras-GTP, with activated Raf initiating a cascade of kinase activation events 
resulting in the phosphorylation and activation of protein kinases ERK-1 and 2 
(Denhardt, 1996; Marais & Marshall, 1996). Active ERK-1/2 translocates to the 
nucleus and activates genes, such as c-fos, by phosphorylating specific 
transactivating factors (Davis, 1995). Activation of Jun nuclear kinase (JNK) and 
other small GTPases results in the nuclear phosphorylation and activation of c-Jun as 
well as other transcription factors. Although IL-4 dramatically activates 1RS-1/2 
phosphorylation, IL-4 activation of the Ras/MAPK pathway is not consistently 
observed. In fact, stimulation of a number of cell lines with IL-4 failed to result in 
any detectable activation of components of the Ras/MAPK pathway (Welham, et al,  
1994; Welham, et al,  1995), and led to the conclusion that IRS-1 phosphorylation 
and association with Grb2/Sos is not sufficient for the activation of cellular 
proliferation in certain cells and requires the activation of other molecules such as 
She (Pruett, et al,  1995). Other studies, however, have shown that IL-4 stimulation 
does lead to the activation of the Ras/MAPK pathway in certain cell types, including 
B cells (Crowley, et al,  1996; Wery, et al,  1996).
The adaptor protein she may play a pivotal role in the ability of certain cells to 
activate the Ras/MAPK pathway in response to IL-4, and it shares some structural
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and functional characteristics with 1RS-1/2. She contains 2 distinct domains capable 
of binding tyrosine-phosphorylated receptor sequences; The C-terminal region of the 
She protein contains an SH2 domain while the N-terminal region contains a PTB 
domain (Songyang, et al,  1993), These domains mediate She’s interaction with 
phosphorylated receptor molecules which leads to the phosphorylation of She itself 
at Tyr 317, serving as a docking site for the SH2 domain of Grb2 (Rozakis-Adcock, 
et a l ,  1992; Salcini, et a l ,  1994). She may link the Grb/Sos complex to 
phosphorylated receptors and thus catalyse Ras activation. Cbl, encoded by the 
proto-oncogene c-Cbl, is also an adaptor molecule and likewise plays a role in the 
activation of signalling pathways by IL-4 and is phosphorylated in response to IL-4 
stimulation (Ueno, et al,  1998). Cytokine-induced phosphorylation of Cbl has been 
demonstrated to link Grb2/Sos to receptor complexes and thus may play a role in the 
activation of the Ras/MAPK pathway (Fukazawa, et al,  1995; Panchamoorthy, et 
al ,  1996). IL-4-induced phosphorylation also leads to C bl’s association with the 
p85 subunit of PI-3-K, and Cbl also contains a proline-rich sequence that can 
interact with SH3 domains of different molecules (Fukazawa, et al,  1996).
1.4.7: The STAT-6 activation pathway
An important development in understanding the mechanism by which IL-4 and other 
cytokines rapidly activate gene expression has been the identification and 
characterisation of molecules termed signal transducers and activators of 
transcription (STAT's). Experiments have shown that JAK activation is required for 
STAT activation (Velazquez, et al,  1992), thus, the STAT activation pathway is 
mostly referred to as the JAK-STAT pathway. STAT-6 is the principal STAT 
activated in response to IL-4 stimulation and is critical in the activation or enhanced 
expression of many IL-4 responsive genes, including class II MHC molecules, 
germline IgE and CD23 (Delphin & Stavnezer, 1995; Kaplan, et al,  1996; 
Nakanishi, e t a l ,  1996; Shimoda, et a l ,  1996). The mechanism for STAT-6
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activation reflects the general model proposed for all STAT activation events, and is 
shown in Figure 1.3.
IL-4 engagement results in the activation of JAKl and JAK3, and the 
phosphorylation of specific tyrosine residues in the receptor cytoplasmic region. 
STAT-6 then binds to the phosphorylated receptor through a highly conserved SH2 
domain, enabling the activated kinases to phosphorylate STAT-6 at a C-terminal 
tyrosine residue (Mikita, et al., 1996). Once phosphorylated, the STAT-6 molecule 
disengages from the IL-4R and forms a homodimer with a second STAT-6 molecule 
through interaction of its SH2 domain with the C-terminal phosphotyrosine residue 
of other STAT-6 molecules. Dimerized STAT-6 complexes then translocate to the 
nucleus where they bind to specific DNA motifs in the promoter regions of 
responsive genes, usually binding to the particular sequence TTC-N4-GAA (Ihle, 
1996; Schindler, et al., 1995). The STAT-6 activation capability of different IL-4RCX 
mutants matched the ability of these receptors to stimulate IL-4-responsive gene 
expression, with mutants that lacked the gene regulation domain or had Tyr to Phe 
mutations in this region inducing little or STAT-6 phosphorylation and DNA 
binding (Ryan, et al., 1996). This suggested that phosphorylation of Tyr residues in 
the gene regulation domain is critical for STAT-6 activation and that activation of 
STAT-6 is a critical step leading to the expression of IL-4-responsive genes. There 
are 3 conserved Tyr motifs in the gene regulation domain of IL-4Ra, and these are 
27 amino acids away from each other. It is these motifs in the gene regulation 
domain that are proposed to be docking sites for the SH2 domain of STAT-6.
Deletion and mutational analysis of the STAT-6 protein itself have revealed and 
defined domains and residues within STAT-6 that are required for DNA binding and 
transcriptional activation. Deletions in the C-terminus blocked its ability to activate 
transcription (Mikita, et al,  1996), reflecting the importance of this region and the 
presence of critical residues. Mutation of a Tyr residue (Y641) in this C-terminal
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region also blocked DNA binding and STAT-6 function, and this residue is predicted 
to be the site of JAK phosphorylation and the target of SH2 domains of other STAT- 
6 molecules. Amino acid substitutions in the DNA binding domain also inhibited 
STAT-6 transcriptional activation, as did mutation of the conserved Arg residue in 
the SH2 domain (R562). The latter mutation is thought to prevent receptor 
interaction and dimerization of the mutated STAT-6 molecules. Naturally occurring 
deletion mutants of STAT-6, termed STAT-6b and STAT-6c, that result from 
alternative splicing have also been characterised (Patel, et aL, 1998). STAT-6b 
contains an N-terminal truncation that attenuates, but does not block, its function and 
co-expression of STAT-6b with full length STAT-6 did not alter the activation or 
function of the full length molecule (Patel, et aL, 1998). In contrast, STAT-6c 
contains a deletion in the SH2 domain and does not become phosphorylated in 
response to IL-4 stimulation.
The exact mechanism by which STATs activate transcription is still to be 
determined. They do, however, form complexes with other well characterised 
transcription factors such as c-Jun and SPl, and thus may activate transcription 
through co-operative interaction with these factors (Look, et aL, 1995; Schaefer, et 
al., 1995). Co-operative action with the transcription factors C/EBPa and NFkB 
appears to be particularly important in the transcriptional activation of the 
immunoglobulin £ gene by STAT-6 (Delphin & Stavnezer, 1995; Shen & Stavnezer, 
1998). Activation of the Ras/MAPK pathway is required for the full function of 
some STAT molecules (David, et al., 1995), and it is likely that Ser/Thr 
phosphorylation has a function in regulating STAT function. A serine residue in the 
C-terminal region of STAT-la, for example, has been shown to be phosphorylated 
in response to activation of the Ras/MAPK pathway (Wen, et al., 1995).
The critical importance of STAT-6 activation in vivo has been demonstrated in 
STAT-6 knockout mice (Huang & Paul, 1998), in which no detectable serum level
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of IgE or infection response can be found. These mice also fail to develop CD4+ T 
cells of the TH2 type in response to Nippostrongylus brasiliensis (Nb) infection 
(Nakanishi, et al,  1996). When the lymphocytes from STAT-6 knockout mice are 
studied in vitro, they fail to show switching to IgE and IgGl in response to EPS and 
IL-4, and also fail to show IL-4-mediated enhancement in expression of CD23, class 
II MHC molecules and IL-4 receptors. The specific immunodeficiency of STAT-6 
-/- mice is thought to result both from a block in IL-4-dependent Th2 cell 
development and from an inability of B cells to target the Ce gene for class 
switching, both because IL-4 is not being produced and because STAT-6 -/- cells 
would be insensitive even if IL-4 were being produced. The action of IL-4 as a co­
mitogen for B and T cells is not ablated in STAT-6 deficient mice, although these 
cells can display a loss of IL-4-dependent lymphocyte DNA synthesis. The 
impairment of IL-4 mediated growth effects in the cells of STAT-6 knockout mice 
may be a consequence of the reduced expression of factors required for IL-4-induced 
proliferation, including reduced IL-4Ra chain and IRS-2 expression (Huang & Paul,
1998). A polymorphism in the human IL-4Ra chain has been reported in patients 
with hyper-IgE syndrome and atopic dermatitis: Q567R in the core STAT-6 binding 
sequence (Hershey, et al,  1997), These patients responded to IL-4 with higher 
levels of expression of CD23 than patients with normal phenotype, implying that the 
IL-4a chain containing R567 have enhanced activity at the STAT-6 docking site and 
signal more vigorously upon IL-4 engagement,
1.4.8: Regulatory pathways of IL-4 receptor signalling
Regulatory pathways are important in the modulation of intracellular signals initiated 
by IL-4 and other cytokines. Just as the 1RS-1/2 and JAK/STAT signalling 
pathways are activated through several different cytokine and growth factor 
receptors, certain negative regulatory pathways also appear to be involved in the 
regulation of signalling by different cytokine receptors.
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Negative regulation of the JAK/STAT Pathway
The JAK/STAT pathway is one of the better characterised signal transduction 
pathways, and its activation is rapid and transient. There are several proposed 
different levels at which negative regulation can be achieved; these include down- 
regulation of the receptor ligand complex, degradation of signalling intermediates, 
inactivation of positive regulators by dephosphorylation and activation of specific 
suppressors.
Negative regulation of JAKs
Protein tyrosine phosphatases are obvious candidates for proteins that modulate 
tyrosine phosphorylation, and the phosphatase SHP-1 (also known as HCP, SH-PTP- 
1 and PTPIC) has been identified as a critical regulator (Fearson & Alexander, 
1997). SHP-1 is an SH2 domain-containing tyrosine phosphatase expressed in 
haematopoietic cells, and its importance is clearly demonstrated in mice which lack 
SHP-1 expression (Shultz, et ah, 1997; Shultz, et ciL, 1993). These mice display 
multiple haematopoietic abnormalities, including hyperproliferation and abnormal 
proliferation of granulocytes and macrophages. They also have an autoimmune-like 
phenotype. The defects present in these mice suggest that SHP-1 functions as a 
negative regulator of both lymphoid and myeloid lineages and, indeed, SHP-1 has 
been shown to directly associate with and dephosphorylate JAK 2 (Jiao, et al,
1996). This association is independent of the SH2 domain.
In certain circumstances, SHP-1 has been noted to have a role in promoting signal 
transduction, with the expression of a catalytically inactive form in HeLa cells noted 
to suppress epidermal growth factor (EGF) and IFN-y—induced STAT activation 
(You & Zhao, 1997). The related phosphatase SHP-2 is generally considered to be a
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positive regulator of signalling (Fearson & Alexander, 1997), but has been shown to 
down regulate signalling through gpl30 (Symes, etal ,  1997).
Suppressors of cytokine signalling (Socs)
Experiments to clone inhibitors of cytokine signalling have recently identified a new 
family of negative regulators, termed suppressors of cytokine signalling or SOCS. 
SOCS-1 was isolated by its ability to suppress macrophage differentiation of Ml 
cells in response to IL-6 (Starr, et al,  1997), and has subsequently been cloned 
independently by several groups. These groups used either a two hybrid screen to 
find proteins interacting with the kinase domain of JAK-2 (Endo, et al,  1997), or a 
screen to find proteins with homology to the SH2 domain of STATs (Naka, et al,
1997). The SOCS family comprises at least 8 proteins (SOCS 1-7, CIS) that are all 
composed of similar structures (Hilton, et al,  1998; Minamoto, et al,  1997; 
Yoshimura, et al,  1995). SOCS play a central role in determining the intensity and 
direction of cellular responses to many cytokines, and appear to switch off signals in 
at least 2 different ways. SOCS-1 functions by binding to activated JAK kinases and 
inhibiting their catalytic activity (Naka, et al,  1997; Starr, et al,  1997) while, in 
contrast, CIS appears to bind directly to phosphorylated receptors and compete with 
signalling intermediates for binding to the receptor (Matsumoto, et al ,  1997; 
Yoshimura, et al, 1995).
All SOCS proteins share a similar structure, including a central SH2 domain, a 
variable N-terminal region (in both length and amino-acid sequence) and a region of 
homology at the C-terminus termed the SOCS box (Hilton, et al, 1998). The SOCS 
box is a sequence of 40 amino-acids that is conserved throughout the SOCS family, 
and this bears no sequence homology to other known functional domains. Pairs of 
the proteins (CIS/SOCS-2, SOCS-l/SOCS-3, SOCS-4/SOCS-5, SOCS-6/SOCS-7) 
are more similar to each other than to the other SOCS proteins, suggesting they have
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diverged to fulfil specific functions. The specific role of each domain of SOCS in 
suppressing cytokine-induced responses remains unclear. The SH2 domain of 
SOCS-1 appears to be involved in the association of SOCS-1 with the 
phosphorylated JH-1 domain of JAK-2, although this interaction is not sufficient for 
the inhibition of a biological response (Endo, et al,  1997). Therefore, although the 
particular functions of the N-terminal and SOCS box regions have not been resolved, 
at least one of these domains appears to be critical for SOCS function.
Database searches have identified an additional 12 proteins that contain a C-terminal 
SOCS box (Hilton, et al, 1998), and these differ from SOCS proteins by having 
protein motifs other than the SH2 domain N-terminal to the SOCS box. The WSB 
(WD-40/SOCS box) proteins (WSBl and WSB2) contain WD-40 repeats, whereas 
others contain ankyrin repeats (ASB-1 to ASB-3) or a SPRY domain (SSB-1 to 
SSB-3) N-terminal to the SOCS box. RAR and RAR-like GTPases also contain a C- 
terminal SOCS box, and this conserved region in all 20 proteins is likely to play a 
similar and important role in each protein. However, whether this role is to inhibit 
kinase activity or to regulate other general functions such as protein stability or 
localisation remains to be determined - and it is the latter role that is considered most 
likely.
The expression of each of the SOCS genes is inducible in response to IL-6. 
Transcription of SOCS-1 and SOCS-3 is rapid and transient in response to IL-6, 
apparent within 20 minutes and declining in 2-4 hours. The kinetics of IL-6 
induction of the other SOCS family members differ considerably, with transcription 
of SOCS-2 and CIS persisting up to 24 hours after cytokine exposure and induction 
of SOCS-5 expression being delayed and only detectable 8-12 hours after 
stimulation. Transcriptional regulation of the SOCS genes is mediated by STAT 
transcription factors, a proposal supported by several lines of evidence. Firstly, the 
expression of dominant negative STAT-3 mutants blocks the IL-6-induced
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transcription of SOCS-1 in M l cells (Naka, et ai,  1997) and, secondly, CIS 
expression is induced by IL-3 and Epo (which mainly signal through STAT-5) 
(Matsumoto, et al,  1997). Since SOCS protein expression is induced by cytokine 
signal transduction pathways, and SOCS function to down-regulate these, they 
appear to form a negative feedback loop. Over time, expression of the SOCS genes 
is down-regulated to allow the cells to respond to future stimulation by cytokine. 
How SOCS inhibit JAK kinase activity is primarily unclear as, unlike SHP-1, the 
SOCS proteins do not appear to contain the motifs characteristic of known enzymes. 
The interaction of SOCS with the phosphotyrosine residues of JAKs may be 
sufficient to interfere with the function of JAK catalytic domains or, alternatively, 
SOCS may function by recruiting other molecules (such as phosphatases) to the 
JAKs. It appears likely that down-regulation of activated JAKs occurs either via 
dephosphorylation by phosphatases, or by specific degradation of phosphorylated 
JAKs.
Negative regulation of STATs
As well as the inactivation of receptors and JAK kinases, activated STAT dimers 
need to be down-regulated to switch off the signal in the nucleus. STAT activation 
is a transient event, and STAT molecules persist for, at most, a few hours after 
ligand stimulation. This inactivation can potentially be achieved in 3 ways: by 
specific inhibitors, by dephosphorylation by phosphatases or by proteolytic 
degradation.
Protein inhibitors of activated STATs (FIAS)
The PIAS family of negative regulators was originally identified using a two-hybrid 
screen for STAT-interacting proteins. PIAS-1 was identified as a specific interaction 
partner for STAT-1, and PIAS-3 was cloned on the basis of homology to PIAS-1
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(Chung, et al,  1997). PIAS-3 specifically associates with STAT-3 but not STAT-1, 
and appears to inhibit signal transduction by suppressing STAT activity. A putative 
zinc-binding motif is conserved in the PIAS family, but no other known motifs are 
present. PIAS-3 is expressed constitutively but associates with STAT-3 only upon 
stimulation of the cell with cytokines such as, IL-6, CNTF and OSM - suggesting 
that it specifically interacts with phosphorylated STAT molecules. The addition of 
PIAS-3 to IL-6-treated cell extracts completely suppressed the DNA binding activity 
of dimers containing STAT-3, although STAT-1 homo-dimers remained functional. 
It is notable that PIAS-3 is able to inhibit the DNA-binding activity of STAT- 
l/STAT-3 heterodimers and, considering that STAT-1 was not found in PIAS-3 
immunoprecipitates, PIAS-3 appears likely to bind to activated STAT-3 monomers - 
functioning either by preventing dimer formation or by mediating the dissociation of 
activated STAT dimers.
Phosphorylation of STATs on a single tyrosine residue at the C-terminus is critical 
for STAT activation and function (Shuai, et al,  1993). Phosphatase inhibitor studies 
have indicated a role for protein tyrosine phosphatases in down-regulating response 
to cytokines (Hague, et al,  1995), and pulse-chase labelling experiments have 
shown that the half-life of activated STATs is short, but turn-over of the proteins 
themselves is considerably slower (Haspel, et al,  1996; Lee, et a l ,  1997). An 
alternative mechanism for inactivating STAT dimers is proteolytic degradation, with 
inhibitors of proteosome activity being shown to stabilise the activation of STATs. 
It is still unclear, though, whether the proteasomes directly target STATs (Kim &
Maniatis, 1996) or regulate signalling intermediates upstream (Yu & Burakoff, 
1997).
1.5: Interleukin-13 (IL-13)
In addition to IL-4, IL-13 is also a pleiotropic cytokine produced by T and B cells. 
IL-4R and IL-13R both share the IL-4Ra chain and promote STAT-6 activation, 
with mice deficient in either IL-4, IL-13, IL-4R or STAT-6 lacking IgE synthesis 
and TH-2 type reactions (Izuhara & Shirakawa, 1999). IL-4 and IL-13 genes are 
localised within a 25kb region on chromosome 5q31, a region which genome 
searches have identified as having a strong linkage with atopy and allergic asthma 
(Ober, 1998). As mentioned in the IL-4 section of this chapter (1.5.2) the IL-4Ra 
chain is an essential component of the IL-13R, along with one of either of two 
known component chains (IL-13Ral or IL-13Ra2). IL-13Ral has been shown to 
bind weakly to IL-13, but when joined in a heterodimer to lL-4Ra acts as highly 
functional IL-13 and IL-4 receptor. In contrast, IL-13Ra2 alone binds to IL-13 with 
high affinity. However a functional role for this latter interaction is unknown, as it is 
not known to be expressed on either B or T cells (Donaldson, et ai,  1998). A 
schematic representation of IL-4 and IL-13 signalling is shown in Figure 1.3. IL-4 
binds and activates both receptor types through interacting with the IL-4Ra chain, 
whereas IL-13 only binds and activates the combined IL-4Ra-IL13Ral receptor 
(through the IL-13Ral chain). The IL-4Ra-yc and IL-4Ra-IL-13Ra-l receptors 
have been named the Type-1 and Type-2 IL-4 receptors, respectively, with Type-1 
being expressed on both T and B cells and Type-2 solely on B cells. Thus, IL-4 can 
stimulate both T and B cells but IL-13 can activate B cells only. Briefly, IL-4 and 
IL-13 signalling pathways lead to IgE and CD23 expression as follows. The IL-4Ra 
chain associates with JAR-1 and the yc chain with JAK-3, whereas the IL-13Ral is 
associated with Tyk-2. Both receptors lead to STAT-6 activation, with JAK-1 and 
STAT-6 but not JAK-3 being activated by IL-13. This implies that STAT-6 
activation is due to the STAT-6 docking to the IL-4Ra chain.
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1.6: B cell and T cell interaction, CD40 and CD40 ligand
CD40 is a 45-50kDa glycoprotein (Panlie & Rosen, 1989) expressed on B cells, T 
cells and FDCs (Banchereaii, et al,  1994). CD40 is a member of the tumour 
necrosis factor (TNF) receptor superfamily which includes, and has a high degree of 
homology with, the TNF-a receptor and Fas, The ligand for CD40 (CD40L) is a 
39kDa member of the TNF family and is found on T cells, mast cells and basophils. 
Levels of CD40L expression on T cells increase as the cells mature (Nonoyama, et 
al ,  1995). As described in section 1.3.4 of this thesis, CD40L directs germinal B 
cell differentiation and the importance of CD40 ligation for B cell growth and 
survival is highlighted through the X-linked immunodeficiency disease, hyper-IgM 
syndrome (Ki’oczek, et al,  1994). This syndrome is caused by mutations in, or the 
defective expression of, CD40L - where serum IgA, IgE and IgG levels are relatively 
low. In addition to its role in isotype switching, B cell CD40-T cell CD40L 
interaction is also involved in rescuing B cells from apoptosis (Holder, et al, 1993).
The promotion of IgE synthesis and CD23 expression on uncommitted naive B cells 
requires a minimum of two signals, the first from IL-4 (or IL-13) and the second 
through CD40-CD40L interaction (Bonnefoy, et a l ,  1995). Burlinson and 
colleagues reported that ligation of CD40 with either trimeric sCD40L or anti-CD40 
monoclonal antibody induced both CD23 and CD25 expression on resting tonsillar B 
cells (Burlinson, et al,  1996). This result contrasted with the data of Valle et al 
(Valle, et al,  1989), who reported that anti-CD40 monoclonal antibody 89 (mAb89) 
stimulation did not lead to CD23 stimulation on tonsillar B cells. Work by Heath et 
al (Heath, et al,  1994) confirmed the theory that anti-CD40 antibodies evoke 
different responses depending on which distinct epitope they recognise and bind to.
Early signalling events following B cell CD40 engagement have been investigated 
by a number of groups, the consensus being that protein tyrosine kinase (PTK)
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activity is an important mediator (Kato, et ai,  1994; Ren, et ai,  1994). However, 
analysis of the cytoplasmic tail of CD40 revealed no intrinsic enzymatic activity, 
suggesting that the observed PTK activity is due to an association with soluble 
kinases (Ren, et al,  1994). Extensive studies have revealed that the src-type kinases 
lyn, fyn and syk and PI-3 kinase were all phosphorylated and activated upon CD40 
ligation (Fans, et al,  1994; Ren, et al,  1994). Engagement of CD40 also resulted in 
the phosphorylation of phospholipase CyZ (PLCy2), but not PLCyl, which is 
consistent with the increased production of inositol-(l, 4, 5)-trisphosphate (IP3). 
When CD40L-expressing T cells were used to stimulate B cells tyrosine- 
phosphorylation and increased cyclic AMP (cAMP) levels were also noted (Kato, et 
al,  1994), along with a role for PKA.
Enhanced CD23 expression is noted when B cells are co-induced with both sCD40L 
and IL-4 (Burlinson, et al,  1996). This increase in CD23 is thought to be due to the 
ability of IL-4 to elevate CD40 levels in B cells, thus increasing the number of 
receptors available for engaging sCD40L.
1.7: CD25 ( IL-2Ra)
CD23 is the main topic of study for the research included in this thesis, although 
CD25 expression is analysed briefly in the LM-PCR experiments detailed in chapter 
5. It is, therefore, necessary to briefly introduce CD25 at this stage.
CD25 is the unique, inducible a  chain subunit of the receptor for interleukin 2 (IL- 
2R). It is 55kDa in size and is one of three IL-2R subunits, the others being the 
constitutively expressed 75kDa |3 and 64kDa yc chains - also termed CD 122 and 
CD 132, respectively. IL-2 is a multi-functional cytokine that modulates the growth, 
differentiation and apoptosis of many cells including B cells, T cells, and monocytes 
(Smith, 1988). CD25 is expressed at an early stage of lymphopoiesis and marks the
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initiation of T cell receptor (TCR) rearrangement and commitment to the T cell 
lineage, prior to expression being lost until induction in mature resting T cells 
(Godfrey & Zlotnick, 1993; Rothenberg, 1992). In human mature B cells, CD25 is 
upregulated in response to B cell receptor (BCR) activation (Benschop & Cambier, 
1999; Burlinson, et al,  1996; Hewitt, et al,  1997) and following IL-4 (Butcher, et 
al ,  1990), anti-CD40 antibody and anti-immunoglobulin stimulation of resting B 
cells (Hewitt et al, 1997; Burlinson et al, 1995).
Expression of human CD25 is regulated by three positive regulatory regions (PRR I- 
III) and two negative regulatory regions (NRR I-II) in the proximal region of the 
CD25 gene. PRR I contains binding sites for NFkB and serum response factor 
(SRF) (Pierce, et al,  1995), and is responsive to mitogenic and antigenic signals 
resulting from TCR activation or stimulation. PRR II is a T cell specific promoter, 
contains binding sites for Ets family protein Elf-1 (Graves & Petersen, 1998) and the 
chromatin associated protein HMG-1 (Landsman & Bustin, 1993), and is involved in 
basal promoter activity (John, et al,  1996). PRR III is similar to PRR II, with the 
addition of GATA and STAT-5 binding proteins, the STAT-5 site being activated in 
response to IL-2 ligation of the IL-2R.
The two negative regulatory regions of the CD25 promoter were identified using 
transient transfection studies (Hewitt, et al,  1997; Smith & Greene, 1989), with a 
31bp region of NRE I being involved in transcription regulation and referred to as 
the negative regulatory element (NRE). NRE is bound by a 50kDa binding protein 
(NRE-BP) which facilitates a repression in NRE activity, with the binding of NRE- 
BP being lost and CD25 expression being reduced upon stimulation of cells with IL- 
4 (Hewitt, et al,  1997). The identity of NRE-BP remains undefined, although an 
interferon-regulated gene called stimulated trans-acting factor of 50kDa (Staf-50) 
has been suggested as a possible candidate for this protein (Tissot & Mechti, 1995; 
Tissot, etal ,  1996).
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1.8: CD23 (FceRII)
1.8.1: Introduction
Human CD23 is a leukocyte cell surface antigen expressed on a wide range of cells 
of haematopoietic lineage, such as B cells, T cells and monocytes (Bonnefoy, et al,
1997). CD23 has multiple functions, particularly in B lymphocytes where it is 
proposed to have roles in the regulation of cell growth and development, IgE 
regulation, antigen presentation, cell adhesion and in the prevention of apoptosis 
(Yokota, et ai,  1988). It is teiTned the low affinity receptor for IgE (FceRII) and is 
known to exist in both membrane bound and soluble forms.
1.8.2: Discovery and distribution
The low affinity receptor for IgE (CD23) has long been a subject of debate, since its 
initial identification by Gonzalez-Molina and Spiegelberg in 1977 (Gonzalez-Molina 
& Spiegelberg, 1977). In fact, it was not until 1987 that Yukawa and colleagues 
(Yukawa, et al ,  1987) brought together two separate avenues of immunological 
research to identify it unequivocally.
Gonzalez-Molina and Spiegelberg (1977) discovered a molecule with low affinity 
binding to IgE in human B lymphocytes that was clearly distinct from the high 
affinity IgE receptor found on mast cells and basophils. In 1981, Kinter and Sugden 
described a panel of monoclonal antibodies that precipitated out a 45kDa 
glycoprotein from the surface of Epstein-Barr virus (EBV) and termed it EBVCS, for 
EBV cell surface antigen (Kintner & Sugden, 1981). However this EBVCS was also 
found to be expressed on normal and, in particular, activated B cells and in 1986 
Thoiiey-Lawson et al detected that it had a rapid turnover from the cell surface of
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transformed B cells. This turnover was determined to be as a result of proteolysis of 
the EBVCS antigen, which was now being termed Blast-2 (Thorley-Lawson, et al,  
1986). Finally in 1987, Yukawa et al showed that antibodies within the CD23 
cluster (including Blast-2) reacted with, and specifically precipitated, the 45kDa 
product of cDNA encoding for the low affinity IgE receptor (FceRII) (Yukawa, et 
al,  1987). Thus, the low affinity receptor for IgE, EBVCS and Blast-2 were one and 
the same entity, and emerged as CD23; a multi-functional receptor with cytokine 
effects.
1.8.3; Structure
Human CD23 is a single chain 45kDa glycoprotein, containing 1 chain of N-linked 
complex carbohydrates, several O-linked carbohydrates and sialic acid residues. 
Features of this glycoprotein are structurally and functionally unique compared to 
other immunoglobulin (Ig) receptors and indeed, unlike other Fc receptors, CD23 
does not belong to the Ig gene superfamily - being a novel type II membrane 
glycoprotein. In type II membrane proteins, their orientation is in the reverse 
configuration to the Ig superfamily, such that the amino terminus lies inside the cell 
and the carboxy terminus outside. The short intra-cytoplasinic tail consists of 23 
residues, the single transmembrane domain of 20 residues and a large C-terminal 
extracellular region of 277 residues. CD23 is also a member of the C-type lectin 
family (Ludin, et al,  1987), a family of proteins which bind carbohydrates in a 
calcium dependent manner (Drickamer, 1988). The region homologous to the C- 
type lectins spans from cysteine 163 to 282, contains 4 highly conserved cysteines 
(positions 191, 259, 273 and 282) and 2 partially conserved cysteines (positions 163 
and 174) (Kikutani, et al,  1986; Ludin, et al,  1987). The lectin domain of CD23 
has been subjected to mutational analysis and found to contain the IgE binding site 
(Bettler, eta l ,  1992).
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CD23 is an unique differentiation antigen for B cells, being restricted to certain 
stages of B cell development. It is expressed on p+/ô+ mature B cells, but not 
immature bone marrow cells, and is thought to be involved in the regulation of 
growth and differentiation of B cells. The presence of CD23 has also been found on 
certain populations of eosinophils and monocytes, and is thought to be an important 
mediator in allergic reactions and in the immune response to parasitic infection 
(Capron & Dessaint, 1986). The binding of IgE to CD23 is calcium dependent 
(Richards & Katz, 1990) and can be inhibited by fucose-1-phosphate (Delespesse, et 
a l ,  1992). In addition, this interaction also appears to involve protein-protein 
interactions, as de-glycosylation of IgE does not eliminate binding (Vercelli, et al,  
1989). The cytokine effects of CD23 are mediated by an epitope distinct from the 
IgE binding site (Mossalayi, et al,  1992), and will be fully discussed later.
The extracellular portion of CD23, as stated, has a domain homologous to the C-type 
lectins and an extended C-terminal tail containing a reverse ROD (Arg, Gly, Asp) 
sequence that may act in cell adhesion. Another feature of CD23 structure is the 
presence of 3 short consensus repeats of 21 amino acids, located between the N- 
glycosylation site and the lectin domain. This repeated region contains 5 heptadic 
repeats of leucine or isoleucine, forming a leucine zipper motif. This region of 
CD23 adopts an alpha-helical coiled-coil structure, representing a "stalk" structure 
separating the lectin heads from the cell membrane. It is believed that this stalk 
region mediates the formation of protein dimers or trimers at the cell surface (Beavil, 
et al ,  1992) and more recent studies have found that, when subjected to protein- 
protein chemical cross-linking, CD23 forms trimers on the surface of cells (Beavil, 
eta l ,  1995)
Similar to other Fc receptors, soluble CD23 (sCD23) fragments are cleaved from full 
length CD23 and released into the extracellular fluids. Five major sCD23 fragments 
of molecular masses 37, 33, 29, 25 and 16kDa have been identified, and are all
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derived from cleavage sites situated in the 45kDa CD23 stalk region. The soluble 
components are first released as the 37kDa oligomeric form, which is subsequently 
cleaved to the other forms, of which the 25kDa form is the most stable (Letellier, et 
al ,  1989). All soluble forms apart from the 16kDa species contain the complete 
lectin domain and significant lengths of coiled-coil, and thus retain the ability to bind 
IgE. The 16kDa sCD23 binds IgE with much lower affinity, a property believed to 
be due to the monomeric nature of this soluble form (Bettler, et al,  1989). All 
fragments bind to IgE, with those larger than and including 25kDa promoting IgE 
synthesis - and the 16kDa fragment thought to inhibit it. All forms of sCD23 are 
also thought to possess other important cytokine activities (Beavil, et al,  1995). The 
rate of cleavage of CD23 is significantly reduced by IgE and anti-CD23 antibodies, 
and is increased after the use of agents that prevent CD23 glycosylation. This 
indicates that the carbohydrate chain exerts a stabilising effect on CD23 (Delespesse, 
et a l ,  1989). Early studies suggested that CD23 was cleaved autocatalytically 
(Letellier, et al,  1990), although CD23 does not resemble any known proteases. 
Marolewski and colleagues demonstrated in 1998 that, in several human cell types, 
the initial release of CD23 from the cell surface is mediated by a membrane bound 
metalloprotease (Marolewski, et al,  1998). This process can be blocked by specific 
protease inhibitors. This group subsequently suggested that the proposal of auto­
proteolysis is a result of the co-purification of the metalloprotease with CD23, and 
speculate that there may be a whole family of these metalloproteases which mediate 
sCD23 fragment cleavage (Marolewski, et al,  1998).
1.8.4: Cytokine effects of sCD23
Human CD23 and its soluble forms display various biological activities in addition 
to their IgE binding function. These effects include: the promotion of myeloid 
colony generation, induction of CD3 expressing human thymocytes (Mossalayi, et 
al ,  1990), facilitation of cell adhesion and antigen presentation by B cells and
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monocytes to T cells (Bertho, et a l ,  1991; Gordon, et a l ,  1989). In order to 
ascertain whether the cytokine effects of CD23 and its binding to IgE were mediated 
by the same epitope, Mossalayi et al (Mossalayi, et a l ,  1992) prepared CD23 and 
sCD23 constructs and assayed their ability to bind IgE, sustain haematopoietic cell 
differentiation and to regulate IgE secretion in B cells. The IgE binding domain was 
subsequently mapped to residues running from Cysl63 to Cys 282, with the cytokine 
activities seeming to require both this domain and Cys288. The assumption was 
made, therefore, that the CD23 domain necessary for cytokine activities is over­
lapping but distinct from the IgE binding domain (Mossalayi, e ta l ,  1990),
1.8.5: Ligands for CD23 other than IgE
In addition to IgE binding, CD23 and sCD23 have been implicated in a number of 
other activities (1.8.4). There are several reported receptors for CD23, including: 
CD21, CDllb-CD18, CDllc-CD18 (Lecoanet-Henchoz, e t a l ,  1995) and the 
recently characterised avp3 (Hermann, et al,  1999) and av^5 (Matheson, et al ,  
2001) vitronectin receptors. The latter receptor was first suggested to exist in 1997 as 
a receptor in the pre-B leukaemic cell line SMS-SB (White, e ta l ,  1997).
CD21
Human CD21 is 145kDa membrane glycoprotein expressed on various cell 
populations including B cells, T cells and follicular dendritic cells (FDCs). CD21 
has been identified as a receptor for the gp350/220 envelope protein of EBV 
(Tanner, et al,  1987) and interferon-a (Declayre, eta l ,  1991), and is also known as 
the complement receptor-2 (CR-2) (Weis, et al ,  1984). CD21 is present on the 
membrane of B cells within a molecular complex, in association with CD 19, Leu 13 
and TAPA-1 (Bradbury, et a l ,  1992). Structurally, CD21 is composed of an 
extracellular domain, of approximately 16 short consensus repeats (SCRs) of 60 to
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75 amino acids, followed by a transmembrane domain and an intracytoplasmic 
domain consisting of 34 amino acids (Weis, et ai, 1988). Aubry and colleagues in 
1992 revealed that CD21 was a ligand for CD23 by the binding of CD23 liposomes 
to cells transfected with recombinant CD21 and, subsequently, in 1994 determined 
the sites of CD23 interaction on CD21 as the SCRs 5 to 8 (Aubry, et a i,  1994; 
Aubry, et a i,  1992). This was accomplished by the use of CD21 mutants bearing 
SCR deletions and the binding was found to involve a lectin interaction, as 
tunicamycin treatment inhibited CD21/CD23 binding in this region. Tunicamycin 
inhibits N-linked glycosylation of proteins during their biosynthesis (Sarfati, et al,
1992). Short consensus repeats 1-2 were also found to be involved in CD21 to 
CD23 binding, but via a protein-protein interaction (Aubry, et ai,  1994).
CDllb-CD18/CDllc-CD18: P2 integrins
C D llb  (17kDa) and C D llc (15kDa) represent the a  chains of P2 integrin adhesion 
molecules which are known to participate in many cell-cell and cell-matrix 
interactions. These a  chains exist as heterodimers with the common P subunit 
known as CD18, to form the CDllb-CD18 (Mac-1) and CDllc-CD18 (pl50, 95) 
glycoprotein receptors (Corbi, eta l,  1988; Kurzinger & Springer, 1982).
Lecoanet-Henchoz and colleagues proved that CD23 bound to CDl lb and CDl Ic on 
human monocytes using CD23 containing liposomes bound to Cos 7 cells 
transfected with CDllb-CD18 and CDllc-CD18 (Lecoanet-Henchoz, et al, 1995). 
They suggested that the interaction involved both lectin and protein-protein 
interactions, as with CD21, as IgE binding to the lectin domain of CD23 inhibits the 
binding of monocytes. CD23 binding to monocytes via CDl lb and C D llc leads to 
a marked increase in nitric oxide levels and the release of pro-inflammatory 
cytokines such as XL-la and p, IL-6, IFN-yand TNF-a (Lecoanet-Henchoz, et a l,
1995).
45
avP3
The avpa integrin is an ubiquitous receptor that interacts with several ligands, such 
as vitronectin (Vn), fibronectin (Fn), osteopontin and metalloproteinase MMP-2 
(Felding-Habermann & Cheresh, 1993). avP3 plays an important role in tumour cell 
invasion, angiogenesis and in the phagocytosis of apoptotic cells (Gladson & 
Cheresh, 1994), and is usually found physically and functionally associated with a 
member of the multispan transmembrane receptor family, CD47. Hermann and 
colleagues concluded that avp3 and its associated CD47 molecule may function as a 
receptor for sCD23 to mediate pro-inflammatory activity and, thus, may be involved 
in inflammatory processes (Hermann, et al, 1999).
avp5
avp5 has recently been described in this laboratory as a further receptor for CD23. 
The presence of a receptor other than CD21 or the p2 integrins C D llb  and CDl Ic 
was originally noted on the human pre-B-like leukaemic cell line SMS-SB (White, et 
a l,  1997). This receptor was found to be involved in the rescue of SMS-SB cells 
from apoptosis, possibly by influencing the expression of Bcl-2 (White, et al,  1997). 
Affinity isolation experiments by Matheson and colleagues (Matheson, et a l,  2001) 
reported that human pre-B like cell lines, including SMS-SB, bind CD23 via the 
avp5 vitronectin receptor (VnR) complex.
1.8.6; Isoforms of CD23
Several lines of evidence suggest that CD23 has two main functions, playing a role 
in B cell growth and differentiation (Gordon, et al, 1987; Kolb, et al, 1990) and 
having a major part in the effector phases of IgE-mediated immunity and allergy
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(Kehry & Yamashita, 1989; Luo, et al,  1991). The existence of two CD23 isoforms 
was proposed and established by Yokota et al (Yokota, et a l,  1988), with the 
difference between the isoforms being solely in 6 or 7 amino-acids in the N-terminal 
cytoplasmic region (see Figure 1.4). The isoforms, termed CD23a and CD23b, are 
generated using different transcription initiation sites and differential RNA splicing 
of transcripts of the single CD23 gene (see Figure 1.5), located on chromosome 19 
(Suter, et a l,  1987; Wendel-Hansen, et al,  1990). The human CD23 gene (EMBL 
accession number: M30447) has been specifically mapped to chromosome 19pl3.3, 
spanning approximately 13kb and consisting of 11 exons (Ludin, et al, 1987). The 
promoter regions of each CD23 isoform will be studied in detail in chapter 4 of this 
thesis and they have been shown to possess distinct response elements. The 
promoter region for CD23a shows two IL-4 response elements (IL-4RE), followed 
by an NFkB site, a glucocorticoid response element (GRE) and a B cell activator 
protein (BSAP) or Pax-5 binding site. By contrast, the CD23b promoter region 
comprises two IL-4RE sites surrounding an NFkB site, and followed by two 
activated protein 1 (AP-1) binding sites. CD23a is found constitutively and cell 
type-specifically in B cells, whereas CD23b is expressed on several cell types of 
haematopoietic lineage following activation with various stimulants (IL-4, IL-13, 
anti-CD40, anti-p chain, PMA). The presence of both cell type-specific and 
stimulant-specific expression of the two CD23 variants suggests that each isoform 
has a different cellular function, despite having identical extracellular domains.
Three species of FcgRII mRNA have been identified which differ only within their 5' 
regions. B cells are known to express all three types, with other cells such as 
monocytes and T cells having only one. Two mRNA's code for CD23a and their 
sequences differ in the 5' untranslated region by 4 nucleotides (Kikutani, et al, 
1986), which is thought to be due to differential splicing. The third mRNA codes for 
CD23b and is completely different from the other two in the 5’ upstream region, in a 
position that corresponds to the exon 2-3 boundary of FcgRIIa mRNA. Cloning and
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sequencing have demonstrated that the difference is explained by a novel exon 
specific for FcgRIIb located between exons 2 and 3 (see figure 1.5).
The regulated manner of CD23 gene expression suggests that CD23a and CD23b are 
involved in B cell function and IgE mediated immunity, respectively. Yokota et al 
in 1992 (Yokota, et a l ,  1992) elucidated a molecular explanation for the functional 
difference between these two isoforms, and demonstrated that endocytosis was 
mediated only through CD23a and that phagocytosis is mediated through CD23b. 
As CD23a and CD23b differ only in 6 or 7 amino acid residues at their N-terminal 
cytoplasmic domain, the suggestion is that these regions must contain critical 
sequences to account for these functional differences. It is thought that it is the 
aromatic amino-acids in the cytoplasmic region that are required for the endocytosis 
of various receptors. This is exemplified by the fact that the FceRIIa contains a 
tyrosine residue at position 6, whereas FcgRIIb has a serine residue at the equivalent
position (Yokota, et a l ,  1992). In a similar w^y, the two amino-acids asparagine 
and proline at positions 2 and 3 of FcgRIIb are essential for phagocytosis. It is
notable that mutations in these important positions have an effect on whether 
endocytosis or phagocytosis of each individual receptor occurs, in fact mutant 
FceRIIb which contains both amino acid residues required for endocytosis and
phagocytosis can mediate both activities (Yokota, e ta l ,  1992).
1.8.7: Epstein-Barr virus (EBV) regulation of CD23 expression
Epstein-Barr virus (EBV)-transformed B cells show increased levels of cell surface 
CD23 expression. EBV is associated with a number of human B cell malignancies, 
including Burkitt's lymphoma, post-transplant lymphoma and central nervous system 
(CNS) lymphoma in AIDS. A proportion of Hodgkin's lymphoma is also EBV 
associated (Filipovich, e ta l ,  1990; Herbst, e ta l ,  1991). EBV infection of primary
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B cells leads to continually proliferating lymphoblastoid cell lines, and the changes 
in B cell growth are likely to play a significant role in lymphomagenesis.
The first genes expressed during EBV infection are EBNA-LP and EBNA-2 (Alfieri, 
et ai, 1991; Allday, et a i,  1989). Initially the latency W promoter (Wp) is used and 
followed by the latency C promoter (Cp), which leads to the expression of EBNA- 
3A, -3B, -3C and EBNA-1 (Bodescot, et al,  1987). In addition to its role in the 
regulation of EBV latency gene expression, EBNA-2 also alters the expression of 
cellular genes. CD23 is upregulated by EBNA-2, as is CD21 (Calender, et al., 1987; 
Cordier, et a i,  1990), with EBV transformed cells highly expressing CD23 being 
immortal (Azim & Crawford, 1988). This transformed cell immortality is suggested 
to be related to the anti-apoptotic properties ascribed to CD23 which are discussed 
by Liu et al (Liu, et al., 1991). EBV transformed B cells express both CD23 
isoforms (a and b) (Cordier, et ai, 1990). Ling and co-workers demonstrated that 
EBNA-2 upregulation of the EBV latency promoter Cp and the cellular CD23 
promoter both utilise a common targeting intermediate known as CBF-1 (Ling, et 
al., 1994).
1.8.8: CD23 and IgE production
As the low affinity receptor for IgE, CD23 has been implicated in IgE regulation 
after the demonstration that anti-CD23 specific antibodies block the spontaneous 
release of IgE by peripheral blood lymphocytes (PBL's) (Sarfati, et a i,  1988), as 
well as IgE production by IL-4-treated normal cells. The cytokines IL-4 and IL-13, 
which induce CD23 expression, have also been found to induce IgE production by 
normal B cells through IgE isotype switching (Punnonen, et a i ,  1993). The 
evidence for this is that IL-4-induced IgE synthesis has been found to be blocked by 
interferons (IFN) y, a  and prostaglandin E2, which also inhibit the induction of 
CD23 by IL-4 on B cells. Bonnefoy et al in 1990 demonstrated that this inhibition
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is restricted to certain CD23 epitopes involved in IgE binding, suggesting that anti- 
CD23 antibodies bind surface CD23 and interfere with T and B cell interaction, 
which is necessary for IgE production (Bonnefoy, et ai, 1990). Further evidence for 
this model is that IgE production is increased on engagement of CD21 by 
recombinant soluble CD23 or anti-CD21 antibody (Aubry, et al., 1992). The above 
data suggest a central role for CD23 in IgE production, and recent investigations 
with CD23 knockout mice have further characterised a negative feedback 
mechanism (see 1.9.10).
1.8.9: CD23 expression in disease
In humans the expression of CD23 is strikingly increased in many atopic 
(Yanagihara, et a i,  1992; Yanagihara, et ai, 1990), autoimmune (Bansal, et al., 
1992; Delespesse, et al., 1991) and leukaemic (Sarfati, etal., 1988) disorders in the 
form of both membrane expression on B cells and monocytes and, more noticeably, 
in terms of soluble CD23 (sCD23) production (Gagro & Rabatic, 1994).
Allergy and atopy
Allergy can be defined as an inappropriate response of the immune system to an 
otherwise harmless challenge from environmental antigens such as pollen or house 
dust mite (Robinson, et al., 1997). Several epidemiological studies indicate that the 
development of atopic disease is linked to circulating levels of IgE (Burrows, et al., 
1989; Naclerio, et ai, 1993; Sears, et ai, 1991) as in healthy individuals the quantity 
of IgE in the serum is low, but in atopy these levels are greatly increased. IgE binds 
to mast cells and basophils via the high affinity IgE receptor (FcgRI), and subsequent 
crosslinking of the FcgRI-bound IgE molecules by antigen leads to the release of the 
pharmacologically-active mediators responsible for allergic tissue damage (Mudde, 
et a i,  1990). Estimates of the numbers of people suffering from allergic disorders in
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the western world range from 5-15%, and are on the increase. Reasons for this are 
unclear, although studies are currently being conducted on environmental pollution, 
housing patterns and lifestyle.
Autoimmune diseases - Rheumatoid arthritis
Increased levels of CD23 have been reported in various chronic inflammatory 
diseases including systemic lupus erythematosus (SLE) (Bansal, et a l ,  1992), 
inflammatory bowel disease (Kaiserlian, et a l ,  1993), glomerulonephritis (Yano, et 
al ,  1992) and rheumatoid arthritis (Hellen, e ta l ,  1991). Rheumatoid arthritis (RA) 
is a long term inflammatory disease of the joints, resulting in severe swelling over 
the affected joints and extreme pain. Pro-inflammatory cytokines are known to be 
particularly important in RA, and a central role for TNF-a and EL-ip in the 
destruction of arthritic joints has been postulated (Elliot, et a l ,  1993), with these 
cytokines also being present in the synovium of RA patients (Brennan, et al,  1989). 
Neutralisation of TNF-a and IL-lp in vivo has led to a marked reduction in disease 
severity and tissue destruction (Williams, eta l ,  1992).
Ikizawa and colleagues (Ikizawa, et a l ,  1993) studied the cellular and molecular 
mechanisms for the elevated serum sCD23 in RA patients. It was postulated that an 
increase in CD5+ B cells in these individuals had an important role in the increase of 
CD23 expression and subsequent release of sCD23 into the serum, although the 
exact mechanisms by which this process led to increased CD23 was not studied. A 
new role for CD23 in inflammation and arthritis was presented by Bonnefoy et al 
(Bonnefoy, et al ,  1996). CD23 expression is increased in RA but IgE is not 
implicated, leading to the conclusion that CD23 interacts with other ligands to 
produce pro-inflammatory mediators. As described in section 1.8.5, CD23 binds to 
C D llb  and C D llc  on monocytes (Lecoanet-Henchoz, et a l ,  1995) and this 
interaction leads to the production of nitric oxide and pro-inflammatory cytokines,
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suggesting CD23 is an inflammatory mediator. Recent evidence also suggests that 
the binding of sCD23 to avp3 is involved in pro-inflammatory immune processes 
(Hermann, et al, 1999).
B cell chronic lymphocytic leukaemia (B-CLL)
CD23 is also over-expressed and abnormally regulated in the most frequent adult 
leukaemic disorder in the western world, B cell chronic lymphocytic leukaemia (B- 
CLL). The hallmark of B-CLL is the accumulation of mature CDS'*" B cells, co­
expressing sIgM, sIgD and CD23 antigens, which have escaped programmed cell 
death and have undergone cell cycle arrest in the GO phase (Montserrat & Rozman, 
1995; O’Brien, et ai, 1995). In Western Europe and north America 30% of reported 
leukaemia cases are B-CLL, and sera from patients has been reported to contain 3- to 
500-fold more sCD23 than control sera (Sarfati, et al, 1988). sCD23 levels have 
been shown to reliably reflect disease activity (Reinisch, et a l,  1994) and 
significantly correlate with tumour load (Beguin, et al, 1993) and prognostic 
evaluation (Sarfati, et al, 1996). The latter study showed that patients with serum 
sCD23 concentrations above the median value of patients in a studied group 
(574U/ml) had significantly shorter survival times. Recently, the effect of STAT-6 
on CD23 expression in B-CLL cells has been studied (Kneitz, et a l,  2000) in order 
to investigate the possibility of constitutive STAT-6 activation. This was considered 
a possibility as both CD23a and CD23b isoform promoters contain STAT-6 binding 
sites and can be upregulated by IL-4 (Kohler & Richer, 1993; Suter, et al, 1989). 
However, experiments revealed no difference between the STAT-6 concentration of 
non-malignant B lymphocytes and B-CLL cells. This leads to the speculation that 
the dysregulation of, hitherto, unknown mechanisms may contribute to the 
generation of B-CLL. CD23a and CD23b promoter STAT-6 binding sites are 
studied and discussed in Chapter 4 of this thesis.
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1,8.10: Studies with CD23 knockout mice
Gene knockout and transgenic technology has been attempted by several groups to 
determine the function of CD23 in relation to IgE synthesis, however the phenotype 
and results from these animals has been controversial. Yu et al developed CD23 
knockout mice (Yu, et a l,  1994) and reported that immunisation of these animals 
with thymus dependent antigen resulted in an increased and sustained IgE level. 
Two other groups, however, also developed CD23 knockout mice but were unable to 
support these findings (Fujiwara, et al,  1994; Stief, et a l,  1994), with the CD23‘/" 
mice having similar IgE responses compared to those of littermate controls. 
Heymen et al have reported that IgE and antigen complexes could augment immune 
responses by interacting with CD23 (Heyman, et a l ,  1993), and that this 
augmentation was not present in CD23"/“ mice. Thus, there was considerable proof 
that CD23 acted as a negative regulator for IgE production.
A transgenic model which over-expressed CD23 by utilising the Thy 1.1 promoter 
was developed by Texido and colleagues (Texido, et a l ,  1994). These mice 
exhibited about 50% suppression of the IgE response following alum/antigen and 
anti-IgD injections and Nippostrongylus brasiliensis (Nb) infection. Expression of 
the transgene in this case was mainly in T lymphocytes, although back-crossing into 
the CD23“/ ' phenotype did demonstrate some expression on B cells. The dramatic 
suppression in IgE responses in these models lends further support to the concept 
that CD23 is a regulator of IgE levels. A recent paper (Haczku, et al,  2000) has 
further determined the role of CD23 in IgE responses, by concluding that CD23 
exhibits a negative regulatory effect on allergic sensitisation and airway hyper­
responsiveness. Haczku and colleagues demonstrated the inhibitory role of CD23 by 
comparing the in vivo effects of gene deficiency and over-expression in transgenic 
mice with those of anti-CD23 treatment. The CD23 knockout mice showed 
increased responses to ovalbumin sensitisation and challenge, while the over-
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expression of CD23 led to an inverse correlation with these changes. In addition, 
anti-CD23 treatment induced negative regulatory effects on both IgE and IgGi, 
although the authors were unclear as to whether this was due to the activation of 
target cells or secondary to the blocking of CD23 binding to other effector 
molecules. This could also be due to anti-CD23 binding to IgE promoting sCD23 
production.
Transgenic and knockout mouse models have provided new insight into 
understanding the immunological functions of CD23, although there are a number of 
limitations to these models. The clinical relevance of observations viewed in mice is 
difficult to extrapolate to humans as there are marked differences in the CD23 
immunobiology between the two species. Firstly, at a molecular level, there is only 
57% amino-acid sequence homology between human and mouse CD23 and, 
furthermore, the murine CD23 is naturally truncated at its carboxy terminus - 
omitting the RGD motif (Delespesse, et al, 1991). In humans most of the regulatory 
effects of sCD23 are ascribed to its IgE binding capacity, whereas mouse sCD23 
does not retain the same extent of IgE binding (Bartlett, et al., 1995). In addition, 
the existence of isoforms of murine CD23 is controversial (Conrad, et al., 1993; 
Richards, et al., 1991) and the supposed single murine isoform (likened to hCD23a) 
is found expressed on mature B cells, T cells and FDCs. This is in direct contrast to 
the existence of the two human CD23 isoforms and constitutive CD23a expression 
only on B cells, with CD23b expression requiring activation on other haematopoietic 
lineages (see 1.9.6). Whether some effects ascribed to CD23 are unique to the 
human situation remains to be resolved but, as it would provoke obvious ethical 
problems to perform in vivo experiments on humans, murine models remain the most 
practical experimental tool. Models more relevant to humans would clearly be a 
great advantage and, on this note, the work of Mayer et al is interesting. Here, 
human-peripheral blood lymphocyte-reconstituted SCID (hu-PBL-SCID) mice were
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used to show the inhibition of CD23 processing correlates with the inhibition of IL-4 
stimulated IgE production (Mayer, et al, 1999).
Altogether, a large body of evidence suggests that, in humans, CD23 plays a 
regulatory role in IgE regulation with antagonistic effects. Crosslinking of CD23 at 
the cell surface with IgE delivers a negative feedback for IgE production and inhibits 
the release of sCD23, whereas sCD23 fragments larger than 25kDa promote 
continuing IgE production. This positive effect upon IgE synthesis is thought to be 
mediated by at least two mechanisms, including sCD23 directly stimulating IgE 
production through CD21 triggering and the ability of sCD23 to trap IgE preventing 
negative feedback through membrane-bound CD23. Allergic disease, therefore, is 
thought to be due to dysregulation of the CD23/IgE feedback mechanisms - perhaps 
due to inappropriate cleavage of CD23 from cell membranes and subsequent 
increases in sCD23-mediated increases in IgE expression. Prime candidates for 
causing CD23 cleavage are a wide range of allergens that have enzymatic activity 
(Stewart & Thompson, 1996). The 25kDa Dei p 1 cysteine protease is one of the 
most studied allergenic enzymes (Robinson, et al, 1997; Thomas, 1993), found in 
the faeces of the house dust-mite Dermatophagoides pteronyssinus. Der p 1 is 
considered to be the most immunodominant allergen involved in the expression of 
IgE-mediated dust-mite hypersensitivity, and has been shown to cleave CD23 (and 
CD25) from cultured human B cells (Schulz, et al, 1995) and also in vivo (Shakib, 
e ta l ,  1998).
Therapies for IgE dysregulation and atopy
Anti-IgE therapy is currently being tested in clinical trials and is successful in 
removing IgE from the body for at least three months, presumably via clearance of 
immune complexes by the reticuloendothelial system. (Heusser & Jardieu, 1997). 
However, repeat injections are necessary, because IgE synthesis levels are not
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affected, and this can lead to serum sickness. An alternative therapy would be to 
develop protocols to elevate membrane CD23 levels prior to B cell activation (Payet, 
et al,  1999). This would be a great benefit, providing techniques to carry out this 
task could be found that did not involve corresponding increases in sCD23 - such as 
the use of metalloprotease inhibitors (Christie, et a l,  1997). Recent clinical, 
epidemiological and serological data have indicated that specific immunotherapy 
against dust mite allergens in young children may prevent the development of new 
allergic reactions (Des Roches, et al, 1997). Therefore targeting the enzyme active 
site of Der p 1, perhaps with a cysteine protease inhibitor, may provide an effective 
way of controlling IgE-mediated hypersensitivity to this allergen and allergic 
asthma.
1.9: Aims of research
The expression of CD23 has important implications in B cell development and IgE 
regulation in both normal human B cells and those from atopic or leukaemic 
individuals. The CD23a isoform is found constitutively expressed on B cells, 
whereas CD23b can be induced on a number of haematopoietic lineages. As CD23 
has such far ranging clinical implications it was considered of major importance to 
study the expression of both these CD23 isoforms, on cells in both the naive and 
activated state.
Firstly in this research, cell lines and primary tonsillar B cells will be phenotypically 
analysed, and their CD23 expression both prior to and following activation will be 
noted. Immunoprécipitation studies will attempt to follow the activation of STAT-6, 
which is thought to be a major contributor in CD23 expression, and mobility shift 
assays will confirm these studies. In addition, mobility shift assays will also attempt 
to confirm NFkB involvement in the CD23 activation pathway. Secondly, the 
promoter regions of each CD23 isoform will be analysed in depth by reporter vector
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construct studies. Full length and precisely truncated promoter region PCR products 
will be inserted into the pSEAP reporter vector, and reporter region activation 
quantified using SEAP (SEcreted Alkaline Phosphatase) assays. These experiments 
will include the activation of each vector construct with various potential stimuli and 
mitogens. Lastly, analysis of the CD23a and b promoter regions will be attempted at 
the level of protein-DNA interactions, using the ligation mediated PCR (LM-PCR) 
technique and in vivo footprinting analysis.
Together, this research will attempt to determine if the two isoforms of CD23 are 
subject to differential regulation and expression and, if so, what implications this 
could have on the role of CD23 both in B cell development and in allergic and 
neoplastic disorders.
Figure 1.1: Schematic representation and overview of B cell lymphopoiesis
B cell development occurs in two main stages; antigen-independent development, 
which occurs in the bone marrow (BM) and antigen-dependent, which takes place in 
the periphery. Antigen-independent B cell lymphopoiesis can be described as a 
progression between 4 primary cell types including the lymphoid progenitor, pro-, 
pre- and immature B cells. Different cell surface markers and proteins are expressed 
throughout differentiation and these are shown on the diagram, as are the specific 
IgH and IgL genes expressed at each stage. B cell fate with or without the presence 
of antigen is shown in the periphery phase of the scheme, as well as the progression 
from mature B cell to memoiy or plasma cell.
58
ex
S  Z
il
> »(/)
ex
ex
a . U % SBa  o
U  D
l . î
| v | I I
Figure 1.2: IL-4 receptor signalling
The IL-4 receptor (IL-4R) is composed of two chains, the IL-4Ra chain and the 
common y chain (yc). Upon IL-4 binding, members of the JAK family are activated 
via phosphorylation which, in turn, leads to the activation of 1RS-1/2 and STAT-6. 
1RS-1/2 activation leads to PI-3-K and Ras/MAPK activation, and ultimately leads to 
either cell growth and differentiation, proliferation or cell survival via the shown 
pathways. STAT-6 signalling is discussed in detail separately.
1RS-1/2 (Insulin Receptor Substrate); PI-3-K (Phosphoinositide-3-Kinase, composed 
of p85 and pi 10 subunits); PKB (Protein Kinase B); PKC (Protein Kinase C)
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Figure 1.3: IL-4 and IL-13 activation of STAT-6
The receptors for IL-4 and IL-13 share the IL-4Ra chain, with the IL-4 receptor also 
comprising the yc chain and the IL-13 receptor including the IL-13Ra chain. IL-4 
can activate both receptors through utilisation of the IL-4Ra chain and, thus, the IL- 
4 and IL-13 receptors can be known as the Type I and Type II IL-4 receptors, 
respectively. Following IL-4 or IL-13 binding, JAK-1 is activated by 
phosphorylation via the IL-4Ra chain and this, in turn, activates STAT-6. 
Phosphorylated STAT-6 then dimerises, is translocated to the nucleus and leads to 
IgE and CD23 expression (in this case). The Type I IL-4 receptor is found on both B 
and T cells, whereas Type II is expressed on B cells only.
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Figure 1.4: Structure of CD23 isoforms (CD23a and CD23b)
The two isoforms of CD23, termed CD23a and CD23b, differ solely by the 7 
(CD23a) or 6 (CD23b) amino acids in their N-terminal cytoplasmic region. The 
identity of each of these amino acids is shown, with S representing serine, Y 
representing tyrosine, Q representing glutamine, G representing glycine, E 
representing glutamic acid, M representing methionine, P representing proline and N 
representing asparagine. The entire cytoplasmic domain is representative of amino 
acids 1-23.
The hydrophobic transmembrane domain of CD23 is in the form of a helix and 
comprises of amino acids 23-44. The remainder of the protein is extracellular. The 
stalk region of the CD23 monomer (amino acids 82-157) consists of a leucine zipper 
domain and multiple heptad repeats. These imply that CD23 exists as a multimer on 
the cell surface, and evidence suggests that this is a trimer. The cleavage points for 
different sized soluble CD23 (sCD23) fragments are located within the leucine 
zipper domain and are indicated on the diagram. The lectin domain of CD23 
consists of amino acids 163 to 321, and contains the site for IgE binding. Disulphide 
bonds are represented by S-S.
This figure was adapted from Marolewski et al, (1998)
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Figure 1.5: Origins of CD23a and CD23b
The two isoforms of CD23 are generated using different transcription start sites and 
differential RNA splicing of the single CD23 gene, located on chromosome 19. 
CD23a mRNA comprises of exons I-XI, while CD23b mRNA omits exons I-II but 
includes the unique exon b. The 5' untranslated (UTR) region of each isoform is 
indicated by the white boxes, exon III is represented by red and the unique translated 
area for the CD23a or CD23b isoform is shown by the black and blue boxes, 
respectively.
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CHAPTER 2
MATERIALS AND METHODS
2.1: MATERIALS
2.1.1: GENERAL CHEMICALS AND MATERIALS
Ail general chemicals and reagents, unless otherwise stated below, were purchased 
from Sigma-Aldrich or BDH Chemicals, both Poole, Dorset, UK. All reagents were 
of 'AnalaR' grade.
CHEMICAL/REAGENT SUPPLIER
Y-[32p] ATP (3000Ci/mmol)
[14^ 1] Chloramphenicol (50mCi/ 
mmol)
Rainbow protein molecular weight markers. 
Hybond TM pcL nitrocellulose membrane
Amersham Life Science Ltd. 
Buckinghamshire, UK.
Bio-Rad Protein Assay
40% Acrylamide/Bis solution, 29:1
Bio-Rad Laboratories Ltd. Hertfordshire, 
UK.
Agarose MP (multi-purpose)
DNA molecular weight marker X (0.07-12.2 
kbp)
DNA molecular weight marker XIV (lOObp 
ladder)
dNTP's (PGR grade)
Boehringer Mannheim Ltd. 
Sussex, UK.
Sheep red blood cells Diagnostics Scotland. Lanarkshire, UK.
Long Ranger TM g^i solution Flowgen. Staffordshire, UK.
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TRIzol ^  Reagent Gibco BRL, Life Technologies Ltd. 
Paisley, UK.
Bacto-agar Oxoid Ltd. Hampshire, UK.
Bacto-tryptone
Yeast Extract
Vent r E  DNA polymerase New England BioLabs inc.
Restriction endonucleases and buffers 
Taq DNA polymerase
Promega UK Ltd. Southampton, 
UK.
T4 DNA ligase
T4 Polynucleotide kinase
RNase OUT TM VH BIO Ltd. Newcastle, UK.
2.1.2: KITS
KIT SUPPLIER
ECL Western Blotting detection system Amersham Life Sciences Ltd. 
Buckinghamshire, UK.
Prime-a-Gene ^  Labelling System Promega UK Ltd. Southampton, UK.
Great EscAPe SEAP Reporter System 2 Clontech Laboratories UK Ltd. Hampshire, 
UK.
Qiagen Plasmid Maxi Purification kit 
Qiagen QIAquick Gel Extraction kit
Qiagen Ltd. West Sussex, UK.
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2.1.3: CELL AND TISSUE CULTURE REAGENTS AND MATERIALS
REAGENT/MATERIAL SUPPLIER
Disposable plastic graduated pipettes Bibby Sterilin Ltd, Staffordshire, UK.
Tissue culture Flasks 
50ml centrifuge tubes 
6 well plates
Corning Costar. Buckinghamshire, UK.
RPMI-1640 medium 
Foetal Calf Serum 
Penicillin/Streptomycin/Glutamine 
Cryovials
Gibco BRL, Life Technologies Ltd. Paisley, 
UK.
Haemocytometer Phillip Harris Scientific. Lanai’kshire, UK.
Trypan Blue
Histopaque
Percoll
Sigma-Aldrich. Dorset, UK.
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2.1.4: CYTOKINES AND MITOGENS
CYTOKINE/MITOGEN SUPPLIER
Recombinant human IL-4 
Recombinant human IL-13
R & D Systems Europe, Ltd. Oxon, UK.
Mouse anti-human CD40 (LOB7/6) 
Isotype IgGI
Serotec. Oxford, UK.
Phorbol 12-Myristoyl 13-acetate (PMA) Sigma-Aldrich. Dorset, UK.
Rabbit anti-human IgM (p-chain specific) Sigma-Immunochemicals. Dorset, UK.
2.1.5: ANTIBODIES
ANTIBODY SUPPLIER
IL-4 STAT (STAT-6) rabbit polyclonal IgG
p-Tyr (phosphotyrosine) mouse monoclonal 
IgG
B Cell, CD47 (BRIC126)
Isotype IgG2b
Autogen Bioclear. Wiltshire, UK.
Protein-A, with horseradish peroxidase (HRP) 
conjugate
Amersham Life Science Ltd. 
Buckinghamshire, UK.
B Cell, avP5/FITC (P1F6) 
Isotype IgGI
Chemicon International Inc. 
Harrow, UK.
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B Cell, CD 19/ R-phycoerythrin (RPE) 
(HD37) Isotype IgGl
DAKO Ltd. Cambridgeshire, UK.
B Cell, CD19/FITC (HD37) 
Isotype IgGl
IL-2 Receptor, CD25/FITC (ACT-1) 
Isotype IgGl
B Cell, CD23/FITC (MHM6) 
Isotype IgGl
B Cell, CD21/FITC (IF8) 
Isotype IgGl
B Cell, CDllb/FITC (2LPMI9c) 
Isotype IgGl
B Cell, CDllc/FITC (KB90) 
Isotype IgGl
T Cell, CD3/FITC (UCHTl) 
Isotype IgGl
Anti-Rabbit IgG, with HRP conjugate 
Anti-Mouse IgG, with HRP conjugate
Scottish Antibody Production Unit (SAPU). 
Lanarkshire, UK.
Anti-human IgM (p-chain specific)/(FITC)
2.1.6; PLASMIDS AND TRANSFECTION REAGENTS
PLASMID/REAGENT SUPPLIER
Gene Puiser Electroporation Cuvettes Bio-Rad Laboratories Ltd. Hertfordshire, 
UK.
pSEAP Control vector 
pSEAP Basic vector 
pSEAP Enhancer vector
Clontech Laboratories UK Ltd. Hampshire, 
UK.
pLW2 Chloramphenicol acetyl -transferase 
reporter vector.
Gift from Professor B Ozanne, CRC Beatson 
Laboratories, Glasgov^, UK.
2.1.7: CELL LINES
CELL LINE SUPPLIER
EDR
Mature human B lymphoblastoid cell line
Gift from Prof. C. Watts, University of 
Dundee, UK.
JIJOYE
Mature human B lymphoblastoid cell line
Gift from Prof. C. Steel, Dept of Medical 
Biology, University of St. Andrews, UK.
P3HR1
Mature human Burkitt's Lymphoma B cell 
line
Gift from Dr L Wilson, Dept of Genetics, 
University of Glasgow, UK.
RAMOS
Mature human Burkitt's Lymphoma B cell 
line
Gift from Dr M.M. Harnett, Dept of 
Immunology, University of Glasgow, UK.
SMS-SB
Pre-BII human ALL cell line
Gift from Prof. B. Ozanne, CRC Beatson 
Laboratories, Glasgow, UK.
NALM-6
Pre-BII human leukaemic cell line
Gift from Prof. R.E. Callard, Institute of 
Child Health, London, UK.
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JURKAT Laboratory Stocks.
Leukaemic T cell lymphoblast
2.1,8: TONSILS
Tonsils were obtained from the paediatric ENT clinic at the Royal Hospital for Sick 
Children, Yorkhill, Glasgow, courtesy of consultant Mr Sadiq. All parents/guardians 
gave formal informed consent to the use of tissue, and the work was approved by the 
North Glasgow Universities NHS Trust Ethics Committee.
2.1.9: OLIGONUCLEOTIDES
All oligonucleotides, apart from NFkB, were synthesised and supplied by MWG- 
Biotech UK Ltd, Waterside house, Peartree Bridge, Milton Keynes, MK6 3BY. 
NFkB was supplied by Promega UK Ltd. Southampton, UK.
OLIGUNUCLEOTIDE NAME OLIGONUCLEOTIDE SEQUENCE
EMSA Studies
STAT-6
NFkB
5' TTTGACGTGAAT 3'
3' AAACTGCACTTA 5'
5' AGTTGAGGGGACTTTCCCAGGC 3* 
3' TCAACTCCCCTGAAAGGGTCCG5'
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TM-PCR Studies (CD25)
CD25 Prom (l) 
CD25 Prom (2) 
CD25 Prom (3) 
Common linker
5' CAGGTTATAAGCCTTGGGG 3’
5’ ATTCTCAGGATCCTTCAGTTCGCCG 3’
5' GGATCCTTCAGTTCGCCGCATCCTTCTCC 3’
5' GCGGTGACCCGGGAGATCTGAATTC 3'
3’ CTAGACTTAAG 5'
T.M-PCR Studies (CD23)
CD23aProm (l) 
CD23a Prom (2) 
CD23a Prom (3) 
CD23b Prom (l) 
CD23b Prom (2) 
CD23b Prom (3) 
Common linker 
CD23a (Rev) 
CD23b (Rev)
5' GCCTTCCGTGGCTCCCCAGGGC 3'
5' GCCCTCTGTGATCGGCCATAGTGGT 3’
5’ CGGCCATAGTGGTATGATTCAGTGTG 3’
5’ GTAGGAGGACTCTCTGGTTCTAACG 3'
5’ CGTTGGCAGAAGCAATGACCCTTAGC 3’
5’ CCTTAGCTACTCCTTTCACCCAGAAG 3’
5’ GCGGTGACCCGGGAGATCTGAATT C 3'
3’ CTAGACTTAAG 5’
5’ CAC TGA CAG CTT CTA TTT TCA TAG ACC 3’
5’ GCT AAA TTC TGC TTG TTC CAA GTT CC 3'
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Reporter vector construct 
studies (CD23a)
Al: Full CD23a Promoter
A2: CD23aProiWAS61
A3: CD23a Prom/AS62
A4: CD23a Prom/AKB
AR: CD23a Prom/Reverse
5' GGCGGTACCAAACTGTCCATATTTGACC
5’ GGCGGTACCAGCCTATTTGCTCAATCATC
5' GGCGGTACCTGGTGGGGTGTCTGCTGGTA
5' GGCGGTACCAGTGGTATGATTCAGTGTGCAGT 
A3'
5’ GCA GAT CTT GAC AGC TTC TAT TTT CAT3'
Reporter vector construct 
studies rCD23b)
B 1 : Full CD23b Promoter
B2: CD23b Prom/AS61
B3: CD23b Prom/AKB 
B4: CD23b Prom/AS62
B5: CD23b Prom/AAPl(l)
B6: CD23b Prom/AAPl(2)
BR: CD23b Prom/Reverse
5' GGC GGT ACC ATG GAG GAA GGT CAA TAT 
TC 3'
5’ GGC GGT ACC GAA GCG GGG CTT CCC AGT 
CCC 3’
5' GGC GGT ACC TGA ATT TCT AAG AAA GGG 3'
5' GGC GGT ACC TGG TGT GAGTAA GGA GGT 
GA 3’
5' GGC GGT ACC TTT TCT GAT TCA ACA CCC 
TC 3'
5' GGC GGT ACC GCA ATA GAG TCA GAG GCC 
AA3'
5' GCA GAT CTG CAC TCA CCC TGG CTT GG 3'
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2.2: METHODS
2.2.1a: CULTURE OF CELL LINES AND PRIMARY TONSILLAR B CELLS
Cell lines and tonsillar B cells were cultured in RPMI-1640 medium supplemented 
with 10% (v/v) heat-inactivated Foetal Calf Serum (FCS), lOOpg/ml 
penicillin/streptomycin and 2mM glutamine. They were incubated at 37 C in a 5% 
CO2 humidified incubator, and were sub-cultured every 2-3 days in accordance with 
experimental requirements and optimal growing concentrations. The cells were 
manipulated aseptically in a laminar flow hood.
2.2.1b: FREEZING DOWN AND THAWING OF CELL LINES
Frozen stocks of routinely used cell lines were stored and maintained in liquid 
nitrogen. To freeze, 10  ^ logarithmically growing cells were centrifuged, 
resuspended in 1ml of chilled freezing media (90% (v/v) heat-inactivated FCS/10% 
(v/v) dimethylsulphoxide (DMSO)) and quickly transferred to cryovials. The cells 
were cooled at a rate of approximately 1°C per hour, being kept at -70°C for 3-4 days 
and then transferred to liquid nitrogen. Cells removed from liquid nitrogen were 
rapidly thawed and immediately washed in 10ml of incomplete medium (no 
FCS/penicillin, streptomycin, glutamine), in order to remove the DMSO. The cells 
were then resuspended in 5ml of complete medium and allowed to recover overnight 
prior to any further manipulations.
2.2.1c: QUANTITATION OF CULTURES AND CELL VIABILITY
Cell concentration and viability was determined using trypan blue staining, and a 
haemacytometer. Dead cells rapidly take up trypan blue as they have lost membrane 
integrity, and can therefore be readily distinguished from healthy viable cells. 20p.l
73
of cell suspension was mixed with an equal volume of trypan blue, loaded onto a 
haemocytometer and counted. The number of live cells per ml of culture was 
estimated by multiplying the average live count of 4 x 16 square area grids by 2 
(accounting for dilution), and then multiplying by 1 x 104, The number of dead cells 
was also determined in this fashion, and the percentage of viable cells calculated.
2.2.2a: PREPARATION OF TONSILLAR B CELLS
As adapted from the method used by Butcher et al (1990), freshly excised tonsils 
were rinsed twice in RPMI-1640 serum-free medium, supplemented with lOOjig/ml 
penicillin/streptomycin and 2mM glutamine. The tonsils were then diced with a 
scalpel, mashed through a wire mesh, spilled into a 50ml Falcon tube with serum- 
free medium and the large clumps allowed to settle. The cell suspension was then 
transferred to a fresh tube, washed twice with serum-free medium and the cells 
pelleted at 350 x g for 5 mins at RT. Cells were resuspended in 20ml of medium, 
and 10ml aliquots layered on to two 10ml cushions of Histopaque. The tubes were 
then centrifuged at 350 x g for 15 min at RT, with the brake off, mononuclear cells 
harvested from the interface, pooled (if from the same donor), diluted into 50ml of 
medium and washed twice - in serum-free medium. Cells were resuspended in 10ml 
of medium, prior to the addition of 1ml AET-SRBC (see following protocol) and 
subsequently pelleted at 90 x g for 3 mins with the brake off, 1ml of FCS was added 
just above the pellet and the tube incubated on ice for 30 min, followed by gentle 
rocking and addition of the entire suspension to a 10ml Histopaque cushion. 
Centrifugation at 350 x g for 20 min, with brake off, was followed by harvesting 
cells from the interface and 3 wash steps as before. The B cells were then 
resuspended in 1.5ml of medium and layered carefully on to a 5 step discontinuous 
percoll gradient (see appendix), which was centrifuged for 30 min at 1400 x g. 
Resting B cells were harvested from the 1.08/1.09g/ml interface, washed twice in 
serum-free and complete medium and transferred to culture in complete medium.
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2.2.2b: PREPARATION OF AET-SHEEP RED BLOOD CELLS
Sheep red blood cells (SRBC) were pelleted at 350 x g and washed twice with 
RPMI-1640 serum-free medium. 102mg of Aminoethylisothiouronium Bromide 
(AET) was then dissolved in 10ml of distilled water, the pH adjusted to 9 with 
NaOH and the solution filter-sterilised. 4ml of the prepared AET was then added to 
the washed SRBC, incubated at 37°C for 40 min, washed 5 times in serum-free 
medium and resuspended in 9ml of serum free medium.
2.2.3: FLOW CYTOMETRIC ANALYSIS OF CELL LINES AND PRIMARY 
TONSILLAR B CELLS
Cells were harvested from culture, washed twice in ice-cold PBS and resuspended at 
1x10^ cells per 100|il of PBS in 12 x 75mm FACS tubes. SjLtl of each FITC- or PE- 
labelled antibody was then added as required for experimental conditions, prior to 
incubation on ice for 1 hr. After incubation, tubes were centrifuged at 350 x g for 5 
min and washed twice in ice-cold PBS. Labelled cells were then resuspended in 
500|U,1 of PBS and analysed on a Becton Dickinson FACScan flow cytometer.
2.2.4: WESTERN BLOTTING 
2.2.4a: PREPARATION OF WHOLE CELL LYSATES
Stimulated or unstimulated cells were isolated from culture, washed twice with 
serum-free RPMI-1640 medium, re-suspended in ice-cold PBS at 5x10^ cells per ml 
and washed by centrifugation at 350 x g for 5 minutes. Cells were then resuspended 
in 500p.l of RIPA buffer (see appendix) and lysed by pipetting. Cells were further 
lysed by incubation on ice for 20 min, and the cellular debris removed by
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centrifugation at 16, 000 x g for 15 min at 4“C. The supernatant was retained and 
the protein concentration of each sample determined by Biorad protein assay, 
followed by storage of aliquoted samples at -70“C.
2.2.4b: PROTEIN CONCENTRATION ASSAY (BIORAD)
BSA standards were diluted to concentrations of 2mg/ml to 0.2mg/ml in dH2 0  in 
descending 0.2mg/ml increments and the Biorad assay buffer diluted 1 in 5 with 
dH2 0 . The solution was then filtered to remove any precipitates, and 1ml was added 
to each of the required number of labelled eppendorf tubes (i.e. enough for all 
standards and samples). 2 0 pl of each standard was added to its designated tube, as 
was each protein sample (diluted 1 in 10 with dH2 0 ). All tubes were then vortexed, 
left for a minimum of 5 min at RT and their contents subsequently added to cuvettes 
for assay. Samples and standards were analysed at A5 9 5  on a Helios y 
spectrophotometer, and the unknown protein concentrations each estimated in 
accordance with the resulting standard curve.
2.2.4c: PREPARATION OF IMMUNOPRECIPITATES
Cells were isolated from culture, washed twice in incomplete RPMI-1640 medium 
and resuspended at 1x10  ^cells/ml in complete medium. They were then stimulated 
over a specific time-course, as indicated in the appropriate results section, and 
recovered by centrifugation for 5 min at 350 x g. Cells were subsequently lysed by 
the addition of 400pl of RIPA buffer (see appendix) and incubated on ice for 20 min, 
after which cell membranes were disrupted by repeated aspiration through a 2 1  
gauge needle. Cellular debris was pelleted by centrifugation at 16, 000 x g at 4°C for 
15 min, and the supernatant transferred into fresh tubes. In accordance with the 
method described by Harlow and Lane in 1988, tl^ e protein solution was then pre­
cleared for 2 hr by rotation with 5|il of Protein-G agarose, prior to the addition of
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Ipg of appropriate antibody and subsequent incubation at 4“C for 4 hr on a rotating 
table. Samples were finally rotated overnight with lOjxl of Protein-G agarose at 4“C, 
in order to allow the immunoprecipitates to be captured. Inununoprecipitates were 
then collected by centrifugation at 320 x g for 5 min, washed twice with RIPA buffer 
and re-suspended in 20pl of protein loading buffer. Each sample was boiled for 3 
min to denature, centrifuged gently to pellet the Protein-G agarose and the protein 
loaded on to an appropriate percentage gel.
2.2.4d: SDS-PAGE ELECTROPHORESIS AND WESTERN BLOTTING
Appropriate percentage acrylamide separating gels were prepared as described by 
Laemmli (1970) and set with an isopropanol overlay, prior to the addition of a 5% 
(w/v) acrylamide stacking layer (Gel compositions are shown in the appendix). 
Samples were added to the gel and electrophoresed at 15mA in running buffer (see 
appendix) until through the stacking gel. When the samples entered the separating 
gel, the current was increased to 25mA and the gel run until completion. Following 
electrophoresis the glass gel plates were removed, the stacking gel cut off and the 
separating gel transferred to a Scotlab wet blotting apparatus. The protein was then 
transfered to a nitrocellulose membrane in protein transfer buffer (see appendix) at 
100mA for 1 hour.
2.2.4e; IMMUNOBLOTTING
Following western blotting, the nitrocellulose membrane was incubated at 4°C 
overnight with either 10% (w/v) marvel or 1% (v/v) TWEEN 20 in order to block 
non-specific antibody binding. The membrane was then rinsed in PBS and 
incubated with primary antibody, which was prepared at 1:1000 with 0.5% (w/v) 
marvel/PBS, at RT for 3 hours. Three 10 min,wash steps with PBS/0.1% (v/v) 
TWEEN were then carried out, followed by incubation for 3 hours with the
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secondary antibody (prepared as with the primary), and another 3 subsequent wash 
steps. The membrane was developed using ECL, following closely the 
manufacturers instructions. Briefly, in the dark room, equal volumes of the two ECL 
solutions were mixed. This was then poured over the nitrocellulose, left for 1 min 
and the excess dabbed off with a paper towel. The membrane was then placed in an 
autoradiographic cassette, covered with a thin polythene sheet and exposed to film 
for the required amount of time before placing in X-omat developer.
2.2.5: ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
2.2.5a: OLIGONUCLEOTIDE PREPARATION
Complimentary oligonucleotides were annealed by mixing together equimolar 
amounts, heating to 80“C for 5 min and allowing them to slowly cool down to RT. 
The annealed oligonucleotide was then radiolabelled at the 5' end by incubating the 
following reaction mixture at 37“C for 20 min:
2pl of annealed oligonucleotide (1.75pmol/jxl)
5pl of dÜ20
Ipl of T4 Polynucleotide Kinase 5 x buffer
Ijxl of T4 Polynucleotide Kinase
Ipl of [Y-32p]ATP (3000Ci/mmol at lOmCi/ml)
The reaction was terminated by adding Ipl of 0.5M EDTA and 89|xl of TE buffer 
(see appendix). Storage was at -70“C.
The EMSA protocol was adapted from the method of Schindler et al, 1994.
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2.2.5b: EMSA
The following reaction mixtures were assembled in microfuge tubes:
NEGATIVE CONTROL
7 pi of dH2Û
2pl of 5 x gel shift binding buffer (BB) 
Opl of extract (RIPA lysate)
POSITIVE CONTROL
5pl ofdHzO
2pl o f  5 X BB ( a p p e n d i x )
2pl of extract (5pg)
COMPETITOR CONTROL
4pl of dH20 
2pl of 5 X BB 
2pl of extract (5pg)
Ipl of specific oligo (1.75pmol)
NON-COMPETITOR
4pl of dH20 
2pl of 5 X BB 
2pl of extract (5pg)
Ipl non-spec.(1.75pmol)
The contents of each tube were briefly spun down and incubated at RT for 10 min, 
prior to the addition of Ipl of the previously [32p]-labelled specific oligonucleotide. 
The mixture was then incubated at RT for a further 20 min, and loaded on to a non­
denaturing polyacrylamide gel.
2.2.5c:  RUNNI NG OF NON- DENAT URI NG GELS AND
AUTORADIOGRAPHY
Reactions were run on a 16 x IScm^ 7% (w/v) acrylamide non-denaturing gel that 
was assembled as follows:
9ml of 40% Acrylamide:Bis Acrylamide (29:1)
2.3ml o f  5 X TBE (appendix)
34.3ml of d H2O
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450|Lil of 10% Ammonium Persulphate 
22.5pl ofTEMED
The gel was pre-run in 0.5 x TBE buffer for at least Ihr at 150V, prior to the addition 
of samples. lOpl of sample loading buffer (250mM Tris-HCl pH7.5, 0.2% 
bromophenol blue, 0.2% xylene cyanol, 40% glycerol) was added to the empty 
wells, in order to visualise sample progression. The sample was electrophoresed at 
150V for 2 and a half hours, dried onto filter paper and visualised by 
autoradiography.
2 .2 .6 ; p S E A P  R E P O R T E R  V E C T O R  S T U D IE S  
2 :2 :6 a ;  P O L Y M E R A S E  C H A IN  R E A C T IO N  (P C R )
In order to study the importance of specific transcription factor binding sites on both 
the CD23a and CD23b promoters, a series of synthetic oligonucleotides were 
designed using the published cDNA sequences of each (EMBL accession number; 
M30447). These oligonucleotides contained both a Kpn I and Bgl II restriction 
enzyme site in order to assist in subsequent cloning steps, and are described in the 
relevant materials and results sections. All PCR reactions were carried out in 
accordance with the method of Saiki et al (1985) in 0.5ml microfuge tubes and 
performed in a Techne Genius PCR machine. Optimal conditions and components 
were determined for each primer and gene amplification, including that the PCR 
annealing temperature was at least 5°C below the Tm of each primer. The reaction 
mixtures are described below, as is an example of the PCR cycle parameters.
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REACTION MIXTURE:
Component
Template DNA 
Upstream Primer 
Downstream Primer 
dNTP mix
10 X Taq Reaction Buffer 
25mM magnesium 
Taq DNA Polymerase 
dH2Ü
Final concentration
lOng/p.1
50pmol
50pmol
Q.2mM
Ix
1.25mM 
0.025u/pl 
to 40pl
COMMONLY USED CYCLE PARAMETERS:
95°C for 2 min
{95“C for 1 min 
(Tm-5°C) for 1.5 min 
72“C for 1.5 min} 
72°C for 7 min
X 35 Cycles
Following the PGR reaction, 2 x loading buffer (Appendix) was added to the 
samples and they were analysed on a 1% (w/v) agarose gel, purified, digested and 
cloned into the pSEAP enhancer vector.
2.2.6b: AGAROSE GEL ELECTROPHORESIS AND PURIFICATION OF 
DNA FROM EXCISED BANDS
A 1% (w/v) agarose gel was prepared by mixing Ig of multi-purpose agarose into a 
total volume of 100ml 1 x TAB buffer (see appendix), boiling and allowing to cool
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to 55“C prior to the addition of 200jal of 0.5mg/ml ethidium bromide. The gel was 
then poured to 1cm thick and allowed to set at room temperature. PCR reaction 
products were subsequently loaded onto the prepared gel, separated by 
electrophoresis at lOOV and the desired DNA band excised using a clean, sterile 
scalpel. The DNA was purified from the agarose by using a Wizard gel extraction 
kit, in accordance with manufacturers instructions. Briefly, the agarose slice was 
placed into a 1.5ml microfuge tube and melted by incubation at 70°C, prior to 
mixing with 1ml of Wizard gel extraction resin. The resin/DNA mix was then 
introduced to a Wizard minicolumn under vacuum, washed by pulling 2ml of 
isopropanol over the DNA/resin complex and dried by continuing to draw the 
vacuum for a further 30 seconds. Any residual isopropanol was removed by 
centrifugation at 10,000 x g for 2 min, followed by DNA elution with 50p,l of water. 
DNA concentration was then estimated, as below, and the DNA aliquoted and stored 
at -20°C until required.
2.2.6c; DNA PURITY AND CONCENTRATION
DNA purity and concentration was measured using a Helios y spectrophotometer. 
The A26o:A280 ratio setting allowed purity to be calculated, with a figure of 1.8 to 
2.0 indicating an acceptably high level of purity. The concentration of DNA was 
calculated by, firstly, diluting the DNA sample I in 100 with the same buffer it was 
resuspended in and, secondly, manipulating the A26O reading as follows;
A260 X 100 X 50
1000 = X mg/ml
where 100 is the dilution factor and 50 is the DNA concentration multiplication 
factor.
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2.2.6d; RESTRICTION ENZYME DIGESTS OF VECTORS AND INSERTS
The following digestion reaction mixture was assembled for each restriction enzyme, 
and incubated at 37°C for 2 hr:
10|0,1 of DN A/vector
2|xl of restriction enzyme
4(il of restriction digest buffer
24ulofdH20
4Qui
After the incubation, a phenol-chloroform extraction was performed, followed by a 
chloroform-only extraction and subsequent precipitation by incubation for 1 hr at 
-70“C with 20|il of ammonium acetate and lOOjal of 100% ethanol. The digest was 
centrifuged at 12, OOOx g for 5 min at 4°C, wa^ed with 70% ethanol and allowed to 
air dry. This step removed restriction digest buffers. After which, the DNA could 
be cut with other restriction enzymes, resuspended in TE buffer (appendix) and 
separated on an agarose gel to verify sizes.
2.2.6e; LIGATION OF VECTORS AND INSERTS
Assuming that:
si = size of insert, sv = size of vector, riv = molar ratio of inserf.vector, t = total 
amount of DNA (vector and insert), i = amount of insert required, v = amount of 
vector required and;
i  =  s i  X t  V =  t  X sv
[ ( s v /r iv  ) +  s i]  s v  +  ( s i  x  r iv )
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The ligation reaction was assembled as such:
vjO-l of vector DNA(100ng/|LLl) 
ijXl of insert DNA (lOOng/ql) 
l|ll of T4 DNA ligase 
1 pi of 10 X ligase buffer 
dHiO to lOpl
The mixture was incubated at 16°C overnight, and then used to transform competent 
cells.
2.2.6f: TRANSFORMATION OF COMPETENT CELLS
lOOpl of competent bacterial cells (JM109 or DH5a) were placed into a sterile pre­
chilled eppendorf tube, and Ipl of purified control plasmid or 5pi of ligation reaction 
added. The suspension was gently mixed, without vortexing, prior to incubation on 
ice for 30 min. The cells were then heat shocked at 42°C for 40 seconds and 
returned to ice. Incubation with lOOpl of SOC medium (see appendix) at 37°C for 1 
hr followed, prior to spreading lOOpl of the mixture onto an LB/Ampicillin agar 
plate. The plate was allowed to dry, inverted and incubated at 37°C overnight.
2.2.6g: SMALL SCALE PREPARATION OF PLASMID DNA (MINI-PREP)
A single bacterial colony was picked from an LB/Amp agar plate and grown up in 
10ml of LB broth, supplemented with 0.05 mg/ml ampicillin, overnight at 31°C. 
1.5ml of the cell suspension was then spun down at 350 x g for 5 min, and the cell 
pellet resuspended in 100ml of STET mixture (9 volumes of STET [see appendix] 
and 1 volume of lOmg/ml lysosyme). The preparation was then boiled for 2 min.
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prior to centrifugation for 10 min at 12, 000 x g. The supernatant was transferred 
into a fresh tube, along with 400pl of 0.3M NaOAc and 500pl of isopropanol, and 
precipitated at -20“C for 1 hr. The precipitate was spun down at 12000 x g for 10 
min at 4“C, washed with 70% ethanol, and resuspended in 30pl of TE buffer. 5pi of 
the prepared DNA was cut out and run on a 1% agarose gel.
2.2.6h: LARGE SCALE PREPARATION OF PLASMID DNA (MAXI-PREP)
After successful analysis of mini-prep DNA, large quantities of "purified" DNA for 
use in salt-sensitive applications - such as PCR or transfection - were required. This 
was prepared using a Qiagen Maxi Plasmid Kit in accordance with the 
manufacturer's instructions, and using the materials and reagents supplied.
Briefly, 200pl bacterial cultures in LB broth, supplemented with 0.05mg/ml 
ampicillin, were grown overnight and harvested by centrifugation at 6, 000 x g for 
15 min at 4°C. The pellet was then resuspended in 10ml of supplied solution PI, 
with a further addition of 10ml of solution P2 prior to incubation at RT for 5 min. 
7.5ml of chilled buffer P3 was then added and the resulting lysate mixed by 
inversion, incubated on ice for 20 min and centrifuged twice at 20, 000 x g for 30 
min at 4°C. The supernatant was then loaded on to a pre-equilibrated Qiagen Maxi 
column and allowed to flow through under gravity, the DNA remaining in the 
column matrix. Three wash steps with buffer QC followed and then elution of the 
plasmid DNA was achieved using buffer QF. Eluate DNA was precipitated out by 
the addition of 10.5ml of isopropanol, centrifugation at 15, 000 x g for 30min at 4°C, 
followed by washing twice with 70% ethanol. After air drying the pellet, the DNA 
was resuspended in 300pl of TE buffer and the DNA concentration determined by 
spectrophotometry. Aliquoted DNA was stored at -20°C.
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2.2.61: ELECTROPORATION OF CELLS
Cells were harvested from culture by centrifuging at 350 x g for 5 min at RT, 
washed with serum-free RPMI-1640 medium, resuspended at a concentration of 6.25 
X 106 cells/ml and chilled on ice for 10 min. Chilled electroporation cuvettes were 
prepared by adding 40jag of plasmid DNA (in TE buffer) to each, and then 0.8ml of 
chilled cell suspension. Cuvettes were transferred to a BIO-RAD electroporator, 
pulsed for 10 seconds at 0.3kV and 960)xF and then placed on ice for a further 10 
min. Cells were transferred to 4.2ml of complete, pre-warmed RPMI-1640 medium, 
rested for 1-2 hr prior to stimulation and then cultured for 48 or 72 hr (depending on 
assay conditions) at 37°C in a 5% CO2 humidified environment.
2.2.6j: pSEAP REPORTER VECTOR ASSAY
The chemiluminescent SEAP assay (Clontech) was carried out as in the 
manufacturer's instructions, and using the reagents provided. Briefly, 125pl of cell 
culture was removed at the required time-point, and cells were pelleted by 
centrifugation at 12000 x g for 10 seconds. The supernatant was then transferred to 
a fresh microfuge tube and, if necessary, could be stored at -20°C until ready for use. 
Sufficient volumes of buffers were allowed to equilibrate to RT, and 1 x dilution 
buffer was prepared by diluting the supplied 5 x buffer with dH2Û. Samples were 
thawed, 15pl added to each well of a 96 well opaque plate and subsequently diluted 
with 45p.l of the prepared dilution buffer. The resulting mixtures were incubated at 
65 °C for 30 min to heat-inactivate their intracellular acetylases, allowed to cool to 
RT and then 60pl of assay buffer was added. The solutions were incubated at RT for 
5 min, prior to the addition of 60ql of diluted CSPD substrate (1 in 20 with 
chemiluminescent enhancer). The plate was then incubated for at least 10 min at 
RT, and the results acquired on a plate luminometer. SEAP assay results were
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normalised using pLW2 co-transfection and subsequent CAT assay, allowing 
transfection efficiency to be taken into account.
2.2.6k: CHLORAMPHENICOL ACETYL TRANSFERASE (CAT) ASSAY
As described by Ono et al in 1991, transfected cells were harvested from culture by 
centrifugation at 350 x g for 5 min and washed twice with 25ml of PBS. Cells were 
resuspended in 100|xl of 250mM Tris-HCl (pH 7.8), and subjected to 3 freeze/thaw 
cycles by immersing in dry ice/ethanol and then a 3TC  water bath at 5 min intervals. 
Samples were then centrifuged at 12, 000 x g for 10 min, the supernatant retained in 
fresh sterile eppendorfs and the cellular acetylases heat-inactivated at 65°C for 10 
min. The protein content of each sample was determined at this point, and they were 
each adjusted to account for concentration and volume. Acetyl co-enzyme A was 
added to a final concentration of 5mM, followed by the addition of 1ml of [^^C]- 
chloramphenicol (0,025|LiCi) and incubation at 37“C for 3 hr. The assay was 
terminated by the addition of 600fxl of ethyl acetate, vortexed for 30 sec and 
centrifuged at 12, 000 x g for 5 min. 520pl of the upper phase was transfered to a 
fresh tube and lyophilised in a speedivac for 30 min, followed by resuspension in 
20|xl of ethyl acetate. Each sample was dotted onto a silica thin layer 
chromatography plate, and separated using the 95% chloroform/5 % methanol 
solvent system for 1 hr. The CAT assay was then visualised by exposing on a 
phosphorimaging screen overnight.
■* ■»
87
2.2.7: IN VIVO FOOTPRINTING UTILISING LIGATION-MEDIATED 
POLYMERASE CHAIN REACTION (LM-PCR) 
2.2.7a: DNA PREPARATION - MAXAM AND GILBERT METHOD (Maxam 
and Gilbert, 1980)
107 cells were harvested from culture and resuspended in 1ml of 10% (v/v) 
incomplete RPMI-1640 medium in dH2Ü, prior to the addition of 40|il of 0.5M 
HEPES (pH 7.3). For in vivo prepared DNA, 5ql of dimethyl sulphate (DMS) was 
added, left for 1 min and the reaction stopped by centrifugation for 5 min at 350 x g. 
The pelleted cells were then washed twice with ice-cold PBS containing 2% (v/v) 
mercaptoethanol, and lysed by rotating at 50°C overnight using the following lysis 
buffer;
20mM of Tris-HCl (pH7.5) 
lOmM of NaCl 
lOmMofEDTA 
lOOpl of 10% (v/v) SDS 
lOOpl of 10% (v/v) NP40 
200)111 of lOmg/ml Proteinase K
Following cell lysis, 1.2ml of 5M NaCl was added to the lysate and proteins 
removed by centrifugation at 5, 000 x g for 40 min. The DNA was then ethanol- 
precipitated from the lysate by incubation at -20°C for 2 hr, followed by 
centrifugation at 12, 000 x g for 15 min at 4“C. The DNA pellet was resuspended in 
200pl of TE buffer and the DNA concentration determined at A260- ^Opl of 98% 
(v/v) piperidine was then added, prior to the DNA being cleaved by heating to 90 C 
for 30 min. The piperidine was evaporated off by lyophilising the sample in a
speedivac, prior to resuspension of the DNA with TE buffer to a concentration of 
Ipg/ml. To prepare naked DNA, cells were lysed prior to DMS treatment,
2.2.7b: LIGATION-MEDIATED PCR OF CD25 AND CD23 PROMOTER 
REGIONS
All of the recipes for solutions used in this technique are described in the appendix, 
and the primers utilised are listed in the relevant results section. An overview of the 
ligation mediated PCR technique is shown on Figure 5.1 (page 157), and was 
described by Algarte et al in 1995. Initially, a first strand synthesis reaction was 
performed, in order to ensure correct annealing of primer 1 to the DNA. This was 
done by assembling the following reaction mixture components:
2|0-g of Maxam and Gilbert technique prepared DNA
5pl of first strand buffer
5 nmol of each dNTP
0.3pmol of primer 1
1 unit of Vent DNA polymerase
sterile dH20 to 25p,l
This rection mixture was then transferred for one cycle of PCR at the following 
parameters:
95°C for 1 min, (Tm-5“C) for 30 min, 76“C for 10 min.
After which the samples were chilled on ice and ligated overnight at 17° following 
the introduction of the following solutions:
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25pl first strand reaction (from above)
20pl dilution solution 
lOjiil 2 X ligation solution
15|il ligation mix (lOOpmol unidirectional linker, 4.5u T4 
DNA ligase, dH20)
After ligation, 9.4p,l of precipitation solution was added along with 220pl of 100% 
ethanol and nucleic acid precipitation was achieved at -20°C for 2 hours. The 
resulting nucleic acid pellet was resuspended in 70pl of dHaO and the following 
reaction mixture assembled and amplified by 18 PCR cycles as follows:
95°C for 1 min, (Tm-5°C) for 2 min, 76°C for 3min
with 5 seconds being added to each successive 76°C step in cycles 2-17, and the 
76“C step being run for 10 min in cycle 18. Samples were chilled on ice for 5 min, 
prior to the addition of 5pl of labelling mix (^ ^P labelled primer prepared as for 
EMSA assay - 2.2.5a) 1 unit of Vent DNA polymerase and mnning of the following 
thermal cycle:
95°C for 3.5 min, (Tm-5“C) for 2 min, 76 IC for 10 min, 95°C for 1 min, (Tm- 
5“C) for 2 min, 76“C for 10 min.
Therefore, two labelling cycles are completed. 300pl of ice-cold stop solution was 
then added and followed by a 400pl phenol chloroform extraction step. The 
aqueous phase was then split into 4 aliquots, ethanol precipitated at -20°C for 2 
hours and the labelled DNA collected by centrifugation at 12, 000 x g for 15 min at 
4°C. Washed DNA samples were then resuspendçd in 8pl of load dye, heated for 
two minutes at 75“C and run on a 6% "long ranger" sequencing gel.
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2.2.7c: FOOTPRINTING GEL PREPARATION AND RUNNING
A 6% (w/v) DNA sequencing gel solution was prepared using the ingredients listed 
in the appendix to this thesis. The solution was then de-gassed by vacuum and 
poured into 40 x 20 x 0.4 cm^ sequencing gel apparatus, prior to the insertion of a 
comb in order to form sample wells. Cling film was placed over the plates and the 
gel was then allowed to set for approximately two hours to allow efficient 
crosslinking of the acrylamide. Once set, the gel was pre-run for 10 minutes, and the 
wells washed out to remove any precipitated urea. 4pl of each LM-PCR sample was 
then placed in a corresponding well on the gel with fine duck-billed tips, and the gel 
electrophoresed at 55W for approximately 3 hours. It was important to maintain a 
gel temperature of 40-50°C to allow efficient running.
Following electrophoresis, the gel was placed on blotting paper and dried down for 
approximately 30 mins. This short drying time was sufficient, as the gel was so thin. 
The gel was then placed on autoradiographic film and the film developed on an X- 
omat developer after a 24 hour exposure.
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CHAPTERS
RESULTS
CHARACTERISATION OF CD23 PROTEIN EXPRESSION IN B 
LYMPHOCYTES AND B CELL LINES.
CHAPTER 3; CHARACTERISATION OF CD23 PROTEIN EXPRESSION IN 
B LYMPHOCYTES AND B CELL LINES. 
3.1; INTRODUCTION
The functional properties of CD23, the low affinity receptor for IgE, have been 
reviewed and discussed in Chapter I, as has the general cell biology of both the 
membrane-bound and soluble forms. Certain signalling mechanisms have also been 
proposed, including the STAT-6 and NFkB activation pathways. CD23 has been 
implicated in IgE negative feedback control mechanisms through knockout mouse 
studies (Haczku, et a l ,  1997), with the soluble form in particular found to be 
elevated considerably in atopic and in some forms of leukaemia (Jung, et a l ,  1995). 
As a result of CD23 being implicated in so many disorders it is a prime candidate for 
further study and, later in this thesis, the differential activation of expression of each 
CD23 isoform (a and b) will be studied in detail through reporter vector constructs 
and LM-PCR studies. This chapter, however, describes the initial studies that were 
required for the long term outcome of this research, and helped to determine which 
experimental techniques and cellular models were to be used to further the study.
It was considered paramount to phenotype and characterise the potential cell lines 
and primary cells that were to be utilised, and also to define candidate CD23 
transcriptional activation pathways. The following pages, therefore, include flow 
cytometric analysis, immunoprécipitation and western blotting studies of IL-4 and 
IL-13 stimulated cells and electrophoretic mobility shift assays (EMSAs) carried out 
using transcription factors suspected to be involved in CD23 activation.
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3.2: RESULTS
3.2.1: Phenotypic analysis of cell lines and primary tonsillar B cells
Cell lines and primary tonsillar B cells were phenotyped using flow cytometric 
analysis for the detection of Cluster of Differentiation (CD) markers expressed on 
their cell surfaces. Flow cytometry is a means of measuring certain physical and 
chemical characteristics of cells or particles as they travel in suspension, one by one, 
past a sensor. A typical flow cytometer is represented on Figure 3.1 and consists of 
a light source, collection optics, electronics and a computer to translate signals into 
data. A laser in the cytometer omits coherent light at a specified wavelength and 
scattered and emitted light is collected by two lenses, one set in front of the light 
source and the other set at right angles to it. Specific bands of fluorescence can be 
measured by a series of optics, beam splitters and filters This information was then 
used to define the cellular origin and maturation status of each cell type. The 
applications of flow cytometiy are numerous and physical characteristics such as cell 
size, shape, internal cellular complexity, and, in this study, any cell component or 
function that can be detected by a fluorescent compound can be examined. Typical 
flow cytometric histograms are shown on Figure 3.2 for the EDR cell line and in 
relation to the unstained cell population, which is represented by the shaded part of 
the graph, the cell surface antigens which are expressed by these cells are clearly 
shifted to the right. Therefore, EDR cells are CD 19 positive, CD3 negative, CD23 
positive, CD25 negative, GDI lb slightly positive, C D llc negative, avp5 negative, 
CD21 positive and CD47 highly positive.
The phenotyping data for all the other cell lines and primary B cells used in the 
course of this thesis are shown on Table 3.1., with "+++" indicating high marker 
expression, "++" showing medium expression and or representing low or 
borderline results. As would be expected, indicates no detectable marker
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expression whatsoever. CD 19 is the universal marker for lymphocytes of B cell 
lineage, with CD3 being the equivalent marker for T cells. CD23 is the low affinity 
receptor for IgE and CD25 is the a  chain component of the IL-2 receptor (Benschop 
& Cambier, 1999; Hewitt, et al,  1997), which can be induced on B cells, but is 
primarily involved in T-cell growth and development. CD21 is a membrane 
glycoprotein and cell adhesion molecule which binds CD23, as do CD 11b and c, 
which represent the a  chains of P2 integrin adhesion molecules (Lecoanet-Henchoz, 
et al,  1995). The avp5 complex is a CD23 receptor expressed on the pre-B cell line 
SMS-SB, as demonstrated in this laboratory (Matheson, et a l ,  2001) as well as on 
the mature human Burkitt's lymphoma cell line Ramos and on Jurkat T cell 
lymphoblasts. CD47 is a widely expressed cell marker, is thought to stabilise 
binding of the avp3 (and possibly avp5) vitronectin receptors to their ligands 
(Lindberg, et al, 1993) and is a recently described thrombospondin receptor (Gao, et 
al,  1996).
Much variation in marker expression was noted between the different cell lines, 
although a general trend was evident. In particular, the pre-B cells (e.g., SMS-SB) 
showed little significant expression of several tested markers, with the exception of 
CD 19, avp5 and CD47. It was, indeed, the lack of the other CD23 binding 
molecules on SMS-SB that led to the identification of av p s  as a CD23 receptor 
(Matheson, et al,  2001). The mature B cell line EDR, however, which is EBV 
transformed, showed high expression of CD 19, CD23, CD21 and CD47. This was 
not entirely unexpected, as EBV transformation has been shown to constitutively 
switch on CD23 expression in the majority of B cell lines (Kintner & Sugden, 1981) 
although P3HR1 cells are also EBV transformed, and show little constitutive CD23 
expression. Further experiments will determine if these cells can be successfully 
induced to express CD23 and CD25.
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The phenotype of tonsillar B cells is also shown on Table 3,1, and dot plots of these 
data are provided on Figure 3.3, with CD 19, CD21 and CD47 being significantly 
expressed. Primarily naive, unstimulated B cells are selected for culture during the 
tonsil cell preparation and purification process. The tabulated data for the tonsillar B 
cells is representative of the trend observed through many sets of tonsils, as each 
individual set showed minor variations in overall levels of markers. This is 
attributed to the fact that tonsils were obtained following excision from several 
different patients and, subsequently, each set was prone to minor physiological 
variations. Those patients harbouring some sort of bacterial infection, for example, 
would invariably have a higher amount of activated B cells in the cell preparation, 
potentially leading to the higher expression of certain markers upon FACS analysis 
(e.g., CD23 and CD25).
3,2.2: CD23 cell surface expression can be induced and increased by IL-4
Much of the work in this thesis was dependent on being able to stimulate CD23- 
negative cells to express the CD23 protein on their cell surface, in order that 
different stimuli, transcription factors and promoters could be studied. The next 
step, therefore, was to determine which cell lines would give a significant rise in 
CD23 expression upon stimulation with IL-4. Analysis was also carried out on 
primary tonsillar B cells. The technique used in this instance was, again, flow 
cytometry - which was used to detect CD23 expression on IL-4-treated and untreated 
cells.
Figure 3.4 shows a FACS histogram of CD23 expression on P3HR1 cells, with a 
clear increase after a 24 hour stimulation with IL-4. This data, and that for all the 
other cell lines (as well as tonsillar B cells), is shown in tabulated form on Table 3.2. 
The pre-B cell line SMS-SB shows no increase in CD23 expression whatsoever, 
which, as it is an immature cell line, is not a surprise. EDR cells show a high
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expression of CD23 prior to stimulation, so no significant increase is observed on 
stimulation. P3HR1 cells on the other hand, which show little CD23 expression 
prior to IL-4 treatment but exhibited a great increase after challenge. Tonsillar B 
cells show a similar activation pattern to the P3HR1 cells, but with an even greater 
level of stimulated expression of CD23. This is due to the fact that tonsillar B cells 
are from primary tissue and are, therefore, more sensitive to activation than 
established and transformed cell lines. It was concluded from these data that future 
experiments would be carried out using the P3HR1 cell line and, wherever possible, 
that primary tonsillar B cells would be preferentially used. At the initiation of these 
experiments primary tonsillar tissue was available only periodically, making these 
preliminary experiments and temporary substitution necessary. The result for Jurkat 
T cells is included in order to demonstrate the fact that T cells can also be induced to 
express CD23, as well as B cells. CD23a is constitutively and cell type specifically 
expressed on B cells, whereas CD23b can be found on other haematopoietic cells 
when induced. Therefore the increase in CD23 expression on Jurkat T cells is due to 
CD23b, but the CD23 rise in B cells can be a result of an increase in expression of 
the a or b isoform.
3.2.3: Stimulation of P3HR1, SMS-SB and tonsillar B cells with IL-4, IL-13, 
anti-CD40, anti-p, chains and PMA
Throughout the course of this research, different stimuli will be used to activate the 
CD23a and CD23b promoters and the following FACS analysis was carried out in 
order to determine the effect of each of these agents on CD23 and CD25 cell surface 
marker expression. Primary tonsillar B cells, EBV-transformed P3HR1 mature B 
cells and SMS-SB pre-B cells were harvested following treatment with various 
potential mitogens and stimulants. The cells were analysed for both CD23 and 
CD25 expression and the reagents used were IL-4, IL-13, anti-CD40, anti-IgM (p 
chain specific) and PMA (phorbol myristoyl acetate). Although the main content of
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this research is carried out on CD23 it was necessary to investigate CD25 
stimulation at this stage, as the CD25 promoter was used as a model in the 
footprinting work discussed in chapter 5.
3.2.3a: Stimulation of CD23 and CD25 on tonsillar B cells
Dot plots for the results for CD23 expression on stimulated primary tonsillar B cells 
are shown on Figure 3.5. CD23 expression is substantially increased by IL-4 and 
PMA, increased to a lesser extent by IL-13, but not at all with anti-CD40 and anti-p. 
IL-4 and IL-13 are thought to activate CD23 expression through a STAT-6- 
dependent pathway, utilising the IL-4Ra chain present in both receptors, and PMA is 
known to activate cells through a PKC (protein kinase C) dependent pathway. Anti- 
CD40 generally stimulates CD23 expression through activation of NFkB 
transcription factors (Berberich, et al,  1994) and, as both CD23 promoter regions 
are known to have these sites, it would be expected that anti-CD40 would be a more 
potent CD23 inducer than this result implies. An explanation for this lack of 
induction could be that the particular anti-CD40 monoclonal antibody used did not 
recognise the specific epitope required for proper binding and activation. Burlinson 
et al (Burlinson, et al,  1996) touched on this subject when they compared their 
results with those of Valle et al (Valle, et al,  1989) and concluded that anti-CD40 
antibodies evoked different responses on tonsillar B cells depending on which 
specific epitope they recognised and bound. Anti-jti chain antibody is known to be a 
general B cell activator. It is a surprise, then, that CD23 expression does not appear 
to be stimulated following the addition of anti-p.. It was proposed that perhaps the 
cells were so highly stimulated that CD23 was being cleaved from the cell surface 
and was, therefore, undetectable through FACS analysis. This interpretation was 
tested by CD23 ELISA of conditioned cell culture medium from both control and 
anti-p stimulated cells, with this result being shown on Figure 3.6. The 
concentration of soluble CD23 in the culture medium of stimulated cells was found
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to be comparable with that of the control cells, therefore, the low expression of cell 
surface CD23 is not a result of enhanced cleavage of CD23 by cell surface proteins.
CD25 expression on tonsillar B cells was stimulated significantly with both IL-4 and 
PMA, with a small increase evident with IL-13 and anti-CD40 (Fig. 3.7). No 
apparent stimulation was observed following treatment with the anti-p chains. These 
data are consistent with work carried out by Hewitt et al (Hewitt, et al,  1997) and 
McKay et al (McKay, et al,  2000), who investigated the IL-4 signalling pathways of 
tonsillar B cells in great detail. These included the JAK/STAT, cAMP/PKA, PKC 
and PI-3 kinase pathways, and it was concluded that IL-4 achieves CD25 up- 
regulation by removing NRE (Negative Response Element) binding activity via a 
cAMP/PKA-sensitive pathway. A small increase in CD25 activation is also apparent 
in the lower right hand quadrant of the plot. This CD25 expression is not on B cells, 
as there is no CD 19 expression evident, and is thought to be due to very small 
numbers of T cells escaping the T cell resetting stage of the tonsillar B cell 
preparation.
3.2.3b: Stimulation of CD23 and CD25 on P3HR1 and SMS-SB cells
P3HR1 cells show similar patterns of response to stimulation to those observed with 
the tonsillar B cells (Table 3.3), although expression of CD23 and CD25 are not 
activated to such a great extent by IL-4 and PMA in the former case. This variation 
may be due to the fact that naive cells are more readily affected by certain stimuli 
than continually passaged cell lines. The P3HR1 cells were thus further concluded 
to be a good candidate as a model system for tonsillar B cells, and were used 
whenever difficulties were encountered in obtaining primary tissue.
The SMS-SB, pre-B ALL cell line, does not express CD23 or CD25 at any time, 
even following stimulation with IL-4, IL-13, anti-CD40, anti-|l or PMA. SMS-SB
99
cells were therefore considered as a good negative control for CD23- and CD25- 
expressing cells throughout the course of this work.
3.2.4: Phosphorylation of STAT-6 is increased following IL-4 and IL-13 
stimulation of tonsillar B cells
Flow cytometric analysis has demonstrated that IL-4 and IL-13 can lead to 
substantial increases in CD23 expression. As discussed, IL-4 and IL-13 aie known 
to act through similar receptors and are both known to activate STAT-6, STAT-6, a 
signal transducer and activator of transcription, is a member of a family of 
cytoplasmic transcriptional activators (STAT's 1-4, 5a, 5b and STAT-6). All STATs 
contain a carboxy-terminai SH2 domain, an SH3 domain and a conserved DNA 
binding region and are linked to receptor ligation via phosphorylation with the Janus 
kinases (JAKS) (Wilks, et ai,  1991). Phosphorylated STAT-6 dimerises and is 
translocated to the cell nucleus, where it binds to a specific response element on the 
DNA and initiates gene expression (see "The STAT-6 Activation Pathway" - 1.4.7).
Experimental evidence was sought to determine if IL-4 and IL-13 were capable of 
stimulating CD23 expression through a STAT-6 dependent pathway in this instance. 
In order to do this, STAT-6 was immunoprecipitated from extracts of control or 
stimulated cells, run on an SDS-PAGE gel and immunoblotted with anti-p-Tyr to 
follow the extent of STAT-6 phosphorylation over a specific period of time. Figures 
3.8 and 3.9 show the anti-p-Tyr immunoblots for IL-4- and IL-13- stimulated 
tonsillar B cells, respectively. A clear increase in STAT-6 phosphorylation was 
observed over the 30 minute time-course with both stimulants, although the result 
for IL-13 stimulation showed a more clear-cut distinction between the treated and 
control cells. It was considered that, perhaps, it was the actual amount of STAT-6 
that was increasing over time, rather than its phosphorylation. Therefore an identical 
experiment was run in parallel, with the exception that blotting was for STAT-6
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itself as opposed to p-Tyr. The results of the STAT-6 immunoblotting are also 
shown on Figures 3.8 and 3.9, and confirm that it is solely tyrosine phosphorylation 
status of STAT-6 that increases upon IL-4 and IL-13 activation, and not the STAT-6 
concentration. It can be concluded through these immunoprécipitation experiments 
that IL-4 and IL-13 stimulate STAT-6 dependant pathways, and it can be 
hypothesised that the increase observed in CD23 expression upon IL-4 and IL-13 
stimulation may occur as a result of this.
3.2.5: Electrophoretic Mobility Shift Assay (EMSA) shows increases in both 
STAT-6 and NFkB activation following stimulation
Flow cytometry has shown in section 3.2.3a that certain stimuli can drive cell 
surface expression of CD23 on tonsillar B cells. Mainly IL-4, IL-13, anti-CD40 and 
PMA were seen to elicit an increase in the presence of CD23, although FACS alone 
could not determine exactly how this was achieved or which transcription factors 
were involved in this process. A technique was required that would allow an insight 
into which DNA binding proteins/transcription factors were activated via each 
potential stimulator of CD23 expression.
The electrophoretic mobility shift or "gel-shift" assay is a method by which 
oligonucleotides, which bind specifically to certain cellular proteins, are radio­
labelled and mixed with a protein extract. Upon recognition and binding of the 
specific protein, and subsequent loading on to a non-denaturing electrophoresis gel, 
the radiolabelled oligonucleotide/protein complex electrophoreses more slowly than 
the unbound radiolabelled oligo). Bands, representing specific binding species on 
the gel, can then be visualised by autoradiography and used to determine activation 
states.
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EMSA was carried out for the specific transcription factors STAT-6 and NFkB, on 
cellular lysates prepared following treatment of tonsillar B cells with IL-4, IL-13, 
anti-CD40, anti-p and PMA. The oligonucleotides used are listed in the Materials 
section of this thesis (2.1.8) Figure 3.10 shows the autoradiograph of a STAT-6 gel 
shift assay following a 24hr stimulation period with all of the potential stimulants. 
The specific STAT-6 binding species, labelled with an arrow, is seen to increase in 
intensity upon stimulation with IL-4 and IL-13, but not with anti-CD40 or PMA. 
Anti-p., in fact, appears to cause a loss of band intensity. This work further supports 
the hypothesis that IL-4 and IL-13 stimulate the expression of CD23 via a STAT-6- 
phosphorylation dependent pathway. How STAT-6 or STATs in general are able to 
activate transcription is unclear, although it is believed that activated STAT's form 
complexes with other transcription factors in the nucleus - such as nuclear factor kB 
(NFKB) (Shen & Stavnezer, 1998).
NFkB, a widely expressed protein which regulates gene expression, is comprised of 
homodimers or heterodimers that belong to the Rel family of proteins (Baldwin, 
1996). It is bound to inhibitor proteins called IkB, of which there are three isoforms; 
iKB-a, P and £. When NFkB is induced, the IkB serine residues are phosphorylated 
and the IkB protein degraded, allowing NFkB to translocate to the nucleus where it 
is able to regulate gene expression (Di Donato, et al,  1997; Maniatis, 1997).
NFkB EMSAs were carried out on whole cell extracts, following stimulation of 
tonsillar B cells with IL-4, IL-13, anti-CD40, anti-p and PMA (Fig. 3.11). Increases 
in specific band intensity are clearly observed from the cell lysates following IL-13, 
anti-CD40 and anti-p stimulation, although IL-4 treatment actually appears to reduce 
the binding to the NFkB oligonucleotide in relation to the non-stimulated cells. The 
latter could indicate that, upon IL-4 stimulation, some sort of negative regulatory 
process blocks NFkB activation. IL-13 is normally associated with the STAT-6 
activation pathway, but the activation of NFkB in these experiments suggests an
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additional role for the IL-13 cytokine in NFkB signalling pathways, perhaps through 
the activation of some intermediary step. PMA treatment causes no change in 
specific NFkB EMSA band intensity. To further investigate the effects of anti- 
CD40, a time-course of exposure to this stimulant was also analysed by NFkB 
EMSA (Fig. 3.12). The autoradiograph for this experiment shows an increase in 
specific band intensity (highlighted by arrow) following 45 minutes of anti-CD40 
stimulation, followed by a further increase after 60 minutes of treatment. Anti-CD40 
stimulation of NFkB is thought to be bi-phasic, however, with NF-kB activation 
increasing with an initial fast response and then a later, presumably more sustained, 
greater response. The fact that this bi-phasic pattern is not shown here could be as a 
result of no shorter time points being taken within the first 15 minute interval.
It should be borne in mind that these EMSA results are representative of 'the 
stimulation and preparation of the protein content of whole cells. These whole cell 
lysate (WCL) stimulations reflect the general results for STAT-6 and NFkB 
activation for the entire cell and not just in relation to the promotion of CD23 
transcription. Also, these results are representative of a whole cell population, which 
may not respond uniformly to stimulation. Therefore, caution should be exercised 
when interpreting these results as in direct relation to CD23, or indeed any other 
specifically expressed protein.
3.2.6: Conclusion and discussion
The preceding experiments have provided valuable information on the cells which 
will be used in the bulk of the research in this thesis; information such as phenotype, 
CD23 expression, susceptibility to stimulation and activation of STAT-6 and NFkB. 
To re-cap, the main findings were as follows: Different B cell lines and tonsillar B 
cells all express varying degrees of particular cell surface markers, including the low 
affinity receptor for IgE, CD23. The EDR mature B cell line has constitutively high
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levels of CD23, which is thought to reflect its EBV-transformed status, whereas the 
immature B cell lines do not. Additionally P3HR1 cells, which are also EBV 
transformed, and tonsillar B cells show low constitutive CD23 levels which aie 
considerably elevated upon stimulation with IL-4 in paiticular. This similaiity 
between P3HR1 cells and tonsillar B cells made the former a suitable substitute for 
the latter when tonsillar tissues was scarce. The immature B cell lines are not 
subject to stimulus-induced CD23 expression.
IL-4 and IL-13 stimulation were both shown to cause an increase in STAT-6 
tyrosine phosphorylation, with no observable increase in actual STAT-6 
concentration. These results led to the hypothesis that IL-4 and IL-13 could activate 
expression of CD23 through a STAT-6-dependent activation pathway. Although, it 
should be noted that from the evidence presented here alone (IL-4 and IL-13 
stimulate both CD23 expression and STAT-6 phosphorylation), it is not possible to 
categorically define a link between the two events. Principally, this is due to the fact 
that the immunoprécipitation experiments were carried out using whole cell protein 
lysates, meaning that the results are representative of all the STAT-6 in the cells and 
not just that which is acting on the CD23 promoters. This fact is also worth noting 
where the EMSA results are concerned, as they are also carried out on proteins from 
whole cell lysates.
These EMSA results confirm that the activation of STAT-6 occurs upon cell 
stimulation with IL-4 and IL-13, with increases in band intensity evident on samples 
treated in such a fashion. They also show that NFkB stimulation is increased upon 
IL-13, anti-|i and anti-CD40 stimulation, with anti-CD40 stimulation of NFkB 
occurring as a bi-phasic response.
It is extremely important to note at this stage that none of the above B cell 
phenotyping or stimulation experiments give information concerning which isoform
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of CD23 was specifically expressed in each case (although the stimulated T cell 
CD23 is likely to be CD23b only). B cells constitutively express CD23a and can be 
stimulated to upregulate the expression of both isoforms, although the monoclonal 
antibodies used for flow cytometry detect only the presence of CD23 and not the 
individual isoforms. This is attributed to the fact that the only observable difference 
between the two isoforms is intra-cytoplasmic and not on the extracellular domain. 
It was considered of great importance to use the information discussed in this 
chapter to design experiments which could hopefully help define the differential 
expression of each isoform, and the subsequent activation of each. This will be 
addressed in depth in the reporter vector construct studies in Chapter 4.
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Figure 3,1: Overview of flow cytometer function
Flow cytometry is a means of measuring certain physical and chemical 
characteristics of cells or particles as they travel in suspension, one by one, past a 
sensing point. A typical flow cytometer is represented on this figure and consists of 
a light source (laser), collection optics, electronics and a computer to translate 
signals into data. Samples enter the system at the interrogation point shown on this 
diagram and light from the laser, which omits coherent light at a specified 
wavelength, is scattered and collected by two lenses, one set in front of the light 
source (towards the forward scatter detector) and the other set at right angles to it. 
Specific bands of fluorescence are measured by a series of optics, beam splitters and 
filters, with the side scatter detector being at right angles to the beam splitter and the 
fluorescence (FL) 1 and 2 detectors detecting light of 530nm (FITC) and 585nm 
(PE), respectively. The dichroic mirror allow light of less than 560nm to pass 
straight through to the FLl detector but reflects light above this frequency towards 
the FL2 detector, hence the ability of the cytometer to separate the fluorescence 
emitted from both wavelengths (e.g.. both FITC and PE labelled cells). This 
information is then used to define the cellular origin and maturation status of each 
cell type. Emitted light from the cells, as well as fluorescent label, is also collected.
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Figure 3.2: Flow cytometric ptienotyping of EDR cells
EDR B cells were harvested from culture, washed twice in ice-cold PBS and 
resuspended at 1x10^ cells per lOOpl of PBS. 3|li1 of each FITC- or PE- labelled 
antibody was then added as required to each sample, (all of the antibodies used here 
were FITC-labelled, apart from anti-CD 19 which was PE-labelled), prior to 
incubation of the samples on ice for Ihr. Cells were then again washed twice with 
ice-cold PBS, resuspended in 500pl of PBS and analysed on a Becton Dickinson 
FACScan flow cytometer.
The y-axis is representative of the number of events counted, and the x-axis (FL-1 or 
FL-2) shows the intensity of signal at each specific wavelength.
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Table 3.1: Phenotyping of cell lines and tonsillar B cells
B cell lines and primary tonsillar B cells were harvested from culture, washed twice 
in ice-cold PBS and resuspended at 1x10^ ceils per lOOpl of PBS. 3pi of FITC- or 
PE- labelled antibody was then added as required to each sample, (all of the 
antibodies used here were FITC-labelled, apart from anti-CD 19 which was PE- 
labelled), prior to incubation of the samples on ice for Ihr. Cells were then again 
washed twice with ice-cold PBS, resuspended in 500pl of PBS and analysed on a 
Becton Dickinson FACScan flow cytometer. FITC-labelled cells were detected with 
FLl and PE-labelled cells with FL2.
The phenotyping data was then translated and compiled as shown; with "+++" 
indicating high marker expression, "++" showing medium expression, "+" or 
representing low or borderline results and indicating no detectable cell surface 
marker presence.
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Figure 3.3: Flow cytometric phenotyping of tonsillar B cells
Tonsillar B cells were prepared from primary tissue as indicated in the methods 
section of this thesis (2.2.2a), harvested from culture, washed twice in ice-cold PBS 
and resuspended at 1x10*5 cettg per lOOpl of PBS. 3p,l of each FITC- or PE- labelled 
antibody was then added as required to each sample, (all of the antibodies used here 
were FITC-labelled, apart from anti-CD 19 which was PE-labelled), prior to 
incubation of the samples on ice for Ihr. Cells were then again washed twice with 
ice-cold PBS, resuspended in 500p.l of PBS and analysed on a Becton Dickinson 
FACScan flow cytometer.
The lower left hand quadrant of the dot plot indicates the unstained cell population, 
the lower right shows FLl-only fluorescing cells (i.e.. FITC-labelled), the upper left 
indicates FL2 only fluorescing cells (i.e. PE-labelled, CD19+ B cells) and the upper 
right hand quadrant is representative of cells which are doubly positive for both PE 
and FITC staining. Thus, the upper right hand quadrant distinguishes B cells which 
also show expression of the tested cell surface marker.
The numbers shown represent the percentage of CD 19 expressing B cells which also 
express the tested cell surface marker.
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Figure 3.4: Flow cytometric analysis of IL-4-stimulated P3HRIB cells
Freshley sub-cultured P3HRI B cells were stimulated for 24hr with InM of IL-4, 
harvested from culture, washed twice in ice-cold PBS and resuspended at 1x10^ cells 
per lOOpl of PBS. 3jil of FITC-labelled anti-CD23 antibody was then added prior to 
incubation of the samples on ice for Ihr. Cells were again washed twice with ice- 
cold PBS, resuspended in SOOjil of PBS and analysed on a Becton Dickinson 
FACScan flow cytometer. FITC-labelled cells were detected with FLl.
The shaded red part of the histogram is representative of unstained cells, the yellow 
peak shows the base-line CD23 expression on unstimulated cells and the green peak 
is indicative of CD23 cell surface expression following IL-4 stimulation.
Table 3.2: CD23 expression on IL-4-stimulated and unstimulated cells
The indicated B cell lines and tonsillar B cells were prepared for flow cytometric 
analysis as above, and the resulting data was then translated and compiled as shown; 
with "+++" indicating high marker expression, "++" showing medium expression, 
representing low results and indicating no detectable cell surface marker 
presence.
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CELL TYPE/LINE CD23 EXPRESSION/- 
IL-4 STIMULATION
CD23EXPRESSION/+
IL-4STIMULATION
EDR +++ +-1-+
JIJOYE + ++
P3HR1 - +++
RAMOS + ++
SMS-SB - -
NALM-6 - -
JURKAT - ++
TONSIL B CELLS - -t-t-+
Figure 3.5: CD23 expression on stimulated tonsillar B cells
Tonsillar B cells were stimulated for 24hr with each of 14ng/ml of IL-4, 6ng/ml IL- 
13, Ipg/ml anti-CD40, 1 |ig/ml anti-|i and 6nM PM A. Cells were then harvested 
from culture, prepared for flow cytometric analysis as before (2.2.3) and analysed on 
a Becton Dickinson FACScan flow cytometer.
Anti-CD23-FITC-labelled CD 19+ B cells are indicated in the upper right hand 
quadrant of the dot plots.
The numbers shown represent the percentage of CD 19 expressing B cells which also 
express CD23.
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Figure 3.6: sCD23 ELISA of anti-|Ll stimulated tonsillar B cells
Tonsillar B cells were stimulated for 24hr with Ijig/ml of anti-ft, supernatant 
removed and analysed for sCD23 concentration by enzyme linked immunosorbant 
assay (ELISA). ELISA protocol provided and carried out by Dr Gillian Borland.
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Figure 3.7: CD25 expression on stimulated tonsillar B cells
Tonsillar B cells were stimulated for 24hr with each of 14ng/ml of IL-4, 6ng/ml IL- 
13, IjO-g/ml anti-CD40, 1 ttg/ml anti-fi and 6nM PM A, Cells were then harvested 
from culture, prepared for flow cytometric analysis as before (2.2.3) and analysed on 
a Becton Dickinson FACScan flow cytometer.
Anti-CD25-FITC-labelled CD 19+ B cells are indicated in the upper right hand 
quadrant of the dot plots, with the lower right hand quadrant showing CD25 
expressing non-B cells.
The numbers shown represent the percentage of CD 19 expressing B cells which also 
express CD25.
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Table 3.3: CD23 and CD25 expression on stimulated tonsillar B cells and the B 
cell lines P3HRI and SMS-SB
P3HRI and SMS-SB cell lines and tonsillar B cells were stimulated separately for 
24hr with each of 14ng/ml of IL-4, 6ng/ml IL-13, Ipg/ml anti-CD40, 1 jag/ml anti-p 
and 6nM PM A. Cells were then harvested from culture, prepared for flow 
cytometric analysis as before (2.2.3) and analysed on a Becton Dickinson FACScan 
flow cytometer.
The resulting data was translated and compiled as shown; with "+++" indicating high 
marker expression, "++" showing medium expression, or representing low 
or borderline results and indicating no detectable cell surface marker presence.
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Figure 3.8: STAT-6 phosphorylation and concentration upon IL-4 stimulation
1x10^ tonsillar B cells per ml were prepared as described in section 2.2.4c. Briefly, 
cells were stimulated over a 30min time-course with 14ng/ml IL-4, lysed in RIPA 
buffer and incubated at 4“C for 4hr with l|Xg of anti-STAT-6 antibody. lOpI of 
protein-G agarose were then added to the solution and samples rotated overnight at 
4°C to allow the formation of immunoprecipitates. Immunoprecipitates were 
collected, washed in RIPA buffer, resuspended in loading buffer, denatured and run 
on a 10% (w/v) polyacrylamide gel. Protein was transferred to nitrocellulose via 
western blotting, as described in 2.2.4d, prior to immunoblotting with anti-p-Tyr and 
anti-STAT-6 antibodies (2.2.4e).
Unstimulated control samples are represented with " and IL-4-stimulated samples 
with
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Figure 3.9: STAT-6 phosphorylation upon IL-13 stimulation
1x10^ tonsillar B cells per ml were prepared as described in section 2.2.4c. Briefly, 
cells were stimulated over a 30min time-course with 6ng/ml IL-13, lysed in RIPA 
buffer and incubated at 4°C for 4hr with Ipg of anti-STAT-6 antibody. lOpl of 
protein-G agarose were then added to the solution and samples rotated overnight at 
4°C to allow the formation of immunoprecipitates. Immunoprecipitates were 
collected, washed in RIPA buffer, re-suspended in loading buffer, denatured and run 
on a 10% (w/v) polyacrylamide gel. Protein was transferred to nitrocellulose via 
western blotting, as described in 2.2.4d, prior to immunoblotting with anti-p-Tyr and 
anti-STAT-6 antibodies (2.2.4e).
Unstimulated control samples are represented with " -” and IL-13-stimulated 
samples with
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Figure 3.10; STAT-6 EMSA of stimulated tonsillar B cell lysate
Tonsillar B cells were stimulated for 24hr with each of 14ng/ml of IL-4, 6ng/ml IL- 
13, Ipg/ml anti-CD40, 1 pg/ml anti-p and 6nM PMA. Cells were then harvested 
from culture, lysed in RIPA buffer and 5pg of lysate added to each EMSA sample 
(2.2.5b). Briefly, 5pg of stimulated or unstimulated extract was added to a lOpl 
reaction mixture containing binding buffer (BB), dH20 , and ^^P-labelled STAT-6 
oligonucleotide (Ip l of specific or non-specific oligonucleotide is added for 
competitor or non-competitor controls, respectively). The reaction mixtures were 
then incubated at room temperature for 20min prior to running on a 7% non­
denaturing gel (section 2.2.5c), diying and autoradiography.
Specific STAT-6 binding species are highlighted by arrow, with the specific stimuli 
used noted at the top of the graph.
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Figure 3.11; NFkB EMSA of stimulated tonsillar B cell lysate
Tonsillar B cells were stimulated for 24hr with each of 14ng/ml of IL-4, 6ng/ml IL- 
13, Ipg/ml anti-CD40, 1 pg/ml anti-p and 6nM PMA. Cells were then harvested 
from culture, lysed in RIPA buffer and 5pg of lysate added to each EMSA sample 
(2.2.5b). Briefly, 5pg of stimulated or unstimulated extract was added to a lOpl 
reaction mixture containing binding buffer (BB), dH20 , and 32p_iabelled NFkB 
oligonucleotide (Ip l of specific or non-specific oligonucleotide is added for 
competitor or non-competitor controls, respectively). The reaction mixtures were 
then incubated at room temperature for 20min prior to running on a 7% non­
denaturing gel (section 2.2.5c), drying and autoradiography.
Specific NFkB binding species are highlighted by arrow, with the specific stimuli 
used noted at the top of the graph.
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Figure 3.12; NFkB EMSA of anti"CD40 time-course stimulated tonsillar B cell 
lysate
Tonsillar B cells were stimulated over a Ihr time-course with Ijig/ml of anti-CD40 
monoclonal antibody. Cells were harvested from culture at the appropriate time, 
lysed in RIPA buffer and 5|ig of lysate added to each EMSA assay (2.2.5b). Briefly, 
5pg of time-course stimulated or unstimulated extract was added to a lOjill reaction 
mixture containing binding buffer (BB), dH2 0 , and 32p_iabelled NFkB 
oligonucleotide (Ifxl of specific or non-specific oligonucleotide is added for 
competitor or non-competitor controls, respectively). The reaction mixtures were 
then incubated at room temperature for 20min prior to running on a 7% non­
denaturing gel (section 2.2.5c), drying and autoradiography.
Specific NFkB binding species are highlighted by arrow, and the time of each 
stimulation noted at the top of the graph.
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RESULTS
REPORTER VECTOR CONSTRUCT STUDIES OF THE CD23a 
AND CD23b PROMOTER REGIONS
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CHAPTER 4:
REPORTER VECTOR CONSTRUCT STUDIES OF THE CD23a AND CD23b 
PROMOTER REGIONS. 
4.1: INTRODUCTION
CD23 expression can be influenced by the presence of IL-4, IL-13, anti-CD40 and 
PMA, and this has been demonstrated in the previous studies. Although STAT-6 
and NFkB pathways were implicated in CD23 transcriptional activation through 
immunoprécipitation and EMSA studies, conclusive isoform (CD23a or b) 
expression patterns remained to be fully elucidated. In order to address the details of 
the separate isoform pathways in this chapter, the CD23a and b promoter regions 
were studied by designing reporter vector constructs for use in stimulation 
experiments. The reporter vector used in this study was one expressing a truncated 
secreted form of alkaline phosphatase (SEAP), which can be detected by 
chemiluminescent assay, and is termed pSEAP. There are several advantages to this 
system, including the fact it is extremely sensitive (detecting as little as lO'^^g of 
SEAP protein), is non-radioactive and that the cells need not be lysed for analysis 
(allowing for further manipulation).
A diagramatic representation of the pSEAP Enhancer vector is shown on Figure 4.1, 
with the significant regions on it highlighted and described: the multiple cloning site 
(MCS) contains 11 unique restriction enzyme digestion sites, is the region of insert 
insertion (Kpn I/Bgl II in this instance) and is located upstream of the SEAP gene; 
the SV40 late polyadenylation signal is inserted downstream of the SEAP coding 
sequence to ensure the proper and efficient processing of the transcript in eukaiyotic 
cells; and the SV40 enhancer increases the transcription from inserted promoters 
(which, from previous experience, is known to be required). The vector contains an
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fl origin for single-stranded DNA production, a pUC19 origin of replication and an 
ampicillin resistance gene for propagation in E.coli. A  synthetic transcription 
blocker (TB), composed of adjacent polyadenylation and transcription pause sites, 
reduces background transcription.
In this chapter, the methodology, results obtained and conclusions drawn when full 
and truncated CD23a and b promoter regions were inserted into the pSEAP reporter 
vector will be discussed, as will stimulation studies of these constructs.
4.2: RESULTS 
4.2.1: The CD23a and CD23b promoter regions: splicing and amplification
In order to fully study the activation of each CD23 isoform, amplification of the 
promoter region of each was initially performed. The upstream elements of the 
CD23a and CD23b promoter regions are shown in diagramatic form in Figure 4.2a, 
along with the specific primer start sites for producing the full promoter and specific 
splice variants. The actual primer sequences are listed in Figure 4.2b. Both CD23 
isoform promoter regions contain several upstream elements, with certain 
differences being noted between each. The CD23a promoter shows, from upstream 
to downstream, two IL-4 response elements (IL-4RE), an NFkB site, a 
glucocorticoid response element (GRE) and a B-cell-specific activator protein 
(BSAP) or Pax-5 binding site. The CD23b promoter also has two IL-4REs but, in 
contrast, these are separated by an NFkB site. The second IL-4RE is then closely 
followed by two AP-1 binding sites. IL~4REs are thought to be the binding sites for 
the signal transducer and activator of transcription STAT-6 (Delphin & Stavnezer, 
1995) and NFkB sites are known to be activated by anti-CD40 antibodies or CD40L 
(Berberich, et a l ,  1994). The B-cell-activator protein is discussed in the 
introduction of this thesis (1.3.2), and is known to a universal B cell activator
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(Zwollo, et al,  1997). API has also been implicated in the activation of 
transcription following anti-CD40 stimulation (Hsing, et al,  1997).
The different primer start sites shown in Figure 4.2a lead to PCR products being 
amplified which represented the CD23a or b promoter regions to their full extent, or 
in truncated shortened forms. The truncated variants allowed analysis of promoter 
region function upon stimulation when increasing numbers of response elements and 
protein binding sites were removed. The CD23b promoter region, for example, was 
progressively truncated to the extent that no known response elements were present 
in the PCR product amplified using the B6 and BR primers, allowing hopefully 
complete analysis of the important sites required for CD23b expression upon each 
type of stimulation. It is worth noting at this point that primers were originally 
designed to remove the GRE and BSAP sites on the CD23a promoter, as well as the 
two IL-4RE and NFkB sites as shown. Unfortunately these PCRs proved to be 
unsuccessful, even after several attempts and trial conditions, and this was thought to 
be perhaps down to the proximity of these sites to the transcription start site of 
CD23a and subsequently the reverse primer. Upon consideration, it was decided to 
continue assembling the vector constructs without these GRE and BSAP sites being 
removed. This allowed for data to be compiled when both IL-4RE sites and the 
NFkB site were removed from the CD23a promoter.
4.2.2: Construction of CD23 promoter reporter vector constructs.
Once amplified, the CD23 promoter region amplicons were ligated into the MCS of 
the pSEAP enhancer vector between Kpn I and Bgl II restriction digest sites prior to 
the transformation of DH5a cells. The reporter vector constructs were then purified 
and prepared from the cultured cells, and characterised by restriction digest mapping 
and DNA sequencing.
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Figure 4.3 shows an agarose gel of the reporter vector constructs digested with Kpn I 
and Bgl II, indicating the separated pSEAP vector and cleaved CD23 promoter 
insert. The linearised vector shows as a band at approximately 4.9kbp and the 
cleaved inserts are shown as bands reducing in size as promoter region deletion 
progresses. This gel clearly shows that inserts of approximately the correct size have 
been inserted into the pSEAP vector, these being 577, 422, 385, 259bp respectively 
for the CD23a promoter truncations and 391, 322, 284, 264, 184, 11 Ibp respectively 
for the CD23b promoter. Restriction digest maps also confirmed that these were the 
correct length, as well as in the proper orientation (not shown). Further and 
conclusive evidence for the successful construction of the reporter vector constructs 
was achieved through sequence analysis of the DNA, and an example of this for the 
CD23a Prom/AS61 is shown in Figure 4.4. There are seen to be two small changes 
in DNA sequence, which are underlined, and these are G^45_^545 and 
transitions. It was not certain, upon looking at the graphic print-out of the sequence, 
as to whether these changed bases were genuinely modified in the PCR process or 
whether the sequencing readout is simply ambiguous at this point. In fact, these 
changes are not situated in any of the sequence that codes for the upstream elements 
being studied and do not lead to the encoding of any inappropriate start or stop 
codons, so they are considered inconsequential. All of the reporter vector constructs 
were thus considered ready for use in the following SEAP assays.
4,2.3; Transfection efficiency of B cells with pSEAP/CD23 promoter reporter 
vector constructs
Electroporation was chosen as the transfection method of choice in these 
experiments, as chemical and lipid transfection methods have been seen, in certain 
circumstances, to interfere with subsequent reporter assay studies (from Tom Carr, 
personal communication). Although a highly successful technique, electroporation 
can be particularly harsh on human B cells unless the electroporation voltage is
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strictly controlled and optimised. In short, enough voltage has to be present to allow 
the vectors to enter the cells, but not so much as to kill them.
4.2.3a; Analysis of cell death in relation to electroporation voltage
A constitutively active pSEAP control vector was electroporated into tonsillar B 
cells at varying voltages, increasing from 0.05 to 0.4kV (voltages which had 
previously been used in T cell electroporations). Following 48hrs of culture, cells 
were stained with 40|ig/ml of propidium iodide and analysed for cell death by flow 
cytometry. These results are shown in Figure 4.5 and indicate that cell death 
increases with electroporation voltage, with the biggest increase being noted with 
0.4kV. This result does not indicate relatively high levels of cell death although, 
upon visual analysis under a microscope, there appears to be a considerable number 
of damaged cells. With hindsight, it would have been extremely informative to have 
analysed the cultures for apoptotic cells - e.g. with annexin-V staining, as well as 
staining for complete cell death. The electroporation voltage of O.BOkV was used in 
all of the following experiments, as this setting resulted in an acceptable level of 
both cell death and control SEAP assay results (not shown).
4.2.3b; Internal control for transfection efficiency / Chloramphenicol Acetyl 
Transferase (CAT) assay
As previously described, SEAP results are detected by chemiluminescence assay on 
culture medium. These are representative of the amount of SEAP being expressed 
by the cells, but give no indication of the transfection efficiency of each 
electroporated set - which could lead to incorrect comparison of results. Therefore, 
an internal control system was required to take account of tranfection efficiency, 
ensuring that results could be attributed to change in stimuli or reporter vector 
construct alone. In order to facilitate this, a pLW2 control plasmid was co-
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transfected into cells with the pSEAP reporter vector. The plasmid pLW2 comprises 
a CAT gene under the control of the HSV (Herpes Simplex Virus) tk promoter, 
which is constitutively active. In each case, a CAT assay was performed as well as 
the SEAP assay to allow results to be correlated with the actual transfection 
efficiency. A representation of the pLW2/CAT reporter vector is shown in Figure 
4.6, and a typical CAT autoradiograph is shown in Figure 4.7. The upper two bands 
of the autoradiograph represent the converted chloramphenicol, with the intensity of 
each band being measured by phosphorimaging analysis. The intensity of the two 
bands in each sample are then added together, and used to perform standardising 
calculations to correct the SEAP results for transfection efficiency. A worked 
example of this calculation is shown in Figure 4.8.
The results which will be shown are all representative of experiments carried out on 
several tonsillar B cell preparations, and it was therefore paramount to account for 
the variability of each such set. In these instances, each non-stimulated vector 
construct result was designated as "100%" and the subsequent stimulated results 
from the same vector correlated accordingly. As implied, each tonsillar set can be 
variable to differing degrees, mainly in cell number and base-line marker expression. 
Many cells were required for each experimental set, hence the necessity to use more 
than one set in each case.
4.2.4: The CD23a promoter is activated with IL-4, whereas the CD23b 
promoter can be triggered by IL-4, anti-CD40 and anti-p chain
Initial studies were performed using only the full CD23a and b promoter constructs 
along with CAT vector transfections into P3HRI cells, which were chosen as they 
perform similarly to tonsillar B cells. As stated earlier, supply of primary tonsillar 
tissue was erratic and a robust and representative cell line model was required. The
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results for the full CD23a and CD23b promoter vector construct stimulations are 
shown on figures 4.9a and b, and show the following trend.
Upon stimulation with anti-CD40 the CD23a promoter transfectant show no 
significant up-regulation of SEAP expression, while a considerable decrease in 
promoter activity was evident with anti-p chain treatment. IL-4 stimulation, on the 
other hand, leads to a two-fold increase in CD23a promoter activity. These results 
were a little surprising, as it was expected that anti-CD40 would lead to activation of 
this promoter through the NFkB site that was present. Anti-p treatment also led to 
interestingly negative results, as this antibody is known to be a dose-dependent 
universal activator of B cell transcription. Explanations for these observations will 
be discussed in due course.
Results for the CD23b promoter reporter vector construct studies (Fig. 4.9b) are 
strikingly different, as anti-CD40, anti-p and IL-4 are all seen to stimulate the 
promoter activity. This suggests differential regulation of each CD23 promoter 
isoform. The above experiments were repeated (with the inclusion of PMA 
stimulation) in tonsillar B cells (Figures 4.10a and 4.10b) and tonsillar B cells were 
also used in all of the succeeding construct studies, utilising both full and truncated 
promoters and including the further addition of PMA as a potential stimulant.
4.2.5: Full and truncated CD23 promoter reporter vector construct studies 
indicate activation occurs through specific response elements
All of the CD23a and b promoter vector constructs were electroporated as before 
into the tonsillar B cells, and stimulated with IL-4, anti-CD40, anti-p or PMA. Upon 
media and cell harvesting for SEAP and CAT assays, respectively, 5x10^ cells were 
also removed from each sample for analysis of CD23 expression by flow cytometry, 
in order to observe if they reacted normally upon stimulation and no adverse effects
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resulted from the electroporation. Figures 4.11 and 4.12 show examples of the dot 
plots resulting from stimulation of cells transfected with the CD23a and b promoter 
reporter vector constructs respectively, with the results for the percentage of 
electroporated B cells expressing CD23 for all of the CD23 constructs and 
stimulation experiments being calculated and presented on Table 4.1. In 
experiments using the CD23a reporter constructs, for example, it was observed that, 
in each instance, IL-4 stimulation resulted in approximately 50-60% of B cells 
expressing CD23. It can be stated that electroporation and transfection of these 
tonsillar B cells does not appear to alter the pattern of CD23 expression by 
stimulated cells, in comparison with the non-electroporated cells discussed in 
Chapter 3. Unfortunately, the flow cytometric analysis in chapter 3 was conducted 
following only a 24hr stimulation period with each of the stimulants, whereas the 
results noted in this chapter were following 48hr simulations. This was because 48hr 
is the optimal time for SEAP protein expression, and secretion in to the culture 
medium, following electroporation with the reporter vector constructs. If time had 
permitted, comparable 48hr stimulation experiments of non-electroporated cells 
would have been accomplished.
4.2.5a: CD23a full-length and truncated promoter reporter vector stimulation 
studies
IL-4 is the primary stimulant involved in the activation of the CD23a promoter (Figs. 
4.9a and 4.10a). It was hypothesised that, if IL-4 was activating CD23a expression 
through a STAT-6 dependent pathway, removal of the IL-4RE/STAT-6 binding sites 
would result in a loss of activation. The truncated CD23a promoter region results 
are shown in Figures 4.13a-d, and are arranged such that results from each stimulus 
are shown in separate graphs.
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When analysed, it can be seen that IL-4 stimulation (Fig. 4.13a) leads to a 60% 
increase in activation of the full length CD23a promoter. However, upon removal of 
only the first IL-4RE, this activation is completely ablated and does not recover upon 
additional truncation. This implies that IL-4 leads to activation of CD23a mainly 
through a pathway which utilises the first IL-4RE on the CD23a promoter. As 
discussed in the introduction, the presence of IL-4 leads to phosphorylation and 
dimerization of STAT-6 which, in turn, binds to the IL-4RE and leads to 
transcriptional activation of CD23.
As anticipated from the initial experiments utilising only the full CD23a promoter 
(Figs. 4.9a, 4.10a), anti-CD40, anti-p. and PMA do not lead to an increase in 
reporter vector expression. In addition, no substantial increase in expression is noted 
following truncation of each promoter region prior to stimulation, although perhaps a 
small rise is evident following the removal of the second IL-4RE with anti-p. 
treatment. This increase in expression is of approximately 10% and it is difficult to 
interpret whether this is an artefact of experimental technique or, perhaps, down to 
the genuine removal of some unknown negative regulator.
4.2.5b: CD23b full-length and truncated promoter reporter vector stimulation 
studies
The results for the full-length CD23b promoter reporter vector construct and its 
truncated forms are extremely informative and interesting, and are shown on Figures 
4.14 a-d.
The full CD23b promoter displays a 100% increase in SEAP expression following 
activation with IL-4 (Fig. 4.14a) and, in contrast to CD23a, there is no significant 
decrease in activation upon removal of the first IL-4RE. Further truncation leading 
to the additional removal of the following NFkB site also fails to induce a drop in
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SEAP expression. Removal of the second IL-4RE, however, leads to the complete 
loss of increased promoter/SEAP activation and expression - which returns to 
baseline levels. This indicates that it is this second STAT-6 binding site that is 
paramount in the IL-4-stimulated induction of CD23b expression, as removal of the 
first STAT-6 site has no observable effect upon gene expression but removal of the 
latter completely abolishes it. No additional changes in promoter activation occurred 
upon the removal of the two API sites.
Anti-CD40 stimulation of the CD23b promoter and its truncated forms is also 
extremely interesting (Fig. 4.14b). Anti-CD40 induces a modest increase in the 
activity of the full-length CD23b promoter of about 20%. However, this activation 
increases to around about 50% following removal of the first IL-4RE site, suggesting 
that an undefined negative regulator of anti-CD40 induced activation was potentially 
present in this deleted area. Further truncation and removal of the next NFkB site 
resulted, not surprisingly, in the promoter activity dropping to the original 
unstimulated level. This made sense, as it was expected that anti-CD40 treatment 
lead to activation of CD23b through a pathway involving the NFkB binding site of 
its promoter.
Treatment of full-length CD23b promoter reporter construct transformed cells with 
anti-R leads to an increase in SEAP expression of approximately 50% (Fig. 4.14c). 
This trend continues right up until the removal of the second API site, and thus 
removal of all the known response elements. This suggests that, either anti-|X can 
activate this promoter through all or some of these sites or that the second AP1 site is 
of the most importance.
PMA activation results, as shown in Figure 4.14d, were altogether more confusing 
than previous data sets. PMA induced an increase in SEAP expression of 
approximately 20% with the full-length CD23b promoter, although this appears to
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decrease slightly upon the removal of the first IL-4RE and NFkB binding site. 
Stimulus induced expression from the CD23b promoter then proceeds to rise to 
approximately 20, 30 and 60% above unstimulated values upon each succesive 
deletion of IL-4RE(2), A Pl(l) and API(2). This bi-phasic trend is unusual and may 
indicate that some sort of repressor element is being removed and that a previously 
unidentified site responsive to the mediators of PMA stimulation is present nearer to 
the transcription start site of the CD23b promoter. Incidentally, further visual 
analysis of the CD23b promoter region led to the identification of a third putative 
API binding site approximately 70bp downstream of the second API site. It is also 
possible that a decrease in insert size means that the vector construct was more easily 
inserted into the cells, and that the cells were less perturbed by the presence of a 
smaller vector. This is thought unlikely, however, as electroporation efficiency is 
accounted for by the insertion of the pLW2 control vector and CAT assay. Also, 
experiments with the CD23a promoter, which has even smaller truncated inserts, do 
not show this phenomenon.
4.3; Conclusion and discussion
The main conclusions of this chapter are that, firstly, the CD23a and CD23b 
promoter regions are differentially activated, as shown in reporter vector construct 
studies. The CD23a promoter shows an increase in activity with IL-4 stimulation 
only, whereas the CD23b promoter is susceptible to all of IL-4, anti-CD40, anti-p, 
and PMA induction. Secondly, truncation of the inserted CD23a and b promoter 
regions indicates that the CD23a promoter appears to utilise the first IL-4RE/STAT- 
6 binding site only, while the CD23b promoter is activated through its second 
available IL-4RE/STAT-6 site. Truncated CD23b promoter reporter vector 
constructs studies following anti-CD40, anti-p and PMA stimulation revealed that 
removal of the NFkB binding site abolished the increase in promoter activity
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following anti“CD40 stimulation, and that anti-p and PMA appear to utilise all or 
some of the identified sites and presently undefined sites, respectively.
Flow cytometry of the electroporated cells following 48hr stimulation showed that 
the cells reacted much like un-electroporated tonsillar B cells and, thus, the actual 
transfection technique does not appear to be damaging the live cells. A small 
increase in cell death was, however, noted upon observation following 
electroporation, but cells surviving the initial shock were considered to show 
perfectly normal responses to stimulation.
If more time had permitted, further analysis using reporter vector construct studies 
would have been attempted. CD23a and b promoter point mutation studies would 
have been carried out to facilitate the removal of certain specific response elements, 
intermediately placed in the promoter region, in addition to the truncated promoter 
experiments - which are representative of successively cleaved promoters, rather 
than the removal of central sites and leaving surrounding ones. The removal of 
central and specific sequences would allow analysis of the possibility that perhaps 
some response elements work together or compensate for the loss of each other. 
This theory has been hinted upon by Delphin and Stavnezer (Delphin & Stavnezer, 
1995), who hypothesised that STAT-6 and NFkB worked together to increase the 
expression of CD23. Also, if further time had been available, treatment of the 
transfected cells with more than one stimulant would have been undertaken. An 
example of this would have been IL-4 in association with anti-CD40, the 
combination of which has been implicated in IgE and CD23 superinduction (Clark & 
Ledbetter, 1994; Richards & Katz, 1997), and also treatment with anti-CD40 and 
anti-R. These latter two experiments, in conjunction with the removal of certain 
response elements, would have been extremely enlightening in relation to the 
proposed co-operation of certain transcription factors. Also, data would have been
132
obtained as to whether compensation for missing response elements is achieved 
upon dual stimulation.
The fact that CD23a and CD23b are differentially stimulated and expressed, and that 
CD23b is also found on other cells of the immune system apart from B cells, 
supports the theory that they are involved in B cell function and IgE-mediated 
immunity, respectively (Yokota, et ah, 1988; Yokota, et al., 1992). However, 
reporter vector construct studies are reliant on removing the promoter region of 
genes from its in vivo environment and placing it in a reporter vector prior to 
transformation. These results, therefore, are really a representation of the ability of 
the CD23a and CD23b promoter regions to stimulate the expression of SEAP in the 
pSEAP enhancer vector - and not for the actual expression of cell surface CD23. 
The CD23 promoter regions may also be subject to negative regulatory signals in 
vivo that may not be present in the reporter vector construct studies. A further 
experimental technique was therefore required to support these findings in vivo and 
a perfect candidate for this was considered to be in vivo footprinting, incorporating 
ligation-mediated PCR. In vivo footprinting allows for the analysis of the binding of 
transcription factors to specific cellular DNA intracellularly, and thus gives promoter 
activation information most closely related to the cells in their natural state.
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Figure 4.1: Map of pSEAP Enhancer vector
The pSEAP enhancer vector is 4,9kb in size and comprises several functional 
regions, which are highlighted that can be described as follows: the multiple cloning 
site (MCS) contains 11 unique restriction enzyme digestion sites, is the region of 
insert insertion (Kpn I/Bgl II in this instance) and is located upstream of the SEAP 
gene; the SV40 late polyadenylation signal is inserted downstream of the SEAP 
coding sequence to ensure the proper and efficient processing of the transcript in 
eukaryotic cells; and the SV40 enhancer increases the transcription from inserted 
promoters (which, from previous experience, is known to be required). The vector 
contains an f l origin for single-stranded DNA production, a pUC19 origin of 
replication and an ampicillin resistance gene for propagation in E.coli. A synthetic 
transcription blocker (TB), composed of adjacent polyadenylation and transcription 
pause sites, reduces background transcription.
CD23 promoter inserts were cloned in to the vector via the Kpn I/Bgl II digest sites 
in the MCS.
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Figure 4.2a; Upstream elements of the CD23a and CD23b promoter regions
The CD23a and b promoter regions are approximately 600 and 400 base pairs in 
length, respectively. Both promoter regions are known to contain several upstream 
elements and putative protein binding sites based on work by Tinnell et al in 1998 
and extensive searches on transcription factor binding site databases (ie 
TRANSFAC). A representation of these sites is shown here, and the specific primer 
start sites for producing the full promoter and specific splice variants are highlighted 
by the arrows, with the primer sequences detailed below .
Figure 4.2b: Primer sequences for amplification of the CD23a and CD23b 
promoter regions
Synthetic oligonucleotides of the CD23a and CD23b promoter regions, containing 
both a Kpn I and Bgl II restriction enzyme site, were designed. These primers were 
then used to amplify CD23 promoter regions of DNA by polymerase chain reaction 
(PCR), as described in section 2.2.6a of the materials and methods chapter.
135
CD23a
A 5’ -
-600 -300 +1
O J — ( g |— 3’
IL-4RE IL-4RE k B  GRE BSAP
A1 A2 AR
A3
A4
CD23b
5’
■300 -100 +1
IL-4RE KBIL-4RE 
—► BR
B1 B2
3’
B3
B4
B5
B6
B
PRIMERS:
Al: Full CD23a Promoter 
A2: CD23a Prom/AS61 
A3; CD23a Prom/AS62 
A4; CD23a Prom/AicB 
AR; CD23a Prom/Reverse 
Bl: Full CD23b Promoter 
B2: CD23b Prom/AS61 
B3; CD23b Prom/AicB 
B4; CD23b Prom/AS62 
B5; CD23b Prom/AAPl(l) 
B6; CD23b Prom/AAPl(2) 
BR; CD23b Prom/Reverse
GGC GGT ACC AAA CTG TCC ATA TTT GAC C 
GGC GGT ACC AGC CTA TTT GCT CAA TCA TC 
GGC GGT ACC TGG TGG GGT GTC TGC TGG TA 
GGC GGT ACC AGT GGT ATG ATT CAG TGT GCA GTA 
GCA GAT CTT GAC AGC TTC TAT TTT CAT 
GGC GGT ACC ATG GAG GAA GGT CAA TAT TC 
GGC GGT ACC GAA GCG GGG CTT CCC AGT CCC 
GGC GGT ACC TGA ATT TCT AAG AAA GGG 
GGC GGT ACC TGG TGT GAG TAA GGA GGT GA 
GGC GGT ACC TTT TCT GAT TCA ACA CCC TC 
GGC GGT ACC GCA ATA GAG TCA GAG GCC AA 
GCA GAT CTG CAC TCA CCC TGG CTT GG
4
Figure 4.3: Restriction digest of pSEAP Enhancer vector containing CD23 4
promoter inserts
Assembled pSEAP reporter vector constructs containing full and truncated CD23 
promoter regions were digested with the restriction enzymes Kpn I and Bgl II, as 
described in section 2.2.6d. The resulting digests were electrophoresed on a 1% 
agarose/lOmg/ml ethidium bromide gel, along with the indicated DNA size marker, 
and viewed under ultra-violet (UV) light.
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SIZE
lOlSbp
517bp
396bp
220bp
LANE:
184bp
l l l b p
10
1. CD23a
2. CD23aAIL-4RE(l)
3. CD23aAIL-4RE(2)
4. CD23aAKB
5. CD23b
6. CD23bAIL-4RE(l)
7. CD23bAKB
8. CD23bAIL-4RE(2)
9. CD23bAAPl(l)
10.CD23bAAPl(2)
Figure 4.4: Sequencing analysis of the pSEAP/CD23a Prom AS61/IL-4RE 
reporter vector construct
Sequencing analysis was carried out by the Institute of Biomedical and Life Sciences 
(IBLS) sequencing service on all of the assembled reporter vector constructs, and a 
representative sequence result is shown here for CD23a Prom AS61.
The sequences of enhancer elements are highlighted, and any changes noted from the 
published sequences are underlined.
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CD23a Promoter AS61sequence:
3’ GNNNGGTNTNNNATTGAANNCNTTNaATGGGCTTGCCaCCCAGATAACATT
BSAP
535 ACACGCATGGCCTCTCCTCKjTGCTCCCCACACCCGGGTGAAGTCCGIGTTA 485
484 TTATTATCTCCATTTCTCAGGTAAGAGAATTGGGCGAGAACTAGAGATGTT 434
433 AAGCAGCAAGTTCCCACAGGGCTGAAGGAGGTGAGTGGTAGCGTCAAGAT 383
GRE
382 GTGGACCACTGTTACTGCACACTGAATCATACCACTATGGCCGATCACAGA 332
331 GGGCCCTGGGGAGCCACGGAAGGCTCTAGGCAGAGGCAGGGCCTCTTGGG 281
280 TTAGAAGGACGGCCTGGAGTTGGGATCCTGCCACCCGGCACTTACCAGCA 230
NFkB S62
229 GACACCCCACCATGAGATTATGTCTCTTGATG/^TTGAGCAAATAGGCT 182 5’
4
Figure 4.5: Analysis of electroporated cell death by propidium iodide (PI)
i
staining.
A constitutiveiy active pSEAP control vector was electroporated into tonsillar B 
cells at varying voltages, increasing from 0.05 to 0.4kv (2.2.6i). Cells were cultured 
for 48hr, stained with 40pg/ml of propidium iodide and analysed for cell death by 
flow cytometry (2.2.3). The graph represents the percentage of Pl-stained dead cells 
counted upon increasing electroporation voltage.
138
1VO
S£0
-€'0
- S Z ' O
- Z ' O
>
w
o
<H
o
>■
z
c
H
<
cti
ri)
. <?()•()
îtS
HL/
W
-3U3
ro iTi (f)ri
(% ) S T T 3 D  a v a a  a o v x N 3 3 H a d
i
Figure 4.6: Map of pLW2 reporter vector
pLW2 is a 3.77kb reporter vector comprising a CAT gene under the control of the 
HS V (Herpes Simplex Vims) tk promoter, which is constitutiveiy active. Restriction 
enzyme digest sites are noted, as is the ampicillin resistance gene which allows for 
selection of transfectants upon transformation of competant cells.
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Figure 4.7; Chloramphenicol Acetyl Transferase (CAT) assay autoradiograph
20pg of pLW2 control plasmid was co-transfected (via electroporation) with 40pg of 
pSEAP reporter vector into 5x10^ B cells, as described in section 2.2.6i of the 
methods chapter of this thesis. Following culture for 48hr in complete RPMI~1640 
medium, cells were harvested and washed twice with ice-cold PBS. The 
chloramphenicol acetyl transferase (CAT) assay was then performed in accordance 
with the protocol in section 2.2.6k. Briefly, cells were resuspended in 250mM Tris- 
HCl (pH 7.8), subjected to 3 freeze/thaw cycles and cellular acetylases heat- 
inactivated at 65"C. Acetyl co-enzyme A was then added to a final concentration of 
5mM, followed by Ijiil of chloramphenicol and incubation at 37°C for 3 hr. The 
reaction was terminated by the addition of 600pl ethyl acetate and the top layer was 
removed and lyophilised, prior to resusperision in 20pl ethyl acetate and thin layer 
chromatography (TLC).
TLC plates were visualised as shown by phosphorimage analysis, with the 
highlighted bands representing converted chloramphenicol. The intensity of these 
bands was measured and used to perform transfection efficiency standardising 
calculations for the corresponding pSEAP assay.
Lanes A-F are representative of samples co-transfected with 20jag of pLW2 control 
plasmid along with 40jlg of each CD23b promoter reporter construct.
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Figure 4.8: Calculation of SEAP results in regards to transfection efficiency
Following CAT assay (2.2.6k) transfection efficiency was calculated by, firstly, 
adding together the two results for band intensity resulting from the pLW2 
electroporated cells, defining the highest of these as 1 and standardising the other 
results accordingly. SEAP results were then adjusted according to the CAT assay 
result determined ratio, and thus were normalised for transfection efficiency.
A minimum of 3 experimental sets for each experiment were performed and, to 
standardise results in relation to variability in prepared primary tonsillar B cells, all 
results were represented in relation to unstimulated cells being termed as 100%. 
Resulting error bars are shown to indicate variability between results from different 
tonsil sets.
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SAMPLE BANDDENSITY
STANDARD
-ISATION
RATIO
pSEAP
RESULT
(RLUs)
ADJUSTED
pSEAP
RESULT
(RLUs)
EXAMPLE (Upper + Lower 
bands) 
X
(Fraction of 
largest x 
value)
Y
Z Z x  1 
Y
A 688.9 1 0.463 0.463
B 484.2 0.702 17.31 24.67
C 637.7 0.926 0.413 0.446
D 660.9 0.959 0.441 0.460
E 538 0.781 0.577 0.739
F 336.7 0.489 0.631 1.29
REPRESENTATION OF COMPILED pSEAP RESULTS:
NON-STIMULATED SAMPLES = 100%
STIMULATED SAMPLES
STIMULATED pSEAP RESULTS x 100 = A% 
NON-STIMULATED pSEAP RESULTS
STANDARD DEVIATIONS AND ERROR BARS
Sa = V XfA-Amean)  ^
n - 1
Figure 4.9: SEAP assay results for P3HRI cell pSEAP/CD23a and
pSEAP/CD23b Promoter reporter vector construct transfections
40|ig of each pSEAP reporter vector construct was electroporated into 5x10^ P3HRI 
B cells, as described in section 2.2.6i of the Methods chapter, along with 20|LLg/ml of 
pLW2. Cells were allowed to rest for 2hr, prior to stimulation with Ipg/ml anti- 
CD40, Ip-g/ml anti-p. and 14ng/ml IL-4 and subsequent 48hr culture in complete 
RPMI-1640 medium. Cells were then harvested (for CAT assay or flow cytometry) 
and 125pl of medium conserved for SEAP assay, which was performed in 
accordance with section 2.2.6J. All reagents were supplied by Clontech in their 
Great EscAPe SEAP Reporter System 2 kit (see Materials 2.1.2 for details) Briefly, 
medium was centrifuged at 12, 000 x g, to remove any cells, and 15p,l was added to 
the wells of a 96 well opaque plate and diluted with 45pl of dilution buffer. 
Intracellular acetylases were then heat inactivated at 65°C, prior to the addition of 
60j.ll of assay buffer and 60|l i 1 of substrate. The reactions were then incubated for 
15min at room temperature (RT), prior to interpretation of results on a plate 
luminometer.
The results on these graphs have been normalised for transfection efficiency by 
pLW2 transfection and CAT assay, and are represented in relative light units 
(RLUs). Error bars are indicative of the differences between triplicate SEAP assays 
on the same experimental cell set, as only one full set of SEAP electroporations 
were carried out with P3HRI cells prior to tonsils becoming available.
A = SEAP assay results for CD23a promoter reporter vector constructs 
B = SEAP assay results for CD23b promoter reporter vector constructs
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CD23a
PROMOTER
K E Y :
1. pSEAP BASIC
2 . pSEAP ENH/CD23 
PROMOTER
3 . pSEAP ENH/CD23 
PROM + ANTI-CD40
4 . pSEAP ENH/CD23 
PROMOTER + A N TI-p
5. pSEAP ENH/CD23 
PROMOTER + IL-4
fs m ^
SAMPLE IDENTIFICATION
CD23b
PROMOTER
1mm
T
fs m "V
SAMPLE IDENTIFICATION
I
m
K E Y :
1. pSEAP BASIC
2 . pSEAP ENH/CD23 
PROMOTER
3 . pSEAP ENH/CD23 
PROM + ANTI-CD40
4 . pSEAP ENH/CD23 
PROMOTER + A N TI-p
5. pSEAP ENH/CD23 
PROMOTER + IL-4
Figure 4.10: SEAP assay results for tonsillar B cell pSEAP/CD23a and
pSEAP/CD23b Promoter reporter vector construct transfections
40|ig of each pSEAP reporter vector construct was electroporated into 5x10^ 
tonsillar B cells, as described in section 2.2.6i of the Methods chapter, along with 
20|.ig/ml of pLW2. Cells were allowed to rest for 2hr, prior to stimulation with 
Ijig/ml anti-CD40, lp.g/ml anti-p. and 14ng/ml IL-4 and subsequent 48hr culture in 
complete RPMI-1640 medium. Cells were then harvested (for CAT assay or flow 
cytometry) and 125pl of medium conserved for SEAP assay, which was performed 
in accordance with section 2.2.6j. All reagents were supplied by Clontech in their 
Great EscAPe SEAP Reporter System 2 kit (see Materials 2.1.2 for details) Briefly, 
medium was centrifuged at 12, 000 x g, to remove any cells, and 15|al was added to 
the wells of a 96 well opaque plate and diluted with 45p.l of dilution buffer. 
Intracellular acetylases were then heat inactivated at 65°C, prior to the addition of 
60|,il of assay buffer and bOpl of substrate. The reactions were then incubated for 
15min at room temperature (RT), prior to interpretation of results on a plate 
luminometer.
The results were then normalised for transfection efficiency by pLW2 transfection 
and CAT assay, and a minimum of 3 experimental sets for each experiment were 
performed using different tonsil sets. To standardise results in relation to variability 
in prepared primary tonsillar B cells, all results were represented in relation to 
unstimulated cells being termed as 100%. Resulting error bars are shown to indicate 
variability between results from different tonsil sets.
A = SEAP assay results for CD23a promoter reporter vector constructs 
B = SEAP assay results for CD23b promoter reporter vector constmcts
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Figure 4.11: Flow cytometric analysis of stimulated CD23 Promoter construct
transfected tonsillar B cells
Tonsillar B cells were electroporated with CD23 full-length and truncated promoter 
reporter vector constructs (along with 20(ig/ml of pLW2) as described in section 
2.2.6i, allowed to rest for 2hr and then stimulated with 14ng/ml IL-4, Ijxg/ml anti- 
CD40, I|xg/ml anti-p, and 6nmol PM A and cultured for 48hr in complete RPMI-1640 
medium. Cells harvested from culture, washed twice in ice-cold PBS and 
resuspended at 1x10^ cells per lOOpl of PBS. 3pi of PE-labelled anti-CD 19 and 3pi 
of FITC-labelled anti-CD23 antibodies were then added prior to incubation of the 
samples on ice for ihr. Cells were then again washed twice with ice-cold PBS, 
resuspended in 500pl of PBS and analysed on a Becton Dickinson FACScan flow 
cytometer.
A representative set of dot plots for both the CD23a and CD23b Promoter constructs 
are shown here, with anti-CD23 FITC labelled CD 19"^  B cells being indicated in the 
upper right hand quadrant.
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Table 4.1: Percentage of CD23a and CD23b promoter reporter construct 
transfected tonsillar B cells expressing CD23 following stimulation
Tonsillar B cells were electroporated with CD23 full and truncated promoter reporter 
vector constructs and analysed as described in the legend for Figure 4.11.
The percentage of electroporated B cells expressing CD23 for all of the CD23 
constructs and stimulations was calculated and is represented on this table.
145
Percentage of electroporated B cells expressing CD23 cell 
surface marker following 48hr stimulation as shown (%)
Pseap
Vector/
Insert
N 0  
Stimulation
+ IL-4 + Anti- 
CD40 + Anti-|i
+ PMA
CD23a
Prom
0.52 53.00 0.75 0.90 1.64
CD23a
Prom/
AS61
0.84 53.90 0.36 0.57 1.80
CD23a
Prom/AS62
0.73 59.30 1.20 1.05 2.67
CD23a 
Prom/ AkB
0.75 60.00 1.12 1.33 1.53
CD23b
Prom
2.30 69,00 2.59 4.60 26.2
CD23b
Prom/
AS61
1.50 71.43 2.80 4.95 27.2
CD23b
Prom/AKB
1.93 62.00 2.23 2.70 20.8
CD23b
Prom/
AS62
2.80 65.20 2.80 3.00 20.00
CD23b
Prom/
A A P l(l)
1.75 70.00 2.40 4.00 23.00
CD23b
Prom/
AAP1(2)
2.70 66.00 2.50 3.60 22.40
Figure 4.13: CD23a full and truncated promoter reporter vector stimulation 
studies.
40|ig of each CD23a pSEAP reporter vector construct was electroporated into 5x10^ 
tonsillar B cells, as described in section 2.2.61 of the methods chapter of this thesis, 
along with 20pg/ml of pLW2. Cells were allowed to rest for 2hr, prior to 
stimulation with (A) 14ng/ml IL-4, (B) Ipg/ml anti-CD40, (C) Ipg/ml anti-p, (D) 
6 nmol PMA and subsequent 48hr culture in complete RPMI-1640 medium. Cells 
were then harvested (for CAT assay or flow cytometry) and 125pl of medium 
conserved for SEAP assay, which was performed in accordance with section 2.2.6j. 
All reagents were supplied by Clontech in their Great EscAPe SEAP Reporter 
System 2 kit (see Materials 2.1.2 for details) Briefly, culture medium was 
centrifuged at 1 2 , 0 0 0  x g, to remove any cells, and 15pl was added to the wells of a 
96 well opaque plate and diluted with 4^^1 of dilution buffer. Intracellular 
acetylases were then heat inactivated at 65“C, prior to the addition of 60pl of assay 
buffer and 60pl of substrate. The reactions were then incubated for 15min at room 
temperature (RT), prior to interpretation of results on a plate luminometer.
The results were then normalised for transfection efficiency by pLW2 transfection 
and CAT assay, and a minimum of 3 experimental sets for each experiment were 
performed using different tonsil sets. To standardise results in relation to variability 
in prepared primary tonsillar B cells, all results were represented in relation to 
unstimulated cells being termed as 100%, Error bars are shown to indicate 
variability between results from different tonsil sets, with those on non-stimulated 
1 0 0 % samples indicating variability between triplicate samples.
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Figure 4.14: CD23b full and truncated promoter reporter vector stimulation 
studies.
40|uig of each CD23b pSEAP reporter vector constmct was electroporated into 5x10^ 
tonsillar B cells, as described in section 2.2.61 of the methods chapter of this thesis, 
along with 20pg/ml of pLW2. Cells were stimulated and analysed as described in 
the legend for Figure 4.13.
(A) + 14ng/ml IL-4, (B) + Ijig/ml anti-CD40, (C) + Ijxg/ml anti-p, (D) + 6nmol 
PMA
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CHAPTERS
RESULTS
IN  VIVO FOOTPRINTING OF THE CD23a AND CD23b
PROMOTERS
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CHAPTER 5: IN VIVO FOOTPRINTING OF THE CH23 AND CD25 
PROMOTERS INCORPORATING LIGATION MEDIATED PCR (LM-PCR) 
5.1: INTRODUCTION
CD23a and CD23b expression has been shown to be regulated by several mitogens 
and stimulants, with the promoter regions of each isoform being clearly, 
differentially and independently activated. The reporter vector studies in Chapter 4 
show that the CD23a promoter is activated with IL-4 only, whereas the CD23b 
promoter is activated with all of IL-4, anti-CD40, anti-p, chain and PMA. It was a 
natural progression, therefore, to study these interactions at the level of promoter 
DNA, and the proteins binding thereto. The technique of in vivo footprinting, 
incorporating ligation-mediated PCR (LM-PCR) was considered ideal for this task.
In vivo footprinting, as a method, is utilised to study protein-DNA interactions in 
intact cells, and can yield interesting and useful results with respect to gene 
expression. However, special methods are required to visualise these results and the 
technique can prove to be extremely problematic. LM-PCR is known to 
substantially increase the absolute signal and signal-to-noise ratio obtained for 
genomic sequencing (Mueller & Wold, 1989). It does so by coupling PCR with 
genomic sequencing to provide specific amplification of a sequence "ladder", while 
preserving the identity and relative quantitative representation of each rung of the 
original cleaved genomic DNA preparation. The application of LM-PCR has made 
in vivo footprinting more readily accessible to organisms with large genomes, as the 
sequence and primers for only one end need be known and utilised.
As described in the appropriate Methods section, DNA was prepared according to 
Maxam and Gilbert (1980) (Maxam & Gilbert, 1980), where naked DNA (prepared 
following cell lysis) was cleaved at every G residue and in vivo alkylated DNA only
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being cut where no proteins were bound. An overview of the basic LM-PCR 
protocol is shown on Figure 5.1, starting at the top of the page with a representation 
of Maxam and Gilbert prepared DNA and putative binding proteins. Primers 1-3 are 
nested and have overlapping start sites, the reason for which will become apparent. 
The first strand reaction was initiated by the annealing of primer 1 followed by the 
subsequent PCR of one strand, thus producing double stranded DNA with a specific 
start point for our promoter. Vent polymerase is used for all of the PCR steps in this 
technique, as it is more faithful and specific than Taq polymerase and ensures high 
fidelity copying of the template DNA. A common linker is then ligated on to the 
opposite end of the first strand product at 17°C overnight, in order to provide an end 
point for the succeeding amplification reactions. This step is then followed by 18 
amplification steps with nested Primer 2 firstly from one end and then the linker 
primer from the other, with the linker primer being identical to the larger part of the 
common linker. The product of this amplification step is thus blunt ended, which 
ensures clear cut footprints upon completion. Following the amplification step, the 
products are then labelled by a two cycle PCR program with nested Primer 3, the 
two steps ensuring that each rung of the ladder is labelled at one end only. Each 
LM-PCR reaction will terminate wherever a G residue is cleaved, thus producing a 
DNA ladder. The resulting products are ran on a 6% sequencing gel which is read 
from the bottom up, as the smallest products are terminated closest to the 
radioactively labelled end.
While LM-PCR has been used successfully by a few investigators to obtain high 
quality in vivo footprint information (Algarte, et a l, 1995; Kara & Glimcher, 1991) 
there are several problems that can significantly compromise data quality. These 
anomalies will be discussed in detail in this chapter and include weak, missing or 
unclear genomic ladders, as well as the general lack of footprint quality. 
Modification and fine-tuning of this technique will be assessed, as will the 
experiments used to determine the correctness and specificity of each primer.
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Limited, but hard earned, data showing CD25 and CD23 promoter footprints will 
also be extensively discussed.
5.2 RESULTS
5.2.1 THE CD25 PROMOTER CAN BE STUDIED THROUGH IN-VIVO 
FOOTPRINTING
Initial studies were carried out on the CD25 promoter, based on studies by Algarte et 
al (Algarte, et a l, 1995). This was pursued in order to ensure that the protocol could 
be effectively and correctly utilised for the purpose of characterising the CD23 
promoter. The CD25 promoter has also been extensively studied and characterised 
in this laboratory, making it ideal for a control study. Figure 5.2a shows a diagram 
of the CD25 promoter, and also the start sites for the primers used in subsequent 
LM-PCR reactions. These primers are listed fully on figure 5.2b. The CD25 
promoter LM-PCR and footprinting was relatively straight forward and is shown on 
Figure 5.3, with the transcription factor binding sites highlighted as shown. These 
areas are possible to determine by "reading" the number of G residues present, 
working from the bottom of the footprinting gel. Although there is an obvious 
problem with the general clarity of the banding on this footprint, which will be 
addressed accordingly later, visible footprints can be identified and are putatively 
thought to be at the API and NRE sites. As well as the work of Algarte et al 
(Algarte, et a l,  1995), this banding pattern also backs up EMSA data resulting from 
the work of J. Curran and A.B. Allen, personal communication, suggesting that 3 
protein species bind to these sites. The narrowness of the footprint lanes in the 
above CD25 promoter footprint made it difficult to define if any doublet bands were 
present, as the resulting ladders contained labelled dots for each rung as opposed to 
the concise straight bands required. This phenomenon was a result of the narrow 
sequencing comb used for the task of loading, and a wider welled gel was required to
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rectify this problem. Further gels were therefore produced using larger 8mm wells, 
and a resulting naked DNA G ladder is shown on figure 5.4. This new well size 
clearly increases the clarity and sharpness on the banding pattern on the gel and 
following this successful footprinting attempt, it was considered appropriate to move 
to the study of the CD23a and CD23b promoters.
5.2.2: LM-PCR AND IN-VIVO FOOTPRINTING OF THE PROMOTER 
REGION OF CD23a
Following the moderately successful generation of the CD25 promoter results, 
footprinting of the CD23a and b promoter regions was attempted. Figure 5.5a 
illustrates the promoter regions and LM-PCR primer start sites for each promoter, 
and Figure 5.5b lists these primers in full. Firstly, in order to ensure banding could 
be visualised, G-ladders of the CD23a promoter regions of naked DNA from 
different cell lines was attempted. This, surprisingly, proved to be extremely 
difficult and time-consuming and, as unforeseen problems hampered the process, 
lead to very few results. Problems ranged from no visible banding, infrequent 
banding, indistinct or low resolution bands and various collaborations of all of the 
above. The LM-PCR and in vivo footprinting techniques subsequently required 
much trouble shooting, modification and refining to attempt to eliminate these 
uncertainties, and this took the form of two specific trains of thought: inaccuracies as 
a result of incorrect gel running or problems with the actual PCR.
Modification of footprinting gels and electrophoresis:
Several attempts at refining the pouring and running of footprinting gels was 
attempted, including the introduction of "Long Ranger" gel solution instead of using 
normal acrylamide:bis acrylamide. This puipose-made sequencing gel solution by 
Flow gen contains acrylamide and a non-disclosed polymer, which allows for longer
152
gel-read lengths and significantly more resolution of doublet and triplet bands. 
Great care was also taken to ensure the correct temperature of the gel for high quality 
gel running, and this was found to be at approximately 55W and 50°C. Gels were 
still not producing quality banding however and it was considered that perhaps gels 
were not setting consistently, leading to gel running anomalies. The gel solutions 
were subsequently "de-gassed" using a vacuum pump prior to pouring and the 
setting wells protected from the air by covering with plastic wrap. Once all of the 
above attempts had been exhausted and no real observable improvement in band 
clarity was achieved, changes and improvements were established to the actual LM- 
PCR procedure.
Refinement and modification of LM-PCR
Promising results were generally always observed following use of freshly prepared 
reaction buffers and labelled Primer 3. Therefore, buffers were always mixed 
directly prior to the immediate requirement and labelled primer of more than one 
half life in age discarded (^^P has a half-life of approximately 14 days). Newly 
excised and prepared Maxam and Gilbert DNA was also always used. Sufficient 
magnesium concentration in the LM-PCR solutions was also paramount, as 
magnesium is essential for primer extension. 50mM of MgSO^ was thus added to 
the amplification solution to produce significantly better results. End-labelling 
reactions of Primer 3 for the labelling mix was also optimised to a 40 minute 
incubation time, with radioactive incorporation studies (TCA precipitation) revealing 
that this time span gives the best percentage of labelling (approximately 90%). The 
actual LM-PCR reaction was also subjected to modification in an attempt to improve 
band clarity, with variations in annealing temperature being tried. Optimum banding 
was observed at annealing temperatures of 5°C below the lowest melting temperature 
of the oligonucleotides used, even though lower annealing temperatures were tried
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and tested. Annealing temperatures too low would have resulted in non-specific 
banding anyway.
Finally, it was considered that perhaps there was something wrong with the actual 
primers used in the CD23 promoter LM-PCR reactions. This was possible, as major 
problems only occurred when the transition was made from the CD25 to CD23 
promoter studies. Primer sequences were re-checked in relation to their DNA 
binding sequences and were found to be correct, and PCR experiments were 
performed using tonsillar B cell DNA and amplifying with each primer set. The 
results of this are shown on Figure 5.6, with the expected band sizes being observed. 
Therefore, the primers appear to be correct and not to blame for the experimental 
failure.
5.2.3: CD23a promoter G ladder
Limited success was achieved with the LM-PCR technique, although actual in vivo 
footprints were elusive. Naked DNA G ladders were produced for the CD23a 
promoter from SMS-SB and P3HR1 cell lines, and cleai' banding pattern differences 
were observed between the two. These ladders are shown on Figures 5.7a and 5.7b, 
along with the known transcription factor binding sites which were determined with 
respect to the position of cleaved G residues. Footprints were attempted, but 
unfortunately not perfected - even after several attempts.
5.2.4: CD23a promoter footprint of stimulated tonsillar B cells
Stimulation experiments were attempted prior to the LM-PCR and attempted 
footprinting of the CD23a promoter region in tonsillar B cell DNA. These studies 
have revealed clear differences in, albeit incomplete, in vivo DNA ladders following 
IL-4, anti-CD40 and anti-p stimulation, suggesting that proteins bind to the CD23a
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promoter differentially and spatially following treatment with various stimuli. A 
representation of these data is shown on the scan in figure 5.8. Unfortunately in 
these instances the actual naked DNA G ladder and unstimulated in vivo DNA ladder 
did not work, the former meaning that footprinting comparisons between DNA with 
and without bound protein could not be made. However these results were 
promising and, perhaps if more time had been available, useful footprinting results 
would have forth-coming. The limited data reveal that upon IL-4 stimulation, 3 
bands are lost in comparison with the anti-CD40 stimulated lane and one band is lost 
in the anti-|l stimulated lane. This is indicative of differential protein (transcription 
factor) binding, and it is suggested that this limited footprint area may be situated 
over the BSAP site in the CD23a promoter. However, as the naked DNA G ladder 
was missing, no further comparisons or assumptions can tinly be made.
5.3: Conclusions and discussion
Although extremely time consuming and resource-draining, the effective utilisation 
of LM-PCR and in vivo footprinting to study the CD23 promoter has remained ever 
elusive. The technique was extensively refined, modified and theoretically improved 
in an attempt to achieve acceptable results for the CD23 promoter as had been 
generated for CD25, but banding patterns were never full established. Primary and 
optimistic results revealed that the naked DNA G ladders can be achieved in SMS- 
SB and P3HR1 cells, and there are observable differences between the two. It was 
considered that both promoters, although from different cell lines, should produce 
similar G ladders and the fact that they did not was surprising. It is suspected, 
though, that these cell lines had DNA with varying degrees of natural alkylation and 
thus, in addition to piperidine cleavage of the DMS (di-methyl sulphate) alkylated G 
residues, other pieces of DNA were also being cleaved. Hyper G cleavage sites have 
also been mentioned by Algarte et al (Algarte, et a l, 1995). Also, if piperidine is
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not completely eliminated when preparing the DNA, it can lead to excess improper 
cleavage of the DNA.
The tonsillar B cell DNA results are very limited but further work on them may be 
extremely interesting, and would have provided a wealth of information to be used in 
conjunction with the reporter vector study results in chapter 3. They indicate that 
upon stimulation with IL-4, anti-CD40 and anti-|Li differential protein binding to the 
CD23a promoter occurs. Further investigation and refining of this technique is 
obviously required, and if the technique had been fully operative during this research 
both the CD23a and CD23b promoters would have been fully studied. A further 
consideration is that perhaps the actual Maxam and Gilbert preparation of DNA has 
to be modified, although Algarte et al's method was followed precisely. It is also 
possible that the technique is proving to be much more difficult with the CD23 
promoter purely because we were trying to study it in B cells and not in T cells as 
were used by Algarte and colleagues. There are several reasons why this could be 
the case, including the fact that the B cells we use are particularly fragile, and the 
DNA could thus be subject to excess cleavage and disruption when the cells are 
lysed, or even when cleaved with the piperidine.
In conclusion, LM-PCR and in vivo footprinting are extremely enlightening 
techniques and, if they work, can provide substantial rewards in the form of results 
and information. Unfortunately in this case the footprinting data was not 
forthcoming, but considerable time and experience was spent on trying to refine the 
technique, making it too important to discount the results altogether.
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Figure 5.1: Ligation Mediated-PCR (LM-PCR) protocol
2pg of Maxam and Gilbert cleaved DNA (2.2.7a) is represented at the top of this 
figure, with numbers 1-3 being representative of overlapping primer start sites, and 
letters A-E the sites of potential DNA cleavage. A potentially in vivo bound protein 
is represented over the B and C cleavage points, and would stop cleavage from 
taking place in the in vivo sample. All of the reagents required for this technique are 
listed in section 2.2.7b of the methods section, as are the actual PCR specifications. 
A first strand reaction mixture was initially performed using PI and Vent DNA 
Polymerase, which is preferentially used because of its high fidelity. A common 
linker was then ligated on to the first strand at 17°C overnight using T4 DNA ligase, 
prior to 18 rounds of amplification with primer P2 (PI and P2 start sites overlap) and 
the linker primer. The resulting amplicons were then labelled from one end only by 
PCR with labelled primer 3. Samples were run on a 6% "Long Ranger" 
sequencing gel, and the resulting autoradiographs analysed from the bottom up.
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Figure 5.2: The promoter region and upstream elements of CD25
The CD25 promoter region is approximately 500 base pairs in length and contains 
several upstream elements as shown here (adapted from Algarte et aU 1995). There 
are two negative regulatory elements (NRRI-II) followed by two positive regulatory 
elements (PRR I-II), and putative IL-4 response elements (IL-4RE)/STAT-6 sites are 
shown as black boxes.
The specific primer start sites for producing the CD25 promoter in vivo footprints 
are highlighted by the arrows, with the primers identified below .
F ig u re  5 ,2 b : P r im e r  se q u e n c e s  fo r  L M -P C R  o f  th e  C D 2 5  p r o m o te r  re g io n
The synthetic oligonucleotides shown here were designed and used to amplify the 
CD25 promoter region by LM-PCR, as described in section 2.2.7b of the materials 
and methods chapter.
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Figure 5.3: In vivo footprinting of the CD25 promoter
Jurkat T cell DNA was prepared in accordance with the method of Maxam and 
Gilbert (Maxam and Gilbert, 1980), as described in section 2.2.7a. Briefly, DNA 
was alkylated on G residues by DMS, either inside the cell or following cell lysis 
(Intracellularly bound proteins protect G residues from alkylation). Piperidine was 
then used to cleave the DNA at the point of alkylation.. 2pg of this prepared DNA 
was then used to perform ligation mediated-PCR (LM-PCR) as described in 2.2.7b, 
along with the reagents required. Briefly, a first strand reaction was initially 
performed using PI and Vent DNA Polymerase, which is preferentially used because 
of its high fidelity. A common linker was then ligated on to the first strand at 17“C 
overnight using T4 DNA ligase, prior to 18 rounds of amplification with primer P2 
(PI and P2 start sites overlap) and the linker primer. The resulting amplicons were 
then labelled from one end only by PCR with 32p labelled primer 3. Samples were 
then run on a 6% "Long Ranger" sequencing gel, and the resulting autoradiographs 
analysed from the bottom up.
Proposed positions of upstream elements are highlighted next to the footprint.
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Figure 5.4: Naked DNA G ladder of the CD25 promoter 4
Jurkat T cell DNA was prepared in accordance with the method of Maxam and 
Gilbert (Maxam and Gilbert, 1980), as described in section 2.2.7a. 2jig of this 
prepared DNA is then used to perform ligation mediated-PCR (LM-PCR) as 
described in 2.2.7b, along with the reagents required. Samples were then run on a 
6% "Long Ranger" sequencing gel, following formation of wells with a larger 8mm 
comb, and the resulting autoradiographs analysed from the bottom up.
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Figure 5.5a: The promoter regions and upstream elements of CD23a and 4
CD23b
The CD23a and b promoter regions are approximately 600 and 400 base pairs in 
length, respectively, and both contain several upstream elements which are shown 
here. The CD23a promoter shows two IL-4 response elements (IL-4RE), an NFkB 
site, a glucocorticoid response element (GRE) and a B-cell-specific activator protein 
(BSAP) or Pax-5 binding site. The CD23b promoter also has two IL-4RE's but, in 
contrast, these are separated by a kB site. The second IL-4RE is then closely 
followed by two AP-1 binding sites. The specific primer start sites for LM-PCR of 
the CD23a and CD23b promoters are highlighted by the arrows, with the primers 
identified below .
Figure 5.5b: Primer sequences for LM-PCR of the CD23a and CD23b promoter 
regions
Oligonucleotides to facilitate LM-PCR of the CD23a and CD23b promoter regions 
were designed and are shown here. These primers were then used to amplify CD23 
promoter regions of DNA by LM-PCR, as described in section 2.2.7b of the 
materials and methods chapter.
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5’ GCC TTC CGT GGC TCC CCA GGG C
5’ GCC CTC TGT GAT CGG CCA TAG TGG T
5’ CGG CCA TAG TGG TAT GAT TCA GTG TG
5’ GTA GGA GGA CTC TCT GGT TCT AAC G
5’ CGT TGG CAG AAG CAA TGA CCC TTA GC
5’ CCT TAG CTA CTC CTT TCA CCC AGA AG
5’ GCG GTG ACC CGG GAG ATC TGA ATT C
3’ C TAG ACT TAA G
I
Figure 5.6: LM-PCR technique trouble-shooting - primer check i
Viability of designed primers was checked by polymerase chain reaction (PCR)
(2.2.6a) of unmodified cellular DNA. Each primer, 1-3, for each CD23 promoter 
isoform was placed in the reaction mixture with a known end point primer (CD23a 
Rev. or CD23b Rev.) and the expected band size calculated. The resulting 
amplicons were then electrophoresed on a 1% (w/v) agarose gel along with DNA 
size markers, and bands photographed and checked for size.
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Figure 5,7: Naked DNA G ladders of the CD23a promoter from SMS-SB and
P3HRI cells
SMS-SB and P3HRI cell DNA was prepared in accordance with the method of 
Maxam and Gilbert (Maxam and Gilbert, 1980), as described in section 2.2.7a. 2fig 
of extracellulaiiy prepared DNA and the CD23a primers were then used to perform 
ligation mediated-PCR (LM-PCR) as described in 2.2.7b, along with the reagents 
required. Samples were then mn on a 6% "Long Ranger" sequencing gel, and the 
resulting autoradiographs analysed from the bottom up.
Proposed positions of upstream elements are highlighted next to the gel banding.
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Figure 5,8: CD23a promoter footprinting of stimulated tonsillar B cells ^
1 X iO’7 tonsillar B cells/ml were stimulated for 24hr with 14ng/ml IL-4, Ipg/ml anti- 
CD40 and I|ig/ml anti~|Ll. Cells were then harvested, prepared in accordance with 
the method of Maxam and Gilbert (Maxam and Gilbert, 1980) (2.2.7a) and ligation 
mediated-PCR (LM-PCR) performed as described in 2.2.7b. Samples were then run 
on a 6% "Long Ranger" sequencing gel, and the resulting autoradiographs analysed 
from the bottom up.
Footprints are denoted by the presence and absence of a rung of the labelled DNA 
ladder.
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GENERAL CONCLUSIONS AND DISCUSSION
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CHAPTER 6: GENERAL CONCLUSIONS AND DISCUSSION
6.1: CD23 (FcgRII) is a multifunctional lymphokine and regulator of IgE 
expression.
CD23 is the low affinity receptor for IgE and is expressed on various cells of 
haematopoietic lineage including B cells, T cells and monocytes. CD23/FceRII is 
also a multifunctional receptor/ligand and cytokine, playing a role in antigen 
presentation, macrophage activation and cell adhesion (Bonnefoy, et ah, 1997). 
There are two CD23 isoforms, termed CD23a and CD23b, with the former being 
constitutively and cell type specifically expressed on B cells and the latter being 
expressed on B cells, T cells and monocytes following activation with various 
stimuli (Yokota, et a l,  1988). The only structural difference noted between the two 
CD23 isoforms is limited to 7 amino acids in the N-terminal cytoplasmic domain, 
and the molecules are generated using different transcription start sites and 
differential RNA splicing of the single CD23 gene located on chromosome 19 
(Suter, et a l,  1987; Wendel-Hansen, et a l,  1990). It has been observed that the 
differential CD23a and CD23b expression could be involved in B cell function and 
IgE mediated immunity respectively (Yokota, et al, 1988).
A large body of evidence suggests that CD23 plays a regulatory role in IgE 
production (Haczku, et al,  2000; Texido, et al,  1994; Yu, et a l,  1994), and cross- 
linking of CD23 at the cell surface with IgE delivers a negative feed-back 
mechanism for IgE production and inhibits the release of sCD23. Cleaved soluble 
CD23 fragments larger than 25kDa are known to promote IgE production. Allergic 
disease is thought to be due to the dysregulation of CD23/IgE feed-back 
mechanisms, probably through increased cleavage of CD23 from the cell surface, 
leading to increased IgE production and release of inflammatory mediators. Soluble 
CD23 is considerably elevated in atopic and neoplastic individuals, and this sCD23
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can originate from either of the a or b isoforms on B cells or just from the b isoform 
on other cells of haematopoietic origin. In this research, the activation of the 
promoter region of each CD23 isoform was studied in great detail, and the 
conclusions discussed herewith.
6.2; Main conclusions
The main findings of this research were principally two fold. Firstly, CD23 cell 
surface expression can be increased considerably on cell lines and naive tonsillar B 
cells upon 24 or 48 stimulation with IL-4, IL-13 and PM A, but only very slightly 
with anti-CD40 and anti-(i. Immunoprécipitation and BMSA studies revealed that 
IL-4 and IL-13 stimulation utilises a STAT-6 phosphorylation dependent pathway, 
with the EMSA's revealing that anti-CD40 leads to NFkB activation.
Secondly, the promoter regions of the two isoforms of CD23 have different 
transcription factor binding sites on them, suggesting that they are differentially 
activated via various signalling pathways. Indeed, reporter vector construct studies 
have shown that these promoters are differentially activated by distinct stimuli, with 
the CD23a promoter being sensitive to IL-4 only, and the CD23b promoter being 
activated by IL-4, anti-CD40, anti-ji and PM A. Reporter vector constructs 
containing truncated promoters revealed that IL-4 stimulation of the CD23a 
promoter required the presence of the first IL-4RE/STAT-6 site, while successful IL- 
4 stimulation of the CD23b promoter was dependent on the second IL-4RE/STAT-6 
site. This data is interesting as it suggests one of the IL-4RE present may be 
redundant in each case.
Limited in vivo footprinting studies have revealed that differential 
protein/transcription factor binding to the CD23a promoter DNA upon treatment 
with various stimuli, although actual promoter region areas could not be defined.
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6.3: Cell surface CD23 expression is upregulated in tonsillar B cells by IL-4 and 
IL-13 and PMA, but not with anti-CD40 and anti-|X
As discussed, IL-4, IL-13 and PMA B cell stimulation results in an increase in cell 
surface CD23 expression, although with anti-CD40 and anti-p no great increase in 
expression is observed (Table 3.3). Further immunoprécipitation (Figures 3.8, 3.9) 
and EMSA (Figures 3.10, 3.11, 3.12) studies revealed that IL-4 and IL-13 
stimulation lead to phosphorylation and activation of STAT-6, and that anti-CD40 
treatment caused an increase in overall cell NFkB activation. IL-4 and IL-13 
stimulation leads to an increase in STAT-6 phosphorylation alone and not the total 
amount of STAT-6 (Figures 3.8, 3.9), although a report (Arinobu , et ai,  2000) has 
indicated that anti-CD40 and anti-|a stimulation leads to increases in actual STAT-6. 
These reports lead to the assumption that perhaps anti-CD40 and anti-ji stimulation 
primes cells for IL-4 and IL-13 activation, by increasing STAT-6 available for 
phosphorylation. This will be discussed further in due course. Reporter vector 
construct studies of the CD23a and CD23b promoter revealed that the CD23a 
promoter was switched on with IL-4 alone, but the CD23b promoter was stimulated 
by all of IL-4, anti-CD40, anti-|Lt and PMA. Flow cytometry analysis of cells 
stimulated in the same way, however, showed no increase in cell surface CD23 
expression with anti-CD40 and anti-p, treatment. Explanations were therefore sought 
as to the source of this discrepancy between expressed and promoted CD23.
It has been demonstrated (Clark & Ledbetter, 1994; Richards & Katz, 1997) that the 
expression of CD23 and IgE are both upregulated on B cells stimulated with IL-4 in 
conjunction with anti-CD40 and, in contrast with IgE production, CD23 can be 
considerably upregulated by IL-4, and moderately so by lipo-polysaccharide or anti- 
CD40 alone (Armitage, et a l,  1992; Gordon, et al,  1991). IL-4 has been shown to 
play a major role in B and T cell immune responses (Paul, 1991), with signalling
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occurring through the two chain receptor consisting of the IL-4Ra and yc chain. The 
IL-13 receptor is very similar to the IL-4 receptor, with both sharing the IL-4Ra 
chain and IL-13 also including the IL-13Rot. Two general IL-4 signalling pathways 
have been described, the first involving 1RS-1/2 (Pernis, et al,  1995) and the second 
involving the STATs. Separate sites on the cytoplasmic domain of the a  chain 
interact with members of the JAK-STAT pathway family and 1RS-1/2 (Ihle & Kerr, 
1995). It is believed that the 1RS pathway is involved in lymphocyte proliferation 
and the STAT pathway central to the induction of specific genes such as CD23 and 
MHC-II (Major histocompatability complex class II).
CD40 stimulation has been shown to use signalling pathways that utilise the NFkB 
transcription factor (Berberich, et ai, 1994). The NFkB family is composed of five 
members including p50, p52, p65 (Rel A), c-rel and Rel-B, and these can all homo- 
and hetero-dimerize in various combinations (Verma, et al, 1995). Single and 
double subunit knockout mice of the NFkB family have shown a variety of mild to 
severe immunological defects (Baeuerle & Baltimore, 1996). CD40 has also been 
shown to stimulate the activation of transcription factors other than NFkB, such as 
AP-1 (Fos/Jun), NF-AT, ATF-2 and the STATs (Hsing, et ai, 1997).
Maximum CD23 induction has been well documented to require a B cell activation 
signal (i.e. CD40L) in addition to the presence of IL-4 "Superinduction", with 
CD40L alone being shown to give a modest induction of cell surface CD23 
expression. Analysis of STAT-6 -/- mice revealed that IL-4-induced expression was 
blocked (Shimoda, et ai, 1996). However Tinnell et al (Tinned, et a i,  1998) noted 
that superinduction with CD40 ligand trimer (representative of native state) and IL-4 
was only very marginally reduced in STAT-6 -/- mice in comparison to normal 
controls (Tinnell, et at., 1998). This implied that, while STAT-6 enhances CD40- 
induced CD23 expression, it is not absolutely required for CD23 superinduction via 
CD40L trimer and IL-4. IL-4 can, therefore, still synergise with CD40 in the
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absence of STAT-6. Likewise, IgE production can still be clearly induced by 
CD40L trimer and IL-4 in the absence of STAT-6 - although this IgE induction is 
strongly enhanced when STAT-6 is present. IgE production is, however, absolutely 
dependent on the presence of IL-4. An explanation for IL-4 and CD40L synergy in 
STAT-6 -/- mice is that an alternative STAT family member is induced, and strong 
EMSA and Western Blot evidence suggests that STAT-3 and STAT-5 are involved 
in IL-4 and CD40L superinduction in the absence of STAT-6 (Tinnell, et at., 1998). 
This theory is also supported by the absence of these STATs in unstimulated 
controls. The involvement of STAT-3 has also been recently discussed by Arinobu 
et al (Arinobu , et a l,  2000), and is activated by IL-4 and IL-13 through the 
utilisation of IL-13Ra (IL-4 can work through both the IL-4 and IL-13 receptor).
Delphin and Stavnezer have also suggested that STAT-6 and NFkB interact with 
each other to produce CD23 expression (Delphin & Stavnezer, 1995). They propose 
that this explains the observed IL-4/CD40L synergy, and promoter analysis 
combined with linker scanning mutagenesis has confirmed this interaction. The 
mechanisms of CD40 signalling are less well understood than those for IL-4, and 
have been reviewed by Hsing et al in 1997 (Hsing, et al,  1997). Binding motifs for 
the transcription factor NFkB, which is known to be induced by anti-CD40 
(Berberich, et al, 1994), are present on the CD23a and CD23b promoters and linker 
scanning mutagenesis has shown that NFkB is important for CD23 superinduction 
with IL-4 and CD40L trimer in mice(Richards & Katz, 1997). Messner et al have 
also shown that the NFkB sites and STAT-6 sites are co-operative in IL-4-induced 
protein expression (Messner, et a i,  1997). Regarding CD40 signalling, there is 
strong evidence to suggest that NFkB family members compensate for the lack of 
others - as do STAT family members. As mentioned, Hsing et al (Hsing, et ai, 
1997) have reported that CD40-induced CD23 expression does not necessarily utilise 
NFkB family members, but can also utilise AP-1, NF-AT, ATF-2 and STAT sites. 
This is interesting as the CD23b promoter has two API sites that could also be
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involved in anti-CD40 stimulation. Reconciliation of the difference between studies 
which have shown the need or lack of need for NFkB in CD23 expression are 
difficult, and clearly more analysis is required in addition to the currently available 
data.
STAT-6 expression is also augmented in B cells stimulated with anti-IgM and anti- 
CD40, and STAT-3 expression is similarly augmented at transcription level. STAT- 
3 augmentation in turn lead to the upregulation of IL-4 and IL-13 signalling and 
activation of CD23 expression. In the research documented in this thesis, anti-p. or 
anti-CD40 stimulation alone did not appear to have a significant effect on CD23 
expression, although the reporter vector construct studies showed that the CD23b 
promoter was activated considerably with both of these stimulants.
Reasons for this discrepancy were sought and, as hinted in the results section, one of 
these could be that the actual epitope recognised by the particular anti-CD40 
antibody used in this experiment was not sufficient to elicit an expressional 
response. This disparity has been touched upon by Burlinson et al in 1996 and 
Challa et al in 1999, who noted epitope dependent synergism and antagonism 
between anti-CD40 antibodies and soluble CD40 ligand (Burlinson, et a l ,  1996; 
Challa, et a l,  1999). However, because activation of the actual promoter was noted, 
and only CD23 cell surface expression was absent, this is not considered to be the 
case.
Anti-CD40 and anti-p have been noted to work synergistically to produce up to 4 
fold increases in STAT-6 activation (Arinobu , et a l,  2000) and, indeed, CD23 
expression. The fact that low CD23 expression was noted in this research with 
either anti-CD40 or anti-p treatment alone was found to be in accordance with the 
results of Arinobu, and perhaps more convincing CD23 stimulation would have been 
achieved if synergistic anti-CD40 and anti-p treatment had been given. Overall, the
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current data are consistent with the model that STAT-6 functions as an enhancer of 
the transcription of IL-4 sensitive genes, rather than being absolutely required. The 
situation in relation to NFkB is possibly likewise.
Information is still required as to why, while the promoter region of CD23b is 
activated by stimulation with either anti-CD40 and anti-p, no observable cell surface 
CD23 increase is seen. It should be noted that, while the promoter constructs give 
valuable information in to the activation of specific response elements of the two 
CD23 isoforms, the gene in vivo will be subject to many other positive and negative 
regulatory effects. It is likely that the promoter regions of each isoform, and also the 
intervening and proximal regions, confer inhibitory and stimulatory effects on each 
other. In short, what happens in vitro may not necessarily be the case in vivo. The 
possibility of translational control has also been considered, with translational 
initiation perhaps being dependent on the attainment of a specific minimum value of 
promoter activation.
Translational control of protein expression
Induction of translation is usually the rate limiting step in protein synthesis, which 
makes it an attractive target for regulation. An example of this phenomenon is the 
kinetics of haemoglobin synthesis(Stryer, 1995). In the absence of haem, 
haemoglobin subunit protein synthesis halts because of the abrupt formation of a 
protein synthesis inhibitor. This inhibitor is a kinase which phosphorylates eIF2, 
thus blocking protein synthesis. A recent paper (Meyuhas, 2000) discusses the 
synthesis of mammalian proteins, and the associated synthesis of translational 
apparatus in relation to several mitogenic and nutritional stimuli. It is suggested that 
perhaps CD23b synthesis requires IL-4, or indeed some other stimuli, in addition to 
the presence of solely anti-CD40 or anti-p to produce surface CD23 expression.
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Thus, IL-4 can enhance the activation of, for example, the anti-CD40 stimulated 
CD23b promoter to such a level that increased cell surface expression is observed.
It should also be noted that, in the reporter vector construct studies, an SV40 
enhancer is present in the vector to increase transcription of the SEAP protein. The 
high increases observed in promoter activity may, therefore, be slightly over 
estimated in relation to the actual in vivo increase in promoter activity.
The fact that the CD23a promoter does not appear to be switched on by either anti- 
CD40, anti-p or PMA indicates that repressors may bind to the NFkB binding sites, 
thus blocking the binding of NFkB proteins to this promoter. The BSAP/Pax-5 site 
on the CD23a promoter supports the theory that CD23a is involved in B cell function 
and development, rather than IgE-mediated immune responses. It is possible, 
therefore, that a repressor is formed at some stage around the immature/mature B 
cell boundary that blocks CD23a activation (other than with IL-4), and leaves 
CD23b to be responsible for IgE-mediated inflammatory responses (i.e. with the 
mitogens tested in this reseai'ch).
6.4: Differential regulation of the CD23a and CD23b promoter
It has been suggested that CD23a expression is involved in B cell function and that 
CD23b is involved in IgE-mediated immune responses (Yokota, et aL, 1988). As 
implied, the presence of a BSAP/Pax-5 site on the CD23a promoter lends support to 
this theory, as does the fact that CD23a is expressed solely on B cells. Pax-5 codes 
for the transcription factor BSAP, which is expressed throughout B cell development 
except in terminally-differentiated plasma cells (Adams, et aL, 1992). Mammalian 
Pax genes encode for developmental regulators which are defined by the presence of 
a highly conserved DNA binding motif of 128 amino acids (Stapleton, et aL, 1993; 
Treisman, et aL, 1991), known as the paired domain. Mice lacking pax-5 exhibit an
173
early block in B cell development, manifested by the absence of pre-B, B and plasma 
cells (Urbanek, et a l, 1994). Anti-sense oligonucleotide-mediated inhibition of 
BSAP synthesis has been used to show that BSAP is involved in the control of 
proliferation of mature B cells (Wakatsuki, et aL, 1994), but cell cycle regulation in 
pro-B cells lacking Pax-5 is normal (Nutt, et aL, 1997). Thus, B lymphocytes do 
not seem to require BSAP early in the developmental pathway, but become 
dependent on this transcription factor in the later stages of B cell differentiation.
Pax-5 is expressed up to and including the activated B cell stage Busslinger et al 
(Busslinger & Nutt, 1998) have shown that, in addition to being a transcriptional 
activator, BSAP can function as a repressor. The repressor and activator functions 
are dependent on the concentrations of BSAP and the context of the protein binding 
site. Sites that lead to the activation of gene expression were found to have a higher 
affinity for BSAP than repressive sites, leading to the conclusion that Pax-5 activator 
functions predominate at low concentrations of BSAP protein and Pax-5 will 
function only as a repressor at higher protein concentrations.
CD23 has been found to be expressed only at the mature B cell stage (Rajewsky, 
1996; Waldschmidt, 1992), and there is some overlap in BSAP and CD23 expression 
(BSAP is expressed right up to the plasma cell stage). CD23a transcription could 
thus be primarily activated by the presence of BSAP in newly mature B cells, and 
this could be highly dependent on the BSAP concentration. This theory is supported 
by the fact that CD23 expression is absent in plasma cells, as is the expression of 
BSAP. It can be surmised, therefore, that the CD23 present in naive B cells will be 
CD23a only, rather than CD23b which is involved in the IgE-mediated response. It 
remains unclear as to what the function of CD23a is, and as to why it would be 
required on newly-developed B cells. Bearing in mind that the only difference in the 
two isoforms is on the 7 amino acid region of the N terminal cytoplasmic region, 
perhaps different intracellular mediators bind to the tail of each isoform and, in the
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case of CD23a, may be involved in preventing B cells from differentiating into 
plasma cells. Upon the withdrawal of BSAP, and the resulting drop in CD23 
expression, B cells would be free to differentiate into plasma cells.
The CD23b isoform can be expressed on B cells, T cells and other haematopoietic 
cells following stimulation with IL-4, anti-CD40, anti-p and PMA. It is thus implied 
that it this isoform that is involved in the IgE mediated immune response and atopy, 
and not in B cell differentiation. It is possible that an intra-cellular protein binds to 
the unique tail region of CD23b to lead to increased proteolytic cleavage of the 
CD23 molecule to produce the elevated sCD23 levels that are indicative of atopy. 
To re-cap, membrane bound CD23 complexes to and is a negative regulator of IgE, 
but sCD23 actually leads to an increase in IgE expression. sCD23 has also been 
shown to rescue the human pre-B like leukaemic cell line SMS-SB from apoptosis 
(White, et a l,  1997), so can be involved in the maintenance of neoplastic cells as 
well.
6.5: Future Studies
Several lines of study have arisen and could be pursued in future following the 
research carried out in this thesis. Reporter vector construct studies were carried out 
using both full-length and truncated forms of the CD23a and CD23b promoter 
regions, and future experiments could be to build constructs with promoter deletion 
mutations as opposed to truncations. This would allow analysis into whether certain 
response elements, and the transcription factors binding to them, can interact with 
one another to compensate for the loss of distinct singular sites. It is possible, for 
example, that when the second IL-4RE/STAT-6 site is deleted on the CD23b 
promoter the first IL-4RE/STAT-6 site (or another unknown site around this area) 
comes into play. Also, further analysis is required on the putative negative
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regulatory effect region observed and removed upon truncation of the CD23b 
promoter past the first IL-4RE/STAT-6 site.
Reporter vector construct studies of the CD23a and CD23b promoter revealed that 
the CD23a promoter was activated by IL-4 alone, but the CD23b promoter was 
initiated with all of IL-4, anti-CD40, anti-p. and PMA. The expression of CD23 is 
upregulated on B cells stimulated with IL-4 in conjunction with anti-CD40 (Clark & 
Ledbetter, 1994; Richards & Katz, 1997). It has also been implied that, while 
STAT-6 enhances CD40 induced CD23 expression, it is not absolutely required for 
CD23 superinduction via anti-CD40 and IL-4 (Tinnell, et a l, 1998). IL-4 can, 
therefore, still synergise with CD40 in the absence of STAT-6 and this suggests that 
an alternative ST AT family member is induced. Follow-on experiments would be to 
co-stimulate the reporter vector construct transformed cells with both IL-4 and anti- 
CD40, and to remove or incapacitate the STAT-6 sites in order to analyse any effects 
on promoter activation. If other sites are involved in CD23 super-induction, and are 
present in the cloned promoter region, they will compensate for the loss of STAT-6 
sites.
To further investigate the evidence by Hsing et al (Hsing, et a l, 1997) that CD40 
induced CD23 expression does not necessarily utilise members of the NFkB family, 
but also AP-1, NF-AT, ATF-2 and ST AT sites, further studies could also involve the 
anti-CD40 stimulation and IL-4 and anti-CD40 co-stimulation of reporter vector 
construct transformed cells, following the removal of NFkB binding sites. The 
CD23b promoter has two API sites that could be involved in anti-CD40 stimulation, 
as well as two STAT-6 sites. The data from these experiments would allow the 
determination of the necessity of the NFkB site for CD40 signalling, and also uphold 
or banish the theory of AP-1 utilisation in this instance.
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Isolation of the promoter regions of eaeh isoform does, as stated, provide valuable 
information on the in vitro regulation of each. An interesting experiment would be 
to build a reporter vector construct containing both the CD23a and CD23b promoter, 
in order to determine if they convey negative and positive regulatory effects on each 
other. Ideally, this construct should contain the intervening DNA regions between 
the two promoters, so that any response elements and regulatory domains within 
these areas could be studied. Logistically, however, an insert of this size would be 
almost impossible to include within the pSEAP reporter vector, so only the minimal 
promoter regions would have to be ligated and inserted.
I have hypothesised that CD23a may be involved in the prevention of mature B cells 
differentiating into plasma cells, and that the expression of CD23a is dependent on 
levels of BSAP. The transformed plasma cell line RPMI-8866, interestingly, 
expresses large amounts of cell surface CD23 (I. Matheson, personal 
communication). It would be of major interest to discover if these cells also 
expressed high levels of BSAP. Alternatively, normal plasma cells could be 
transfected with Pax-5/BSAP and the resulting CD23 levels measured in order to 
analyse the proposed link between the expression of the two proteins.
In summary, the research in this thesis has provided valuable information into the 
regulatory mechanisms of each CD23 isoform and, as a result, has opened a wealth 
of avenues for future research.
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APPENDIX:
SOLUTIONS AND BUFFERS:
SOLUTION REAGENTS AND COMPOSITION
DNA LOADING DYE (5X) 0.25% (w/v) Bromophenol blue, 30% 
Glycerol
EMSA BINDING BUFFER (5X) 20% Glycerol, 5mM MgCl2 , 2.5mM 
EDTA, 2.5mM DTT, 250mM NaCl, 
50mM Tris-HCl (pH 7.5), 0.25mg/ml 
poly dl-dC
LB AGAR 15g Bacto-Agar to IL LB media. 
Autoclave, cool to 55°C, supplement 
with 0.05mg/ml Ampicillin
LB BROTH/MEDIA lOg Bacto-Tryptone, 5g Bacto-Yeast 
extract, lOg NaCl. pH to 7.5, dH20 to 
IL, supplement with 0.05mg/ml 
Ampicillin
LM-PCR AMPLIFICATION SOLN 400mM NaCl, 50mM MgS0 4 , 1% (v/v) 
Triton-X-100, 0.1% (w/v) Geletin, 
200mM Tris-HCl (pH 8.9)
LM-PCR DILUTION SOLN ISmM MgCl2 , 50mM DTT, 0.0125% 
(w/v) BSA, llOmM Tris-HCl (pH 7.5)
LM-PCR FIRST STRAND BUFFER 
(5X)
200mM NaCl, 25mM MgS0 4 , 0.5% 
(w/v) Geletin, 50mM Tris-HCl (pH 8.9)
LM-PCR LABELLING MIX 1 X Amplification mix, 2mM each dNTP, 
2.3pmol p^P]- labelled Primer 3
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LM-PCR LIGATION SOLN (2X) 20mM MgCl2 , 40mM DTT, 6mM ATP, 
0.01% (w/v) BSA, 500mM Tris-HCl (pH 
7.7)
LM-PCR LOADING DYE 98% de-ionised formamide, lOmM 
EDTA, 0.25% (w/v) xylene-cyanol, 
0.25% (w/v) Bromophenol blue
LM-PCR PRECIPITATION SOLN 0.1% yeast transfer RNA, 2.7M Na 
Acetate (pH 7)
LM-PCR STOP SOLN 67jag/ml yeast transfer RNA, 4mM 
EDTA, 260mM Na Acetate (pH 7), 
lOmM Tris-HCl (pH 7.5)
MAXI-PREP (QIAGEN) PI 50mM Tris-HCl (pH 8), lOmM EDTA, 
lOOixg/ml RNase A
MAXI-PREP (QIAGEN) P2 200mM NaOH, 1% (w/v) SDS
MAXI-PREP (QIAGEN) P3 3M K Acetate. pH to 4.8
MAXI-PREP (QIAGEN) QC IM NaCl, 50mM MOPS (pH 7), 15% 
(v/v) Isopropanol
MAXI-PREP (QIAGEN) QF 1.25mM NaCl, 50mM Tris-HCl (pH 
8.5), 15% (v/v) Isopropanol
PBS(PHOSPHATE BUFFERED 
SALINE) (lOX)
1.37M NaCl, 26.8M KCl, 42mM 
Na2HP0 4 , 14.7mM KH2PO4 . pH to 7.2
PROTEIN LOADING BUFFER (4X) 200mM Tris-HCl (pH 8), 8% (w/v) SDS, 
0.4% (w/v) Bromophenol blue, 40% 
(v/v) Glycerol, 20% (v/v) p- 
Mercaptoethanol
PROTEIN TRANSFER BUFFER 48mM Tris, 39mM Glycine, 1.3mM 
SDS, 20% (v/v) Methanol
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RIPA BUFFER 50mM Tris-HCl (pH 7.4), 1% (v/v) 
NP40, ImM Na Deoxychoiate, 150mM 
NaCl, ImM EGTA, ImM Na3 V 0 4 , 
ImM NaF, ImM PMSF, 2pg/mi 
Leupeptin, 0.5mM DTT
SDS-PAGE RUNNING BUFFER 25mM Tris-HCl (pH 8.3), 250mM 
Glycine, 0.1% (w/v) SDS
SOC MEDIUM 2g Bacto-tryptone, 0.5g Bacto-yeast, 
O.OIM NaCl, O.OIM MgCla, O.OIM 
MgSOa, 0.02M Glucose
STET 8% (v/v) Sucrose, 2.5ml 2M Tris (pH 8), 
40ml 250mM EDTA (pH 8), 10ml 
Triton-X-100, dHzO to 200ml
TAE BUFFER (50X) 242g Tris, 18.6g EDTA, 57ml of Glacial 
Acetic acid, dH20 to IL
TBE BUFFER (lOX) 0.9M Tris-HCl, 0.9M Boric acid, 2mM 
EDTA. pH to 8.3
TE BUFFER lOmM Tris-HCl (pH 8), ImM EDTA
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COMPOSITION OF GELS:
PERCENTAGE OF GEL REAGENTS AND COMPOSITION
10% SDS-PAGE SEPARATION GEL 10% (w/v) Acrylamide/Bis Acrylamide, 
0.375M Tris-HCl (pH 8.8), 0.1% (w/v) 
SDS, 0.05% (w /v) Ammonium  
Persulphate, 0.0003% (v/v) TEMED
12% SDS-PAGE SEPARATION GEL 12% (w/v) Acrylamide/Bis Acrylamide, 
0.375M Tris-HCl (pH 8.8), 0.1% (w/v) 
SDS, 0.05% (w /v) Ammonium  
Persulphate, 0.0003% (v/v) TEMED
5% SDS-PAGE STACKING GEL 5% (w/v) Acrylamide/Bis Acrylamide, 
0.13M Tris-HCl (pH 6.8), 0.1% (w/v) 
SDS, 0.1% (w/v) Ammonium Persulphate, 
0.0007% (v/v) TEMED
6 % LONG RANGER' SEQUENCING 
GEL FOR FOOTPRINTING
9.6ml 'Long Ranger’ gel solution (50% 
v/v), 16ml of 5 X TBE, 40.4g Urea, 70mg 
Ammonium Persulphate, mix, dissolve, 
filter. Add 25|ul TEMED.
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